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Abstract	
	
Since	1933,	studies	have	explored	the	concept	of	trauma	induced	secondary	cardiac	
injury	 (TISCI),	 yet	 till	 2012,	 it	 had	 not	 been	 defined	 as	 the	 incidence	 of	 cardiac	
events	 and	 rise	 in	 cardiac	 biomarkers	 following	 traumatic	 injury.	 Despite,	
improvements	 in	 early	 outcomes,	 trauma	 patients	 have	 reduced	 long-term	
mortality	with	cardiac	disease	being	the	major	contributor.	Although	many	putative	
mechanisms	have	been	suggested	for	TISCI,	the	underpinning	pathophysiology	still	
remains	unclear.	
	
In	this	thesis,	a	prospective	study	of	290	critically	 injured	patients	identifies	a	13%	
incidence	 of	 adverse	 cardiac	 events	 (ACE)	 with	 consistently	 raised	 serum	 h-FABP	
levels	 in	these	patients.	H-FABP	was	found	to	be	a	good	predictor	of	ACE	through	
ROC	analysis	and	a	h-FABP	of	16.8	ng/ml	used	to	define	trauma	induced	secondary	
cardiac	 injury	 (TISCI).	 TISCI	 was	 associated	 with	 longer	 hospital	 stay	 and	 higher	
mortality.	Patients	who	developed	ACE	had	higher	plasma	levels	of	adrenaline	and	
noradrenaline	 with	 a	 correlating	 increase	 in	 plasma	 h-FABP.	 On	 multivariate	
analysis,	hypertension	was	the	only	independent	risk	factors	for	ACE.	
	
The	increase	in	serum	cardiac	biomarkers	was	reflected	by	an	increase	in	serum	h-
FABP	 in	 our	 group’s	 trauma	 hemorrhage	 murine	 models.	 The	 hearts	 of	 these	
models	were	used	 in	 the	 experiments	 that	 form	 the	 last	 experimental	 chapter	 of	
this	 thesis.	 Protein	 expression	 studies	 confirm	 this	 increase	 in	 serum	 h-FABP	 by	
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evidence	 of	 concurrent	 leaching	 in	 the	 cardiac	 tissue,	 along	 with	 Troponin	 I.	
Myocardial	 injury	was	evident	on	electron	microscopy	with	evidence	of	 interstitial	
and	 organelle	 oedema,	 myofibrillar	 degeneration,	 nuclear	 condensation	 and	
changes	in	mitochondrial	morphology.	Immunohistochemistry	and	western	blotting	
protein	 studies	 demonstrate	 the	 translocation	 of	 the	mitochondrial	 death-related	
protein	AIF	 to	 the	 cytosol	 and	nucleus,	where	 it	 becomes	 its	 active	pro-apoptotic	
form.		
	
This	thesis	propositions	the	utility	of	the	cardiac	biomarker	h-FABP	in	predicting	ACE	
and	 outcomes	 in	 critically	 injured	 patients.	 Although	 increasing	 serum	
noradrenaline	 and	 adrenaline	 levels	 are	 associated	 with	 higher	 incidence	 of	 ACE	
and	 biochemical	 evidence	 of	 cardiac	 injury	with	 rising	 h-FABP	 levels,	multivariate	
analysis	negates	their	value	as	independent	predictors	of	ACE.	Leaching	out	of	the	
proteins	h-FABP	and	Troponin	I	in	the	murine	cardiac	tissue	confirmed	the	value	of	
serum	 measurements	 of	 these	 proteins	 as	 markers	 of	 cardiac	 injury.	 This	 was	
associated	with	widespread	ultrastructural	myocardial	damage	in	the	TH	mice	with	
changes	 in	 mitochondrial	 morphology.	 The	 mitochondrial	 damage	 seen	 is	
associated	with	the	translocation	of	the	mitochondrial	death-related	protein	AIF	to	
the	 cytosol	 and	 the	 nucleus	 where	 I	 propose	 its	 canonical	 signaling	 leading	 to	
nuclear	degradation	and	cell	death	is	the	driver	of	cardiac	dysfunction.		
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nt-Pro	BNP	 N-terminal	(NT)-pro	hormone	Brain	natriuretic	peptide	
OD	 Optical	density	
PBS	 Phosphate	buffered	saline	
PE	 Pulmonary	emboli	
PLAR	 Professional	Legally	Appointed	Representative		
PVD	 Peripheral	vascular	disease	
PVDF	 Polyvinylidene	difluoride	
RAD	 Right	Axis	Deviation	
RBBB	 Right	Bundle	Branch	Block	
RIPA	 Radioimmunoprecipitation	assay	
ROC	curve	 Receiver	Operating	Characteristic	
ROS	 Reactive	Oxygen	Species	
rpm	 Revolution	Per	Minute	
RT		 Room	Temperature	
RTA	 Road	Traffic	Accident	
SAH	 Subarachnoid	Haemorrhage	
SBP	 Systolic	Blood	Pressure		
SDS	 Sodium	Dodecyl	Sulfate	
SIRS	 Systemic	Inflammatory	Response	Syndrome	
TACID	 Trauma	Associated	Cardiac	Injury	and	Death		
TBI	 Trauma	Brain	Injury	
TH	 Trauma	Haemorrhage	
TISCI	 Trauma-Induced	Secondary	Cardiac	Injury		
TMB	 3,3'5,5'	-	Tetramethylbenzidine	
TNF		 Tumour	Necrosis	Factor	
TNFR	 Tumour	Necrosis	Factor	Receptor	
UTI	 Urinary	Tract	Infection	
VAP	 Ventilator	Acquired	Pneumonia	
VTI	 Velocity	Time	Integral		
μl	 Microlitre	
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1.1	Burden	of	Disease	
	
Injury	 is	 defined	 as	 the	 transfer	 of	 energy	 leading	 to	 tissue	 damage.	 This	 still	
remains	 a	 pertinent	 global	 health	 issue,	 contributing	 to	 9%	 of	 global	 mortality,	
which	translates	to	5	million	deaths	every	year	(1).	It	is	the	leading	cause	of	death	in	
young	 people	 in	 the	 UK,	 with	 a	 total	 of	 48000	 cases	 of	major	 trauma	 each	 year	
resulting	in	19500	deaths(2).		
	
Road	 traffic	 accidents	 (RTA)	 alone	 account	 for	 24%	 of	 trauma	 deaths	 and	 are	
predicted	 to	 be	 the	 fifth	 leading	 cause	 of	 mortality	 by	 2030.	 About	 1.25	 million	
deaths	 a	 year	 occur	 due	 to	 RTA	 injuries,	with	 20-	 50	million	more	 suffering	 from	
non-fatal	injuries	(3).	It	is	estimated	that	3500	lives	are	lost	each	day	secondary	to	
RTAs.	 Unsurprisingly,	 there	 is	 a	 large	 incongruence	 in	 mortality	 rates	 between	
economic	 regions	 worldwide.	 Despite	 owning	 only	 56%	 of	 registered	 vehicles	
worldwide,	 90%	deaths	 due	 to	RTA	occur	 in	 low/middle	 income	 countries	 due	 to	
the	lack	of	safety	law	enforcement	(3).	
	
Although	globally	we	have	seen	a	17%	decrease	in	violence,	in	middle/low	income	
countries	of	 the	Americas	 there	has	been	a	5%	 increase	with	 incidence	 rates	 that	
are	 four	 fold	 higher	 than	 the	 global	 average	 (3).	 Trauma	 also	 contributes	 to	 a	
greater	 disease	 burden	 in	 this	 population	 owing	 to	 high	 rates	 of	 violence	 against	
women	and	homicide,	with	75%	attributed	to	gun	crime	(3).		
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Figure	1.1	Global	trends	of	deaths	attributable	to	injuries	from	2000-2012	(3)	
	
It	is	estimated	that	for	every	death	due	to	traumatic	injury,	two	people	are	left	with	
life	changing	injuries.	In	addition	to	reduced	physical	function,	patients	are	left	with	
chronic	pain,	cognitive	 issues	and	psychological	distress.	Globally,	 trauma	 leads	 to	
an	astonishing	loss	of	12%	of	total	DALY	(Disability	adjusted	years)	due	to	all	causes	
(4,5).		
	
Although	 trauma	 only	 contributes	 to	 0.2%	 of	 A&E	 workload,	 its	 immediate	
treatment	costs	more	than	£300	million	with	annual	economic	output	estimated	to	
be	 in	 between	£3.3-3.7	 billion	 (2).	Worldwide	 injuries	 lead	 to	 a	 loss	 of	 3%	of	 the	
global	gross	domestic	product	(4).		
	
Despite	 the	 global	 improvements	 in	 outcome,	 trauma	 still	 remains	 a	 significant	
burden	on	health	and	socioeconomic	outcomes	in	the	UK	and	worldwide.		
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1.2	Causes	of	Death	in	Trauma	
	
The	 temporal	 pattern	 of	 death	 in	 trauma	 has	 historically	 been	 described	 as	
trimodal.	More	recent	studies	have	noted	shifts	due	to	changes	in	pre-hospital	care	
and	resuscitation	practices.	The	majority	of	deaths	associated	with	trauma	occur	in	
the	acute	phase,	within	hours	of	injury	(6,7).	The	leading	cause	of	death	in	trauma	
patients	 is	catastrophic	brain	 injuries	and	then	secondly	major	haemorrhage	(7,8).	
The	 advent	 of	 the	 London	 Trauma	 System	 (LTS)	 and	 its	 introduction	 of	 triaging	
patients	to	specialised	Level	I	trauma	centres	has	led	to	significant	improvements	in	
patient	outcomes	in	a	short	period	of	time	(9).	In	just	over	3	years,	mortality	within	
the	 first	 72	 hours	 reduced	 from	 14%	 to	 7%.	 The	 establishment	 of	 the	 LTS	 was	
preceded	 by	 the	 development	 of	 major	 haemorrhage	 protocols	 involving	
optimisation	of	transfusion	practices,	the	use	of	tranexamic	acid	and	the	promotion	
of	 damage	 control	 resuscitation	 and	 surgery	 all	 being	 central	 to	 the	 reduction	 in	
mortality	and	improvement	in	trauma	care	(9).		
	
On	 hospital	 admission,	 patients	 who	 survive	 the	 acute	 post	 injury	 phase,	 have	 a	
greater	risk	of	developing	multiple	organ	dysfunction	(MODs)	during	their	hospital	
admission.	 Improvements	 in	 critical	 care	 protocols	 have	 significantly	 reduced	 the	
incidence	 of	 MODs	 over	 time,	 however	 mortality	 remains	 unchanged	 (7,10).	 In	
patients	who	develop	MODs,	although	deaths	primarily	due	to	cardiac	dysfunction	
have	declined,	 it	 still	 contributes	 to	MODs	 in	5%	of	 the	non-survivors(10,11).	 In	a	
large	study	of	 the	German	Trauma	registry,	Frohlich	2013	showed	that	circulatory	
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failure	occurred	in	in	33%	patients(12,13).	A	single	centre	study	by	the	same	group,	
also	showed	that	trauma	patients	remain	at	risk	of	higher	long-term	mortality	rate	
when	 compared	 to	 gender	 and	 age	 matched	 non-injured	 group	 (10-14).	
Cardiovascular	disease	was	 the	highest	 cause	of	mortality,	 contributing	 to	22%	of	
deaths	in	trauma	patients	post	discharge	(14).	
1.3	Preclinical	Evidence	for	Cardiac	Dysfunction	in	Trauma	
	
Most	of	the	evidence	for	the	existence	of	myocardial	dysfunction	following	trauma	
haemorrhage	 comes	 from	 rodent	 models.	 Professor	 Chaudry’s	 group	 has	
significantly	contributed	to	this	field	since	1993.	They	have	focused	on	depression	in	
myocardial	 function	 and	 explored	 the	 mechanistic	 contribution	 of	 sex	 hormones	
and	 inflammatory	 proteins.	 Their	 model	 uses	 rats	 that	 are	 anaesthetised	 with	
methoxyfluorane	and	subjected	to	a	5	cm	midline	laparotomy.	Vascular	access	lines	
are	placed	 in	 the	carotid	artery,	 femoral	artery	and	 femoral	 vein	and	 the	 rodents	
are	 bled	 to	 a	mean	 arterial	 pressure	 of	 40mmHg.	 Initial	 resuscitation	 is	 with	 the	
withdrawn	 blood	 and	 Ringer’s	 lactate	 over	 60	 minutes.	 Their	 model	 exhibits	 a	
reduction	 in	 left	 ventricular	 function	 as	measured	 by	 a	 reduction	 in	 the	maximal	
rate	of	pressure	in	the	left	ventricle,	ventricular	peak	systolic	pressure	and	cardiac	
output.	 (15-21).	 Mechanistically,	 the	 group	 demonstrated	 that	 an	 estrus	 state	
attenuates	the	deleterious	effects	of	trauma	haemorrhage	(TH)	on	cardiac	function	
(15-25).	They	also	showed	that	progesterone	and	castration	mitigated	the	reduction	
in	 cardiac	 function	 through	 reduction	 in	 testosterone	 levels	 (15,26,27).	 	 Further	
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studies	have	implicated	IL-6	in	cardiac	dysfunction	in	trauma,	highlighting	potential	
protection	afforded	by	modulation	of	 its	downstream	signaling	 leading	to	reduced	
production	 of	 various	 cytokines	 and	 cell	 adhesion	 molecules	 (28).	 These	
inflammatory	 cytokines	 were	 reduced	 by	 estradiols	 (21).	 Although,	 pre-clinical	
models	have	alluded	to	many	associative	factors	 in	cardiac	dysfunction	 in	trauma,	
the	absolute	mechanism	has	not	been	clearly	defined.	
1.4	Clinical	Evidence	for	Cardiac	Dysfunction	in	Trauma	
	
The	clinical	manifestation	of	cardiac	dysfunction	specifically	evidence	of	myocardial	
ischaemia	 and	 arrhythmias	 have	 been	 previously	 studied	 in	 trauma	 patients	 but	
furthermore	 studies	 have	 investigated	 the	 relevance	 of	 cardiac	 biomarkers	 in	
trauma	patients.	These	will	be	discussed	later	in	Section	1.6.4.	
	
In	 a	 retrospective	 case	 note	 study	 conducted	 by	 Ismailov	 et	 al.,	 the	 incidence	 of	
acute	 myocardial	 infarction	 (AMI)	 in	 trauma	 patients	 was	 found	 to	 be	 3%,	 and	
associated	with	thoracic	injury,	abdominal	and	pelvic	injuries.	Further	examination	
through	 logistic	 regression	 revealed	 that	 in	 patients	 less	 than	 45	 years	 old,	
abdominal	and	pelvic	injuries	were	associated	with	65%	increased	risk	of	developing	
AMI.	They	also	 found	 that	blunt	 cardiac	 injury	was	an	 independent	 risk	 factor	 for	
dysrhythmias,	however,	 thoracic	 injury	was	not	an	 independent	risk	 factor.	 In	 this	
cohort,	patients	younger	than	50	years	had	a	four-fold	increase	in	risk	of	developing	
arrhythmias	 (29).	 In	 younger	 patients	with	 less	 likelihood	of	 underlying	 ischaemic	
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heart	 disease	 and	 the	 increase	 in	 risk	 seen	 with	 abdominal	 and	 pelvic	 injuries	
potentially			
	
Seguin	et	 al	 conducted	a	prospective	 study	 into	 the	occurrence	of	 arrhythmias	 in	
critically	injured	patients.	They	reported	the	occurrence	of	Atrial	Fibrillation	(AF)	at	
5%,	with	8%	of	those	patients	developing	cardiogenic	shock	(30).	Using	multivariate	
analysis,	this	group	also	found	that	age,	degree	of	shock,	blunt	thoracic	 injury	and	
insertion	 of	 pulmonary	 artery	 catheters	 were	 all	 risk	 factors.	 Furthermore,	 they	
demonstrated	 that	direct	 thoracic	 injury	 led	 to	a	17-fold	 increase	 in	 risk.	 In	2006,	
the	 same	 group	 repeated	 the	 study	 to	 determine	 further	 risk	 factors,	 revealing	 a	
similar	incidence	of	AF	incidence	(5.5%).	However,	in	this	study,	thoracic	injury	was	
not	an	independent	risk	factor	but	shock,	catecholamine	use	and	number	of	regions	
injured	were	all	risk	factors	when	cofounders	were	adjusted	for	(31).	
	
In	a	retrospective	study	conducted	by	Hadjizacharia	et	al	in	2011,	it	was	noted	that	
the	patients	who	developed	atrial	 arrhythmias	 (AA)	were	older,	more	 likely	 to	be	
male,	more	 severely	 shocked	 on	 admission	 and	 had	 a	 higher	 prevalence	 of	 blunt	
and	 head	 injuries.	 On	 multivariate	 analysis,	 being	 aged	 >55	 years	 was	 the	 only	
independent	risk	factor.	The	AA	group	also	had	worse	outcomes	with	a	19%	greater	
risk	of	mortality.	This	study	also	noted	that	AA	patients	who	received	beta-blockers	
during	their	admission	had	15%	reduced	risk	of	mortality	(26).	
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1.5	Trauma	Induced	Secondary	Cardiac	Injury	
	
	In	 2012,	 our	 group	 conducted	 a	 retrospective	 study	 on	 a	 panel	 of	 cardiac	
biomarkers	 in	 a	 cohort	 of	 135	 patients.	 In	 this	 study,	 13%	 patients	 had	 adverse	
cardiac	 events	 (ACE).	 In	 the	 patients	 who	 developed	 ACEs,	 serum	 h-FABP	 levels	
were	 three	 times	 higher	 and	 BNP	 levels	 were	 1.5	 times	 higher	 and	 this	 was		
associated	 with	 greater	 injury	 severity	 and	 shock.	 The	 rise	 in	 cardiac	 biomarkers	
was	 not	 associated	 with	 thoracic	 injury	 nor	 head	 injuries.	 There	 was	 also	 no	
difference	 in	 pre-existing	 diseases	 such	 as	 hypertension,	 hypercholesterolaemia,	
diabetes	 and	 ischaemic	 heart	 disease.	 This	 raised	 the	 possibility	 of	 further	
underlying	mechanisms	for	secondary	cardiac	injury	in	trauma	patients(32).		
	
In	a	follow	up	study,	De’Ath	went	on	to	look	at	the	association	of	 inflammation	in	
ACEs	 (33).	 In	 this	 study,	 patients	 with	 higher	 levels	 of	 circulating	 inflammatory	
cytokines	–	tumor	necrosis	factor	(TNF)	α,	interleukin	(IL)-6	and	IL-8	had	a	hundred-
fold	 increase	 in	 serum	 heart	 fatty	 acid	 binding	 protein	 (h-FABP).	 Multivariate	
analysis	also	revealed	that	age,	injury	severity	score	(ISS)	and	IL-6	were	independent	
predictors	of	myocardial	damage,	as	predicted	by	h-FABP.	This	study	also	found	that	
patients	 admitted	 with	 raised	 levels	 of	 troponin	 I	 and	 elevated	 inflammatory	
cytokine	had	increased	risk	of	mortality(33).		
	
This	 was	 the	 first	 study	 designed	 to	 examine	 the	 possibility	 of	 identification	 of	
cardiac	 injury	and	prognostication	 in	trauma	patients	using	a	panel	of	biomarkers.	
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Although	retrospectively	conducted,	it	demonstrated	the	rise	of	cardiac	biomarkers	
in	 trauma	 patients	 and	 the	 association	 with	 inflammation.	 These	 studies	
successfully	validated	the	preclinical	evidence	on	cardiac	injury	in	a	clinical	setting.		
1.6	Cardiac	Biomarkers	
	
Myocardial	 injury	 is	 diagnosed	 using	 a	 combination	 of	 clinical	 features.	 It	 may	
manifest	 clinically	 as	 chest	 pain,	 palpitations,	 syncope	 or	 cardiovascular	 collapse.	
These	 are	 often	 seen	 in	 addition	 to	 electrocardiogram	 (ECG)	 changes	 such	 as	 ST	
elevation,	arrhythmias,	conduction	abnormalities	such	as	bundle	branch	blocks	and	
T	 wave	 inversion.	 In	 the	 absence	 of	 information	 of	 patient’s	 pre-existing	 co-
morbidities	or	unequivocal	clinical	signs,	cardiac	biomarkers	can	aid	diagnosis	(34).		
The	ideal	biochemical	marker	should	allow	for	early	detection	of	cardiac	injury	with	
high	sensitivity	and	specificity.	A	potential	prognostic	biomarker	would	therefore	be	
a	 protein	 abundant	 in	 the	myocardium	with	minimal	 or	 absence	 of	 expression	 in	
non-cardiac	tissues,	be	released	and	detectable	in	blood	stream,	be	stable	enough	
for	detection	and	be	assayed	in	quick	and	cost-effective	method.		
	
1.6.1	Troponin-	I	
Troponin	is	a	three	part	structural	protein	involved	in	the	calcium	mediated	muscle	
contraction	 of	 the	myocyte.	 It	 is	made	 up	 of	 the	 calcium	binding	 troponin	 C,	 the	
inhibitory	(Cardiac	Troponin	I)	cTnI	(23	kDa)	and	the	tropomyosin	binding	Troponin	
T	(37kDa).	Current	assays	are	cardiospecific	and	targeted	at	the	cardiac	isoforms	of	
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Troponin	 I	 and	 T.	 During	 development	 of	 myocardial	 ischaemia,	 the	 troponin	
subunits	 are	 released	 from	 the	 contractile	 apparatus	 and	 leak	 through	 the	 cell	
membrane,	 reaching	 peak	 concentrations	 in	 the	 serum	 around	 6	 hours	 (35).	 The	
advent	of	ultra-sensitive	troponin	measurement	platforms	has	changed	the	clinical	
utility	of	troponin	significantly.	Due	to	their	much	lower	limits	of	detection,	AMI	in	
patients	with	chest	pain	can	be	ruled	out	through	serial	measurements	at	6	hours.	A	
serum	 concentration	 of	 less	 than	manufacturers	 reference	 value	 followed	by	 less	
than	50	%	 increase	on	a	 serial	measurement	6	hours	 later	 is	 considered	 to	be	an	
exclusion	for	AMI(36).	Studies	have	also	demonstrated	its	prognostic	value	in	other	
conditions	including	pulmonary	emboli	(PE),	sepsis	and	in	the	perioperative	setting	
(37).		
	
The	 development	 of	 right	 ventricular	 strain	 and	 cardiac	 dysfunction	 is	 a	 poor	
prognostic	indicator	in	patients	with	pulmonary	embolism.	Raised	cTnI	levels	in	PE	
has	 been	 associated	 with	 cardiac	 dysfunction,	 increased	 rates	 of	 serious	 adverse	
event	 (SAE)	 and	 mortality	 (38,39).	 Identifying	 these	 patients	 for	 prompt	
thrombolysis	has	been	suggested	for	improving	patient	outcomes	(Beccattini	2007).		
	
In	 sepsis,	 system	 inflammatory	 response	 syndrome	 (SIRS)	 and	 its	 associated	
hypotension,	hypoperfusion	and	tachycardia	have	all	been	 indicated	to	contribute	
to	 increased	myocardial	 stress(8).	 In	 line	 with	 this,	 SIRS	 has	 also	 been	 shown	 to	
induce	reversible	as	well	as	irreversible	cardiac	dysfunction	(6).		Furthermore,	cTnI	
has	been	shown	to	be	higher	in	patients	admitted	to	intensive	care		unit	(ICU)	with	
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septic	 shock,	 and	 correlates	 with	 left	 ventricle	 (LV)	 dysfunction	 and	 associated	
poorer	outcomes	(40-43).	A	meta-analysis	of	162	studies	on	the	predictive	value	of	
cTnI	 on	 mortality	 in	 septic	 patients	 revealed	 that	 raised	 cTnI	 concentration	 was	
associated	with	a	two-fold	increase	in	mortality,	however,	it	was	not	found	to	be	an	
independent	 factor	 (44).	 It	 calculated	 the	 pooled	 area	 under	 the	 curve	 (AUC)	 on	
receiver	operating	characteristic	(ROC)	analysis	as	0.68	indicating	that	cTnI	is	a	good	
predictor	of	mortality	in	septic	patients.	In	these	studies,	the	manufacturers	guided	
the	serum	concentration	threshold	for	cardiac	injury	(44).		
	
The	myocardium	 is	 exposed	 to	multiple	 deleterious	 factors	 during	 critical	 illness.	
Hypotension,	 hypoperfusion,	 fluid	 overload,	 circulating	 cytokines	 and	 tachycardia	
may	all	be	experienced	by	trauma	patients,	and	can	increase	the	myocardial	oxygen	
requirements	of	critically	 ill	patients.	Patients	admitted	to	 ICU	have	demonstrated	
higher	levels	of	cTnI	indicative	of	myocardial	injury		
(41,45,46).	 	 This	 underlying	 cardiac	 injury	 as	 indicated	 by	 the	 rise	 in	 serum	 cTnI	
levels	does	not	always	manifest	clinically,	yet	it	is	associated	with	worse	outcomes	
such	as	increased	requirements	for	organ	support,	longer	hospital	stays	and	greater	
mortality	(45).		
	
1.6.2	Brain	Type	Natriuretic		Peptide	
Brain	 type	 natriuretic	 peptide	 (BNP)	 is	 a	 37	 kDa	 cardiac	 neurohormone	 that	 is	
systhesised	 in	 the	 ventricular	 myocardium	 and	 secreted	 into	 the	 bloodstream	 in	
response	to	myocardial	stretch.	Stretch	stimuli	leads	to	an	immediate	increase	in	its	
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expression	and	its	release	as	a	prohormone	(pro-BNP),	this	 is	then	cleaved	into	its	
active	form	BNP	and	inactive	form	NT-proBNP.	The	inactive	form	NT-proBNP	has	a	
longer	 half-life	 and	 therefore	 remains	 in	 the	 bloodstream	 longer	 than	 BNP.	 The	
active	 BNP	 	 acts	 on	 natriuresis,	 smooth	 muscle	 relaxation,	 inhibition	 of	 renin-
angiotensin	 system	 and	 inhibition	 of	 sympathetic	 activity(47).	 BNP	 has	 been	
primarily	used	 in	the	diagnosis	of	acute	and	chronic	heart	 failure	(48).	 It	has	been	
shown	to	be	useful	in	the	prognostication	in	AMI,	with	higher	levels	associated	with	
greater	 ischaemic	 insult	 and	 left	 ventricular	 dysfunction	 (49,50).	 It	 has	 also	 been	
shown	to	predict	postoperative	MI,	cardiovascular	mortality	and	overall	mortality	in	
elective	patient	(51).		
	
The	 increase	 in	pulmonary	 venous	pressure	 in	PE	 leads	 to	 raised	 right	 ventricular	
pressure	 causing	 to	myocardial	 stretch.	Multiple	 prospective	 studies	 have	 shown	
that	nt-proBNP	correlates	well	with	the	development	of	serious	adverse	events	 in	
PE	 (39,52-57).	 A	meta-analysis	 of	 studies	 investigating	nt-proBNP	 in	 PE	 found	 the	
combined	 OR	 for	 mortality	 to	 be	 6.2	 (58).	 Higher	 levels	 were	 associated	 with	
increased	 rates	 of	 inotropic	 support,	 intubation	 and	 mortality.	 In	 a	 prospective	
study	 of	 113	 patients	 with	 PE,	 nt-proBNP	 was	 almost	 six	 times	 higher	 at	 10,678	
ng/ml	in	the	non-survivors	compared	to	1895	in	the	survivors.		A	persistently	raised	
nt-proBNP	 level,	 with	 circulating	 concentrations	 of	 >7500	 ng/ml	 that	 remained	
raised	at	24	hours	was	 found	 to	be	 the	 strongest	predictor	of	mortality	 (56).	 The	
same	 research	 group	went	on	 to	 compare	 the	 efficacy	of	 nt-proBNP	and	 cTnI	 for	
risk	 stratification	 of	 normotensive	 patients.	 In	 their	 risk	 stratification	model,	 they	
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found	 that	 patients	 with	 nt-proBNP	 of	 <600ng/ml	 did	 not	 develop	 any	 serious	
adverse	events	(SAE)	and	therefore	could	potentially	be	managed	less	aggressively	
(59).		
	
In	 sepsis,	 an	 increase	 in	 serum	 BNP	 levels	 has	 been	 associated	 with	
echocardiographic	changes	of	reversible	and	sustained	cardiac	dysfunction	(60)	(11)	
(61)	(11,60,61).	Raised	BNP	levels	 leads	to	an	8-fold	 increase	 in	mortality	 in	septic	
patients(62).		It	was	noted	to	be	a	moderate	predictor	of	mortality	in	sepsis	with	a	
AUC	 of	 0.65	 on	 ROC	 analysis.	 These	 raised	 BNP	 levels	 used	 in	 combination	 with	
clinical	acumen	could	help	delineate	patients	at	greater	risk	of	adverse	outcomes.	
These	 results	 have	 also	 been	 reproduced	 in	 the	 general	 critical	 care	 patient	
population	(63,64).		
	
1.6.3	Heart	Related	Fatty	Acid	Binding	Protein	(h-FABP)	
Heart	 related	 fatty	 acid	 binding	 protein	 (h-FABP)	 is	 a	 relatively	 new	 cardiac	
biomarker;	 first	 discovered	 as	 a	marker	 of	myocardial	 injury	 in	 1988.	 It	 is	 a	 small	
14kDa	 cytosolic	 protein	 that	 acts	 a	 transporter	 of	 fatty	 acids	 from	 the	 cell	
membrane	to	the	mitochondria	for	oxidation.	 It	 is	released	as	early	as	90	minutes	
post	 myocardial	 ischaemia,	 reaching	 peak	 concentrations	 within	 the	 plasma	 at	 6	
hours.	Values	of	6-7	ng/ml	are	considered	to	be	indicative	of	cardiac	ischaemia.	In	
AMI,	it	has	been	shown	to	exhibit	greater	sensitivity	in	comparison	to	troponin	with	
a	better	negative	predictive	value,	however	due	 to	 its	 lack	of	 specificity,	 troponin	
remains	the	gold	standard	for	the	diagnosis	of	AMI.	Furthermore,	Cardiac	TnI	was	
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superior	at	predicting	AMI	in	patients	presenting	with	chest	pain	in	comparison	to	
h-FABP	(AUC	on	ROC	analysis	0.82	vs.	0.78).	However,	due	to	its	greater	sensitivity,	
h-FABP	had	a	better	negative	predictive	value	but	this	made	it	lower	specificity	(65).	
The	 lower	 specificity	 may	 be	 owed	 to	 its	 expression	 in	 other	 tissues	 including	
skeletal,	brain,	lung	and	kidney,	albeit	in	much	lower	concentrations(66).	The	role	of	
h-FABP	has	been	investigated	in	prognostication	of	acute	coronary	syndrome	(ACS)	
and	has	been	shown	to	be	effective	in	predicting	adverse	cardiac	events	and	death	
(67-69).		
	
Similarly	to	cTnI	and	BNP,	h-FABP	has	also	been	shown	to	be	a	potentially	valuable	
tool	 in	 prognostication.	 In	 PE,	 it	 has	 been	 shown	 to	 be	 raised	 in	 patients	 who	
develop	adverse	outcomes	and	those	who	die	within	30	days	of	admission	(70-73).	
Raised	 h-FABP	 levels	 on	 admission	 was	 related	 with	 a	 17-fold	 increased	 risk	 of	
developing	adverse	outcomes	and	33-fold	risk	of	mortality	(74).		Higher	levels	of	h-
FABP	 were	 also	 associated	 with	 right	 ventricular	 dysfunction	 as	 seen	 on	 echo	
cardiogram(70,71).	In	a	meta-analysis	comparing	the	three	biomarkers,	h-FABP	was	
shown	to	have	a	greater	propensity	for	predicting	adverse	outcomes	and	mortality	
in	PE	in	comparison	to	troponin	and	BNP	(75,76).	A	retrospective	analysis	of	h-FABP	
levels	 in	 intermediate	 risk	 PE	 patients,	 thrombolysed	 according	 to	 current	
guidelines,	 did	 not	 show	better	 outcomes	 between	 the	 groups	who	were	 h-FABP	
positive	and	those	who	were	not	(77).	In	combination	with	clinical	acumen,	its	value	
mostly	lies	in	ruling	out	those	at	low	risk,	rather	than	guiding	treatment.		
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In	 sepsis,	 h-FABP	 levels	 on	 admission	 to	 critical	 care	 units	 (CCU)	 predict	
development	of	organ	dysfunction	and	mortality	with	greater	 accuracy	 than	 cTnI.	
Patients	 with	 higher	 h-FABP	 levels	 required	 earlier	 mechanical	 ventilation	 and	
inotropic	 support	 (78).	 There	 was	 no	 difference	 in	 h-FABP	 levels	 In	 those	 who	
required	 organ	 support	 overall	 (78,79).	 In	 an	 emergency	 department	 setting,	 a	
study	of	99	patients	with	severe	sepsis	showed	h-FABP	levels	to	be	predictive	of	ICU	
admission	(80).	Due	to	the	differential	distribution	of	h-FABP	in	other	tissues,	it	has	
been	postulated	as	a	marker	of	global	ischaemia	in	critical	 illness,	however	due	its	
low	expression	in	other	tissues,	it	may	only	be	an	indirect	marker	(78).		
	
1.6.4	Cardiac	biomarkers	in	trauma	
1.6.4.1	Troponin	in	Trauma	
Cardiac	biomarkers	have	been	used	to	evaluate	direct	and	indirect	cardiac	injury	in	
trauma	patients.	 In	2012,	Eastern	Association	for	the	Surgery	of	Trauma	published	
guidelines	on	blunt	cardiac	injury	which	included	diagnosis	and	management	based	
on	 clinical	 suspicion,	 ECG	 changes	 and	 cTnI	 levels.	 On	 review	 of	 the	 current	
evidence,	 they	 recommend	 that	blunt	 cardiac	 injury	 (BCI)	 can	be	 ruled	out	 if	 ECG	
and	troponin	I	are	normal.	In	studies	that	looked	at	BCI,	cTnI	levels	of	1.05-	2ng/ml	
were	 found	 to	 have	 good	 predictive	 value	 of	 cardiac	 injury	 and	 were	 therefore	
suggested	as	a	prognostic	marker	to	guide	the	monitoring	requirements	of	trauma	
patients	(81-83).		
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In	a	large	study	of	728	patients,	Edouard	et	al.,	demonstrated	that	cTnI	was	raised	
in	12%	of	their	trauma	population	unrelated	to	blunt	cardiac	contusion.	In	the	cTnI	
positive	 group,	 8%	 were	 due	 to	 underlying	 coronary	 artery	 disease.	 In	 the	 cTnI	
patients	without	pre-existing	co-morbidities,	there	was	a	29%	mortality	rate	within	
the	first	48	hours	compared	to	3%	in	the	cTnI	negative	group.	On	subgroup	analysis,	
release	of	cTnI,	was	found	to	be	associated	with	chest	and	head	injury.	
	
In	a	study	of	89	patients	with	mild	trauma,	 it	was	shown	that	patients	with	raised	
troponin	 I	 levels	 were	more	 likely	 to	 develop	 cardiac	 complications	 unrelated	 to	
pre-existing	cardiac	comorbidities.	However,	the	nature	of	the	patients’	injuries	and	
particularly	the	presence	of	chest	injuries	was	not	explored	in	this	study	(84).		
	
In	 a	 large	 retrospective	 study	 of	 trauma	 patients	 to	 identify	 risk	 factors	 for	 the	
development	of	cardiac	injury	in	trauma	patients	who	develop	sepsis,	patients	who	
had	 troponin	measurements	 during	 their	 admission	were	 identified.	 The	 study	 of	
this	 population	 revealed	 that	 a	 pre-existing	 diagnosis	 of	 chronic	 obstruction	
pulmonary	disease	(COPD),	injury	severity,	ventilator	acquire	pneumonia	(VAP)	and	
urinary	 tract	 infection	 (UTI)	 were	 all	 risk	 factors	 for	 the	 development	 of	 indirect	
cardiac	 injury	 in	 these	patients.	When	 the	hazard	 ratio	was	 adjusted	 for	 age,	UTI	
posed	a	greater	risk	in	those	above	the	age	of	8.	Due	to	the	retrospective	nature	of	
the	study,	not	all	patients	had	troponin	ordered,	only	those	that	at	the	time	were	
deemed	to	have	signs	of	cardiac	ischaemia	(85)	
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In	a	paediatric	study	looking	at	direct	cardiac	injury,	27%	of	the	patients	had	raised	
cTnI	but	none	of	these	patients	had	abnormal	ECGs	and	25%	had	changes	on	ECG,	
however,	 they	 did	 go	 on	 to	 have	 higher	 rates	 of	mortality.	 Their	 raised	 troponin	
levels	were	related	to	a	greater	degree	of	hypotension	and	the	group	hypothesised	
that	this	may	have	been	an	indicator	of	global	hypoperfusion	leading	to	myocardial	
ischaemia	rather	than	direct	injury	(86).		
1.6.4.2	BNP	in	Trauma	
In	a	 small	prospective	 study	of	26	patients,	nt-ProBNP	was	 shown	 to	be	 raised	 in	
critically	 injured	 patients	 and	 correlated	 with	 MODs	 and	 a	 reduction	 in	 cardiac	
index.	Although,	this	study	did	not	comment	on	role	of	direct	mechanical	 injury	in	
the	release	of	BNP,	all	of	the	patients	had	significant	thoracic	injuries	(87).		
	
Firese	et	al,	conducted	a	prospective	study	on	134	trauma	patients	which	showed	
that	BNP	levels	rose	with	fluid	resuscitation	and	was	higher	in	those	who	went	on	to	
develop	pulmonary	oedema.	However,	the	serum	levels	did	not	cross	the	threshold	
of	100	pg/ml	seen	with	ACS	 (88).	Surprisingly,	 the	volume	of	 fluid	 infused	did	not	
correlate	with	BNP	levels,	which	was	further	corroborated	by	a	smaller	study	where	
the	degree	of	haemorrhage	nor	the	volume	of	fluid	used	in	resuscitation	correlated	
with	BNP	levels.	(88,89).		
	
A	further	study	by	Friese’s	group	in	2010	also	demonstrated	that	an	increase	in	BNP	
>75ng/ml	over	24	hours	was	predictive	of	the	need	for	mechanical	ventilation	(90).	
On	investigating	the	prognostic	value	of	BNP	in	trauma,	Stewart	et	al.	demonstrated	
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that	 BNP	 did	 not	 correlate	with	 LV	 ejection	 fraction	 (LVEF),	 length	 of	 ICU	 stay	 or	
hospital	stay.	Patients	who	had	evidence	of	LV	dysfunction	on	echocardiogram	did	
not	have	higher	levels	of	BNP	(91).		
1.6.4.3	H-FABP	in	Trauma	
Due	to	the	relative	novelty	of	H-FABP,	its	use	in	trauma	studies	has	been	limited.	In	
a	prospective	study	of	55	poly	 trauma	patients	with	direct	 thoracic	 injury,	h-FABP	
levels	were	higher	in	patients	with	thoracic	injuries	but	not	in	patients	with	cardiac	
injury.	 However,	 the	 author	 does	 not	 clarify	 how	 cardiac	 injury	 was	 defined,	
especially	only	41%	of	patients	had	abnormalities	on	ECG	or	echocardiograms	(92).	
The	use	of	h-FABP	as	a	cardiac	biomarker	will	be	confounded	by	 its	expression	 in	
brain	 tissue.	 In	 a	 small	 but	 insightful	 study	 conducted	 by	walder	 et	 al,	 they	 shed	
some	 light	on	 the	 contribution	of	 traumatic	brain	 injury	 (TBI)	 to	 the	 release	of	h-
FABP.	 In	 this	 prospective	 study	 of	 45	 patients,	 although,	 h-FABP	was	 elevated	 in	
both	the	isolated	TBI	as	well	as	TBI	associated	with	polytrauma,	the	levels	were	1.5	
higher	in	the	polytrauma	group	at	6	hours,	3	times	higher	at	24	hours	and	4	times	
higher	at	48	hours.	Furthermore,	 the	presence	of	concurrent	cardiac	complication	
in	 the	 isolated	 head	 injury	 group	 was	 not	 explored	 in	 this	 study	 (93).	 This	
differential	 rise	 in	H-FABP	 in	 addition	 to	 clinical	 signs,	 ECGs	 and	 echocardiogram,	
lend	to	its	potential	usefulness	as	an	early	cardiac	biomarker	in	trauma.	
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1.7	Catecholamines	and	Adverse	Cardiac	Events	
	
The	 stresses	 of	 events	 preceding	 traumatic	 injury	 in	 combination	with	 the	 severe	
injuries	sustained	by	trauma	patients	evoke	a	significant	sympathetic	response	and	
therefore	 a	 catecholamine	 surge.	 In	 this	 study,	 the	 cardiac	 effects	 of	 the	
catecholamines	 release	 will	 be	 explored.	 Similar	 studies	 in	 septic	 patients	 have	
shown	 raised	 catecholamine	 levels.	 The	 adrenergic	 response	 in	 severe	 sepsis	 has	
been	shown	to	induce	myocardial	cell	necrosis	and	changes	to	intracellular	calcium	
concentration.	Intracellular	calcium	depletion	secondary	to	increased	cellular	stress	
causes	disruption	to	the	mitochondrial	activity	and	leads	to	apoptosis	and	necrosis.	
(8,94).	In	patients	with	subarachnoid	haemorrhage,	catecholamine	surge	associated	
with	significant	injury	has	been	noted	to	lead	to	cardiac	injury	and	dysfunction	(95)	
with	evidence	for	pre-hospital	beta-blockade	showing	mixed	outcomes	(96-99).	
1.8	Pathological	changes	in	the	Myocardium	following	trauma	
haemorrhage	
	
Forensic	 pathologists	 have	 expressed	 academic	 interest	 in	 histological	 changes	 of	
the	 myocardium	 following	 trauma	 for	 decades.	 In	 1980,	 a	 case	 series	 of	 the	
postmortem	 histological	 examination	 of	 15	 homicidal	 victims	was	 published.	 This	
showed	 myofibrillar	 degeneration	 in	 11	 of	 the	 15	 patients	 which	 the	 authors	
attributed	to	stress	induced	catecholamine	release	(100).		In	a	further	postmortem	
study	 of	 24	 trauma	 patients,	 myocardial	 histology	 revealed	 the	 presence	 of	
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contraction	bands,	myofibrillar	fragmentation	and	positive	staining	for	calmodulin,	
used	as	a	marker	of	early	ischaemia	(101).		
More	 recently,	 a	 large	 human	 study	 looking	 at	 histological	 changes	 of	 the	
myocardium	 in	 trauma	 patient	 hearts	 postmortem	 has	 demonstrated	 both	
macroscopic	 as	 well	 as	 microscopic	 architectural	 changes.	 Examination	 of	 the	
myocardium	of	125	trauma	patients	demonstrated	a	variety	of	histological	changes	
in	 keeping	 with	 ischaemia	 and	 necrosis	 including	 congestion,	 interstitial	 edema,	
fragmentation	 of	 myocytes,	 haemorrhage,	 leukocytic	 infiltration,	 coagulative	
necrosis,	 hyaline	 degeneration	 of	 myocytes,	 cytoplasmic	 vacuolation,	
collagenisation	 of	 myofibers,	 hypertrophy	 of	 few	 myocytes	 and	 focal	 mild	
interstitial	fibrosis.	However,	It	is	difficult	to	assign	causality,	as	the	effect	of	mode	
of	death	and	pattern	of	injury	was	not	analysed	alongside	the	histological	changes	
(102).	Regardless,	this	is	an	impressive	study	and	the	first	of	its	kind	to	provide	such	
large	amounts	of	histological	data	on	the	effect	of	trauma	on	the	human	hearts.		
Animal	 studies	 have	 demonstrated	 that	 traumatic	 injury	 leads	 to	 cardiomyocyte	
apoptosis(103,104)	 (103);	 (104).	 Mechanistic	 studies	 have	 elucidated	 a	 TNF-α	
driven,	 caspase	 dependent	 pathway	 as	 the	 cause	 for	 this	 myocardial	 apoptosis	
(103).	In	rat	models,	2	hours	of	TH	has	been	shown	to	be	associated	with	increased	
expression	 of	 the	 pro-apoptotic	 protein	 Bax	 and	 reduction	 of	 the	 anti-apoptotic	
protein	 Bcl-2,	 leading	 to	 increased	 cardiomyocyte	 apoptosis	 as	 seen	 on	 H&E.	
Furthermore,	this	correlate	with	creatine	kinase	(CK)	and	lactate	hydrogenase	(LDH)	
as	biomarkers	of	cardiac	injury.	This	study	also	demonstrated	that	administration	of	
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hydrogen	sulfide,	a	regulator	of	mitochondrial	transition	pore	opening,	reduced	the	
deleterious	effects	of	TH	serum	(104).	The	involvement	of	the	mitochondria	in	the	
reduction	of	 cardiac	 function	was	 corroborated	by	 a	murine	 study	demonstrating	
concurrent	 reduction	 in	 mitochondrial	 function	 with	 reduced	 adenosine	
triphosphate	 (ATP)	 production,	 reduced	 expression	 of	 mitochondrial	 respiratory	
complex	 (MRC)	 proteins,	 increased	 release	 of	 cytochrome	 C	 into	 the	 cytosol	 and	
increased	caspase-3	cleavage	(105).	
Ischaemic	 injury	of	 the	heart	has	been	associated	with	myocardial	necrosis	 (106).	
More	 recently,	 the	 processes	 that	 define	 different	 cell	 death	 mechanisms	 have	
been	noted	 to	cross	over	 (107).	 	Although,	 there	has	been	 interesting	 insight	 into	
cardiac	 dysfunction	 and	 cell	 death,	 we	 are	 still	 unclear	 as	 to	 what	 pathways	 are	
involved.	
1.9	Cell	Death	Pathways	
	
The	 release	 of	 cardiac	 structural	 proteins	 such	 as	 cTnI	 and	 h-FABP	 requires	
disruption	 of	 the	 cellular	membrane.	 Tissue	 injury	 releases	 damaged	 deoxyribose	
nucleic	acid	(DNA),	toxins	and	 inflammatory	proteins.	These	can	all	act	directly	on	
the	cell,	potentially	disrupting	its	membrane,	leading	to	necrosis	or	initiation	of	cell	
death	via	the	extrinsic	or	intrinsic	pathways	of	apoptosis.	
	
A	cell	is	considered	dead	if	it	has	undergone	irreversible	permeabilisation	of	its	cell	
membrane	 and	 complete	 fragmentation.	 Although,	 historically,	 cell	 death	 was	
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thought	to	occur	either	by	necrosis	or	apoptosis,	 it	has	become	apparent	that	the	
fate	 of	 a	 dying	 cell	 is	 not	 so	 binary	 in	 nature.	 It	 can	 however,	 be	 divided	 into	
accidental	 cell	 death	 and	 programmed	 cell	 death.	 Accidental	 cell	 death	 occurs	
following	 significant	 direct	 exposure	 to	 severe	 adverse	 conditions	 such	 as	 toxins,	
chemicals,	temperature	or	mechanical	 injury.	The	noxious	 insult	 itself	 leads	to	cell	
membrane	lysis,	hence	oedema	of	cell	organelles.	The	pathway	of	the	programmed	
cell	death	processes	and	the	final	 fate	of	 the	cell	 is	dependent	on	the	trigger,	 the	
initial	site	of	activation	and	concurrent	activation	of	other	pathways.	The	pathways	
are	not	always	linear	with	many	points	of	cross	talk	{Galluzzi:kj}.	
1.9.1	Apoptosis	
Apoptosis	described	as	a	programmed	cell	death	mechanism	 is	 thought	 to	 reduce	
collateral	 damage	 by	 the	 formation	 of	 apoptosomes,	 which	 are	 then	 cleared	 by	
phagocytosis.	On	electron	microscopy,	apoptosis	 is	characterised	by	deep	staining	
of	 the	nuclear	mass	 (pyknosis)	and	 formation	of	 condensed	cell	bodies	 (apoptotic	
bodies).	 Apoptosis	 can	 be	 further	 differentiated	 to	 death	 receptor	 driven	
(extrinisic/type	I)	or	mitochondria	driven	(intrinsic/type	II).		
1.9.2	Extrinsic	Death	Receptor	Pathway	
The	 extrinsic	 pathways	 are	 dependent	 on	 activation	 of	 death	 domain	 containing	
receptors.	 The	 two	 well-studied	 receptors	 are	 Fas	 Ligand	 receptor	 and	 TNF	
Receptor	(TNFR).	The	activation	of	these	receptors	leads	to	cleavage	of	procaspase	
8	 to	 caspase	 8,	 and	 in	 turn	 the	 activation	 of	 caspase	 3	 and	 7	 and	 thereon	 the	
proteolytic	cleavage	of	proteins	which	leads	to	apoptosis	(106).	TNFα	upregulation	
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is	well	reported	in	trauma	so	extrinsic	pathways	of	apoptosis	may	well	be	at	play.	In	
vitro	 studies	 have	 shows	 that	 TNFα	 antagonism	 reduces	 cell	 death	 in	
cardiomyocytes	incubated	in	trauma	serum	(103).			
	
	
Figure	1.2	Schematic	diagram	of	the	extrinsic	pathway	of	apoptosis	highlighting	Fas	
and	TNF	receptor	signaling	and	associated	downstream	players	(107)	
	
1.9.3	Intrinsic	Cell	Death	Pathways		
The	 intrinsic	 cell	 death	 pathways	 are	 initiated	 by	 a	 combination	 of	 external	 and	
internal	 stimuli.	 A	 delicate	 balance	 of	 pro-apoptotic	 and	 anti-apoptotic	 the	 Bcl-2	
proteins	 govern	 the	 intrinsic	 pathways.	 Under	 physiological	 conditions,	 the	 anti-
apoptotic	proteins	of	the	family	maintain	the	integrity	of	the	mitochondria.	Noxious	
external	 stimuli	 and	metabolic	disturbance	within	 the	 cell,	 for	example	 release	of	
reactive	oxygen	species	(ROS)	or	excess	calcium,	leads	to	activation	of	BH3	proteins	
and	 its	 subsequent	 its	 translocation	 from	 the	mitochondria	 to	 the	 cytosol.	 In	 the	
cytosol,	 BH3	 proteins	 act	 to	 either	 directly	 antagonise	 pro-apoptotic	 proteins	 or	
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activate	 the	 apoptotic	 proteins	 Bax	 and	 Bak.	 Activated	 Bax	 and	 Bak	 oligomerise,	
leading	to	their	conformational	change	and	insertion	in	to	the	outer	mitochondrial	
membrane	where	they	form	pores.	The	changes	in	mitochondrial	permeability	and	
concurrent	membrane	potential	can	lead	to	three	outcomes;	influx	of	calcium	and	
ROS	 into	 the	 cell	 directly	 leading	 to	 necrosis,	 release	 of	 cytochrome	 C	 causing	
induction	 of	 apoptosis	 through	 caspase	 9	 dependent	 pathways,	 or	 the	 release	 of	
caspase	 independent	 death-	 associated	 protein	 AIF-1	 (Apoptosis	 inducing	 factor	
1)(106).		
	
Figure	1.3	Schematic	diagram	of	the	intrinsic	pathways	of	apoptosis	demonstrating	
the	central	role	of	the	mitochondria	in	inducing	cell	death(107)	
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In	trauma	as	described	above,	the	sequelae	of	events	following	the	initial	impact	of	
the	 injury	 occur	 due	 to	 bleeding	 and	 tissue	 damage.	 Significant	 bleeding	 leads	 to	
poor	 perfusion,	 hypoxia,	 anaerobic	 respiration	 and	 acidosis,	which	 can	 all	 lead	 to	
the	 activation	 of	 the	 intrinsic	 pathway.	 The	 role	 of	 Bcl-2	 has	 been	 highlighted	 in	
improving	 immune	 cell	 survival	 in	 trauma	 haemorrhage	 and	 in	 apoptosis	 in	
haemorrhagic	shock	(108).	In	a	small	clinical	study,	Bcl-2	was	seen	to	rise	by	50%	on	
the	second	day	in	comparison	to	admission	and	was	related	to	increased	infection	
rates	(109)	
1.9.4	Apoptosis	Inducing	Factor	
Apoptosis	 inducing	 factor	 (AIF)	 is	 a	 mitochondrial	 flavoprotein	 that	 exists	 in	 the	
intermembrane	space	attached	to	the	mitochondrial	inner	membrane.	The	nuclear	
coded	 AIF	 gene	 gives	 rise	 to	 a	 67kDa	 protein	 with	 a	 mitochondrial	 localization	
sequence.	 Maturation	 of	 the	 precursor	 leads	 to	 the	 cleavage	 of	 mitochondrial	
localization	 sequence	 (MLS)	 and	 its	 attachment	 to	 the	 mitochondrial	 inner	
membrane.	Apoptotic	signaling	 leads	to	 its	 further	proteolytic	cleavage	causing	 its	
release	from	the	mitochondrial	 inner	membrane	in	its	57	kDa	truncated	form.	The	
activation	of	the	intrinsic	cell	death	pathway	by	Bcl-2	related	proteins	leads	to	the	
permeabilisation	of	 the	mitochondrial	outer	membrane	 releasing	 the	apoptogenic	
AIF	 into	 the	 cytosol,	 which	 then	 translocates	 to	 the	 nucleus	 where	 it	 leads	 to	
peripheral	 chromatin	 condensation,	 DNA	 fragmentation	 and	 blebbing	 associated	
with	 irregular	 shaped	 nuclei.	 Susin	 et	 al	 demonstrated	 these	 characteristic	
apoptotic	 nuclear	 changes	 in	 healthy	 heLA	 cell	 nuclei	 incubated	 in	 medium	
containing	 AIF	 (110).	 Although	 apoptosis	 occurred	 in	 the	 absence	 of	 cytosolic	
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proteins,	once	 the	nuclei	was	heat	 treated,	 the	apoptotic	changes	were	not	seen,	
suggesting	the	need	for	nuclear	proteases	to	aid	AIF	in	its	apoptogenic	actions.		
1.10	Rationale	for	Research	
	
	The	retrospective	studies	conducted	by	De’Ath	in	addition	to	the	previous	studies	
showing	the	prognostic	value	of	cTnI,	BNP	and	h-FABP	 in	 traumatic	 injury	provide	
good	 founding	evidence	 for	 the	presence	of	myocardial	 injury	 in	 traumatic	 injury.	
Through	prospective	design	and	analysis,	 the	objective	of	work	 in	 this	 thesis	 is	 to	
further	investigate	the	pattern	of	cardiac	injury	and	try	to	delineate	its	causes	and	
underlying	mechanisms	driving	these	effects.	
		
Cardiac	biomarker	detection	 in	 trauma	patients	 is	complicated	by	the	presence	of	
multiple	 organ	 injury,	 tissue	 injury	 and	 hypoperfusion.	 In	 order	 to	 explore	 the	
impact	of	trauma	directly	on	cardiac	tissues,	a	murine	model	of	trauma	will	be	used	
to	 allow	 direct	 examination	 of	 cardiac	 tissue	 following	 trauma	 haemorrhage	
through	the	use	of	microscopy	and	protein	analysis.	
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1.11	Study	Aims	
	
The	 overarching	 goal	 of	 this	 thesis	 is	 to	 further	 the	 understanding	 of	 trauma	
induced	secondary	cardiac	injury	(TISCI).	For	this	purpose,	this	study	aims	to:	
1. Describe	 the	 clinical	 manifestations	 of	 TISCI,	 potential	 risk	 factors	 and	 its	
effect	on	outcomes	
2. Identify	potentialbiomarkers	of	TISCI	
3. Determine	 whether	 there	 is	 a	 potential	 role	 for	 catecholamines	 in	 the	
pathogenesis	of	TISCI	
4. Determine	the	cellular	mechanisms	driving	myocardial	injury	in	TISCI	
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2.1	Introduction	
	
This	 chapter	 summarises	 the	 materials	 and	 methods	 used	 in	 Chapters	 3-5.	 The	
clinical	 study	 methodologies	 apply	 to	 bother	 chapters	 3	 and	 4	 as	 well	 as	 the	
principles	of	enzyme-linked	immunoassays	(ELISA).	It	is	presented	separately	rather	
than	within	each	chapters	for	ease	of	reference	and	to	avoid	repetition.	Chemicals	
and	 reagents	 used	 throughout	 the	 thesis	 are	 listed	 in	 this	 chapter,	 alongside	 the	
manufacturer	and	catalogue	number.	All	were	of	biological	or	analytical	quality.		
2.2	Prospective	Observational	Study-	TACID	
	
Following	a	retrospective	review	of	patients,	which	demonstrated	a	rise	 in	cardiac	
biomarkers,	 and	 an	 increased	 incidence	 of	 cardiac	 events,	 Trauma	 Associated	
Cardiac	Injury	and	Death	(TACID)	was	designed	to	prospectively	validate	this.		
2.2.1	Study	Design	
TACID	was	designed	as	a	single	centre,	prospective,	observational	cohort	study	
performed	at	Royal	London	Hospital,	a	major,	level	I,	urban	trauma	centre	in	the	
United	Kingdom.	
	
The	 study	 was	 reviewed	 and	 approved	 by	 the	 Cambridge	 3	 Research	 Ethics	
Committee.	(Reference	No.	10/H0306/47)	
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2.2.2	Study	Population	
All	 adult	 patients	 above	 aged	 16	 and	 above,	 who	 triggered	 the	 trauma	 team	
activation	 and	 presented	 with	 an	 abnormal	 primary	 survey	 were	 screened	 for	
recruitment	 in	 the	 study.	 Patients	 were	 assessed	 by	 research	 personnel	 and	
enrolled	between	the	hours	of	8:00	and	20:00	if	found	to	have	an	abnormal	primary	
survey.		
Exclusion	criteria	were:	
• Patients	<	16	years	of	age	
• Patients	transferred	from	other	hospitals	
• Patients	not	expected	to	survive	>	72	hours	
• Pregnant	
• Prisoners		
• Penetrating	cardiac	injuries	
• Trauma	team	leader	deemed	recruitment	inappropriate	
• Patients	 were	 retrospectively	 excluded	 if	 they	 or	 a	 personal	 consultee	
declined	to	give	consent	for	the	research	study	
2.2.3.	Consent		
Due	 to	 the	 severity	 of	 their	 injuries	 most	 of	 our	 patients	 are	 incapacitated	 on	
admission.	A	system	approved	by	the	research	ethics	committee	was	established	in	
order	to	gain	consent	for	the	recruitment	of	these	patients	in	this	study.		
On	admission,	the	emergency	department	(ED)	consultants	who	were	familiar,	but	
independent	to,	the	study	act	as	the	patients’	advocate	and	the	Professional	Legally	
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Appointed	Representative	(PLAR).	Once	consent	is	granted	by	the	PLAR	the	patient	
can	be	ethically	recruited	to	the	study,	and	subject	personal	(next	of	kin)	or	patient	
consent	can	then	be	sought	retrospectively	 in	a	time	dependent	manner.	Patients	
are	assessed	daily	to	determine	if	they	have	capacity.	If	the	patient	is	not	deemed	
to	have	capacity,	consent	 is	sought	from	their	next	of	kin	who	act	as	the	patient’s	
legally	authorised	representative	(LAR).		
Patients	and	their	next	of	kin	are	provided	with	detailed	study	 information	sheets	
and	approached	after	allowing	time	for	them	to	consider	their	 involvement	 in	the	
study.	The	patient	 is	withdrawn	from	the	study	 if	either	the	patient	or	next	of	kin	
refused	consent.	If	the	patient	is	permanently	incapacitated	they	are	able	to	remain	
in	 the	 study	 under	 LAR	 consent.	 Patient	 who	 die	 acutely	 or	 prior	 to	 receipt	 of	
appropriate	LAR	consent	from	a	next	of	kin	can	remain	enrolled	in	the	study	under	
PLAR	 consent.	 A	 database	 logging	 all	 consent	 attempts	 was	 maintained	 to	
document	adherence	to	these	consent	procedures.	
2.2.4	Data	Collection	
Data	 was	 collected	 prospectively	 by	 the	 research	 personnel	 on	 patient	
demographics,	mechanism	of	injury,	 injury	time,	time	of	arrival	 in	the	ED,	baseline	
vital	 signs,	 daily	 physiological	 data,	 Injury	 Severity	 Score	 (ISS),	 Abbreviated	 Injury	
Scale	(AIS),	past	medical	history	and	concomitant	cardiac	medication.	The	patients	
were	reviewed	daily	 to	record	any	occurrence	of	cardiac	events	during	admission,	
the	 length	 of	 stay	 and	 mortality.	 Patients	 with	 adverse	 cardiac	 events	 had	
echocardiograms.	
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2.2.5	Blood	sampling	from	trauma	patients	
Within	20	minutes	of	arrival	to	ED,	patients	had	10	millilitres	of	blood	drawn	from	
the	femoral	vein	or	antecubital	vein	in	addition	to	clinical	bloods.	Blood	was	drawn	
into	 a	 4·5-ml	 Vacutainer®	 containing	 3.2%	 (0·109	 mol/l)	 buffered	 sodium	 citrate	
(Becton	 Dickinson,	 Plymouth,	 UK).	 Blood	 was	 collected	 on	 admission,	 24	 hours	
following	 admission	 and	 72	 hours	 following	 admission.	 These	 time	 points	 were	
chosen	to	help	identify	immediate	and	late	biomarkers	of	cardiac	injury.	
2.2.6	Sample	Handling	
The	citrated	blood	was	centrifuged	for	10	minutes	at	1750g	within	1	h	of	collection.	
Plasma	was	collected	and	then	centrifuged	further	for	10	minutes	at	1750g	before	
being	 transferred	 into	 0·6-ml	 Eppendorf	 tubes	 and	 subsequently	 frozen	 at	 −80°C	
until	 ready	 for	 processing.	 Plasma	 stored	 at	 -80oC	 was	 thawed	 to	 37oC	 prior	 to	
biochemical	analysis.		
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2.3	Enzyme	Linked	Immunosorbent	Assays	
	
2.3.1	Technique	
Enzyme-linked	immunosorbent	Assay	(ELISA)	is	a	quantitative	immunoassay	for	the	
measurement	of	an	analyte	of	interest	in	a	liquid	sample.	In	biological	samples,	it	is	
used	to	detect	antibodies,	antigens,	proteins	and	glycoproteins(111).		
	
The	ELISAs	are	 carried	out	on	96-well	plates	often	pre-coated	with	 ligand	binding	
specific	reagent	and	dried	to	form	the	solid-phase.		The	cardiac	biomarkers	were	all	
measured	 using	 sandwich	 ELISAs	 and	 the	 Catecholamines	 were	 measured	 using	
competitive	ELISAs.		
	
In	a	sandwich	ELISA,	the	plates	are	coated	with	a	capture	antibody,	specific	to	the	
protein	of	 interest.	The	sample	along	with	controls	of	known	concentration	of	the	
antigen	of	interest	is	incubated	in	the	wells	of	the	plate.	Any	antigen	specific	to	the	
antibody	will	bind	and	after	incubation,	any	excess	unbound	antigen	is	washed	and	
subsequently	a	detection	antibody	is	added.	 In	the	following	ELISAs,	the	detection	
antibody	was	attached	to	horseradish	peroxidase.	Following	incubation,	the	excess	
is	 washed	 and	 a	 chromogenic	 substrate	 such	 as	 tetramethylbenzine	 (TMB)	 was	
added.	After	15-20	minutes	of	 incubation;	an	acid	 is	added	 to	cease	 the	 reaction.	
This	is	an	indirect	visualisation	method	as	the	chromogen	does	not	directly	bind	to	
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the	 antigen	 of	 interest	 but	 to	 its	 corresponding	 detection	 antibody,	 thereby	
increasing	the	specificity	of	the	assay	(111).		
In	a	competitive	ELISA,	the	sample	is	initially	incubated	with	a	specific	antibody	for	
the	 antigen	 of	 interest.	 Then	 this	 sample,	 now	 containing	 antigen-	 antibody	
complexes	 is	 added	 to	 the	 wells	 coated	 with	 purified	 antigen	 of	 interest.	 Any	
unbound	 antibody	 will	 bind	 to	 the	 antigens	 on	 the	 wall	 of	 well.	 So	 higher	 the	
concentration,	 the	 lower	 the	 remaining	 amount	 of	 free	 antibody.	 Then	 detection	
antibody	is	added,	followed	with	a	chromogen	and	stop	substrate	as	above(111).		
	
Figure	2.1:	Schematic	diagram	of	enzyme-linked	immunosorbent	assay	formats-	(a)	
Competitive	ELISA	and	(b)	Sandwich	ELISA	(112)	
	
Sandwich	ELISAs	are	extremely	sensitive	due	to	the	utilisation	of	two	antibodies	and	
they	 allow	 for	 accurate	 determination	 of	 concentration	 of	 an	 analyte	 in	 a	 crude	
sample,	 even	 without	 prior	 purification.	 The	 competitive	 ELISAs	 are	 useful	 in	
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detecting	 small	 substrates,	 particularly	 when	 they	 only	 have	 a	 single	 antibody	
binding	site(111).			
2.3.2	Materials		
All	ELISAs	were	commercially	manufactured,	ready-to-use	kits	with	standard,	plates	
and	 reagents	 all	 included.	 Limits	 of	 detention	 and	 normal	 reference	 range	 as	
specified	by	the	manufacturers	have	been	summarised.		
	
Table	2.1	Manufacturers	of	Biomarker	ELISAs,	limits	of	detection	and	normal	
reference	values	
	
Biomarker	 Manufacturer	 Limits	of	Detection	 Manufacturers’	
Reference	
H-FABP	 Hycult	Biotech		
Cat	No.	HK402	
0.1-25	ng/ml	 <1.6	ng/ml	
Nt-ProBNP8-29	 Biomedica,		
Cat	No.	BI-20852W	
0-6400	pmol/l	 <392	pmol/l	
Troponin	I	 Signosis		
Cat	No.		
0.1-	25	ng/ml	 <0.1	ng/ml	
Catecholamine	 Diasource	
Cat	No.	KAPL	10-1600	
	 	
Noradrenaline	 0-	0.05	ng/ml	 <0.1	ng/ml	
Adrenaline		 0-	0.01	ng/ml	 <0.6	ng/ml	
Dopamine	 0-	0.025	ng/ml	 <0.1	ng/ml	
	
	
2.3.3	H-FABP	ELISA	
1. 96	 well	 plates	 used	 were	 labelled	 appropriately	 on	 a	 matching	 schematic	
diagram	along	with	appropriate	Eppendorf	tubes.	
2. 50	μl	of	diluted	peroxidase-conjugated	second	antibody	was	added	to	each	
well.		
3. 50	μl	in	duplicate	of	standard,	samples,	or	controls	into	appropriate	wells.		
4. The	plate	was	covered	and	incubated	for	60	minutes	at	room	temperature		
5. 	The	plates	were	washed	4	times	with	wash	buffer	using	a	plate	washer	with	
200ul	of	wash	buffer.		
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6. 100	μl	of	TMB	substrate	was	added	to	each	well.		
7. The	 tray	 was	 covered	 with	 foil	 and	 incubated	 for	 15	 minutes	 at	 room	
temperature.		
8. The	reaction	was	stopped	by	adding	100	μl	of	stop	solution	
9. The	 solutions	 in	 the	 wells	 were	 mixed	 thoroughly	 by	 gently	 swirling	 the	
plate.		
10. The	plate	was	read	within	30	minutes	after	addition	of	stop	solution	at	450	
nm	using	a	plate	reader	
2.3.4	BNP	ELISA	
1. 96	 well	 plates	 used	 were	 labelled	 appropriately	 on	 a	 matching	 schematic	
diagram	along	with	appropriate	Eppendorf	tubes.	
2. Standards	 of	 predetermined	 concentrations	 were	 reconstituted	 with	
distilled	water.	
3. 150	 μl	 of	 assay	 buffer	 is	 added	 to	 all	 wells	 expected	 the	 blank.	 This	 is	
followed	by	30	μl	of	the	standard	or	sample	in	its	respective	wells.		
4. This	is	followed	by	50	μl	of	conjugate	into	each	well	except	the	blank.	
5. The	 plate	 is	 covered	 in	 foil	 and	 incubated	 overnight	 (16-25	 hours)	 in	 the	
fridge	at	4oC	
6. The	 plate	was	washed	 using	 a	 plate	washer.	 300	 μl	 of	washer	 buffer	was	
used	per	wash	and	this	was	repeated	five	times.	On	the	 last	cycle	all	wells	
are	aspirated	
7. Following	 this,	 200	 μl	 of	 substrate	 is	 added	 to	 wash	 well	 and	 the	 plate	
incubated	at	room	temperature	for	20	minutes.		
8. 500	μl	of	stop	solution	is	then	added	to	each	well.	
9. Absorbance	 is	 measured	 at	 450nm.	 The	 blank	 OD	 is	 subtracted	 from	 the	
values	of	the	standard,	control	and	sample.		
10. A	standard	curve	was	constructed	using	the	OD	values	of	the	standards.	
11. The	control	was	used	to	verify	the	standard	curve.	The	acceptable	range	for	
the	concentration	of	the	control	is	provided	per	kit.	
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2.3.5	Troponin	I	ELISA	
1. 96	 well	 plates	 used	 were	 labelled	 appropriately	 on	 a	 matching	 schematic	
diagram	along	with	appropriate	Eppendorf	tubes.	
2. The	 standards	 provided	 as	 0,	 2,	 7.5,	 30	 and	 75	 ng/ml	 were	 reconstituted	
using	1	ml	of	distilled	water	and	left	to	stand	for	20	minutes.	
3. 100	μl	of	standard	or	sample	was	added	to	each	well	followed	by	100	μl	of	
enzyme	conjugate	reagent.	
4. After	mixing	on	a	plate	shaker	for	30	seconds,	the	plate	was	left	to	incubate	
for	90	minutes.		
5. The	mixture	is	aspirated	and	the	plate	washed	in	a	plate	washer	with	300	μl	
of	diluted	wash	buffer	and	the	process	repeated	5	times.	The	wash	buffer	is	
aspirated	following	the	last	wash.	
6. 100	μl	of	TMB	is	added	to	each	well	and	placed	on	the	plater	shaker	for	10	
seconds	and	left	to	incubate	for	20	minutes.		
7. Then	reaction	is	halted	by	the	addition	of	100	μl	of	stop	solution	to	each	well	
and	the	plate	is	placed	on	the	shaker	for	30	seconds	till	all	wells	have	gone	
from	blue	to	yellow	in	colour	
	
2.3.6	Catecholamine	ELISA	
2.3.6.1	Acylation	of	samples	
1. 96	 well	 plates	 were	 labelled	 appropriately	 with	 corresponding	 schematic	
diagrams	and	eppendorf	tubes.		
2. 10μl	of	standards	and	300μl	of	samples	were	added	to	each	well.	
3. 250μl	Distilled	water,	50μl	Assay	buffer	and	50μl	Extraction	buffer	
4. The	plate	was	incubated	for	30min	at	RT	on	shaker	at	500rpm	
5. Supernatant	was	removed	and	1ml	wash	buffer	into	each	well	and	the	plate	
was	incubated	for	5min	at	room	temperature	on	shaker	at	500rpm	
6. Supernatant	 was	 removed	 and	 1ml	 wash	 buffer	 into	 each	 well	 and	
incubated	for	a	further	5min	at	room	temperature	on	the	shaker	at	500rpm	
7. Supernatant	was	removed	and	the	plate	blotted	dry	
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8. 150μl	of	acylation	Buffer	was	added	 followed	by	25μl	of	acylation	 reagent	
and	incubated	for	15min	at	room	temperature	on	a	shaker	at	500rpm	
9. The	supernatant	was	removed	and	the	plate	blotted	dry	
10. 1	 ml	 wash	 buffer	 was	 added	 into	 each	 well	 and	 the	 plate	 incubated	 for	
10min	at	room	temperature	on	shaker	at	500rpm	
11. The	supernatant	was	decanted	and	the	plate	was	blot	dried.	
12. 175μl	of	HCL	was	added	and	incubated	for	10min	RT	on	shaker	at	500rpm	
2.3.6.2	Competitive	Catecholamine	ELISA	
1. 25μl	of	reconstituted	enzyme	solution	was	added	into	each	well	
2. 25μl	standards	and	50μl	Samples	were	added	(along	with	25μl	HCL	into	each	
well	for	the	dopamine	ELISA)	
3. The	plate	was	 incubated	 for	30minutes	at	 room	temperature	on	 shaker	at	
500rpm	
4. 50μl	of	the	appropriate	antiserum	(Dopamine,	noradrenaline	or	adrenaline)	
was	added.	
5. The	plate	was	incubated	for	a	further	120	minutes	at	room	temperature	on	
a	shaker	at	500rpm	
6. Plates	were	washed	 using	 a	washer,	 3	 times	with	 300μl	 of	wash	 buffer	 in	
each	well	
7. 100μl	 Enzyme	 conjugate	 into	 each	 well	 and	 incubated	 for	 30	 minutes	 at	
room	temperature	on	a	plate	shaker	at	500rpm	
8. The	plate	was	washed	again	3	times	with	300μl	of	wash	buffer	in	each	well	
9. 100μl	of	substrate	was	added	and	the	plate	covered	with	foil	and	incubated	
for	30	minutes	at	room	temperature	on	a	shaker	at	500rpm	
10. The	plate	was	washed	3	times	with	300μl	of	wash	buffer	in	each	well	
11. 100μl	stop	solution	was	added	and	read	at	450nm		
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2.3.7	Quantification	of	results	
The	samples	were	read	at	450nm	on	a	plate	reader.	A	standard	curve	was	produced	
from	the	controls	with	known	values	using	GraphPad	Prism.	This	generates	a	curve	
fit	by	plotting	the	mean	absorbance	for	each	standard	concentration	on	the	vertical	
(Y)	 axis	 and	 the	 corresponding	 concentration	 on	 the	 horizontal	 (X)	 axis	 on	 a	
logarithmic	axis.	The	concentrations	read	from	diluted	samples	were	multiplied	by	
the	 dilution	 factor.	 Any	 sample	 with	 concentration	 variance	 between	 duplicates	
greater	than	15%	was	repeated.		
2.4	Animal	Models	
	
The	 animal	 model	 for	 TISCI	 was	 developed	 by	Dr	 Johanna	Wall	 as	 part	 of	 her	
doctoral	thesis.	The	methodology	has	been	reproduced	with	her	permission.	
	
All	animal	procedures	described	in	this	thesis	are	regulated	under	a	specific	animal	
project	 licence	 (Procedure	 Project	 Licence	 (PPL)	 –	 PC5F29685)	 approved	 by	 the	
Animal	welfare	and	Ethical	Review	Body	at	Queen	Mary	University	of	London,	and	
the	 UK	 Home	 Office,	 in	 accordance	 with	 the	 EU	 directive	 2010/63/EU	 on	 the	
protection	 of	 animals	 used	 for	 scientific	 purposes.	 The	 PPL	 includes	 all	 the	
experimental	 procedures	 required	 for	 the	 pre-clinical	 studies,	 including	 the	
induction	 of	 haemorrhage	 and	 traumatic	 injury,	 imaging	 procedures,	 dosing	
substances	and	blood	/	tissue	samplings.	This	PPL	was	renewed	on	December	2016	
and	has	been	granted	for	5	years	(to	December	2021).		
		 	 	 	
	 56	
2.4.1.	Mice	
Male	 C57BL/6	 wild-type	 mice	 weighing	 25	 –	 30	 grams	 were	 supplied	 by	 Charles	
River	 Laboratories	 (Margate,	 UK)	 and	 housed	 in	 accordance	 with	 the	 UK	 Home	
Office	Guidance	 in	 the	Operation	of	Animals	 (Scientific	 Procedures)	Act	 1986	 and	
received	a	standard	diet	and	water	ad	libitum	prior	to	undergoing	anaesthesia.	Mice	
were	randomly	allocated	to	experimental	group.		
2.4.2	Anaesthesia	
Isoflurane	 (Abbott	 Labs	 ltd,	 Berkshire,	 UK)	 in	 combination	 with	 100%	 medical	
oxygen	 was	 continuously	 delivered	 via	 nose	 cone	 for	 both	 induction	 and	
maintenance	of	 general	 anaesthesia	 throughout	 the	duration	of	 the	 experiments.	
All	animals	were	culled	at	the	end	of	the	experiment	whilst	still	anaesthetised.		
2.4.3	Surgery	
After	induction	of	anaesthesia,	the	left	jugular	vein	and	carotid	were	cannulated.	A	
pressure	 transducer	was	 connected	 to	 the	 line	by	way	of	 a	 three-way	 connector.	
Pressure-controlled	 haemorrhage	 of	 arterial	 blood	 via	 the	 carotid	 catheter	 was	
conducted	 over	 10	minutes	 to	 achieve	 a	 target	MABP	 of	 60	 –	 70mmHg	 or	 30	 –	
40mmHg	 (depending	 upon	 the	 experimental	 group	 allocation).	 The	 target	 blood	
pressure	was	then	maintained	over	a	60-minute	period.	To	produce	truamtic	injury	
in	 the	 mice	 models	 bilateral	 hind	 limb	 fracture,	 laparotomy	 and	 rectus	 muscle	
crushing	were	carried	out.	Fractures	were	performed	using	a	closed,	manual	3-point	
bending	 technique.	 A	 2cm	 midline	 laparotomy	 was	 performed,	 with	 internal	
inspection	of	the	abdominal	viscera	in	order	to	exclude	inadvertent	iatrogenic	injury	
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and	 /	 or	 bleeding,	 followed	 by	 crushing	 of	 the	 rectus	 muscle	 and	 then	 the	
laparotomy	was	closed	using	5.0	monofilament	suture	material.	
2.4.4	Observation	periods	
After	 trauma-haemorrhage	 and	 resuscitation	 episodes,	 animals	 underwent	 a	 60-
minute	 observation	 period.	 During	 this	 time,	 core	 temperature	 was	 continuously	
monitored	 and	maintained	with	 the	 use	 of	 a	 heat	mat	 and	 lamps.	 Temperature,	
MABP	 and	 %	 of	 inhaled	 anaesthetic	 required	 to	 maintain	 a	 surgical	 plane	 of	
anaesthesia	were	recorded	at	10-minute	intervals.		
	
Table	2.2	Summary	of	conditions	of	models		
	
	
Sample	
	
Time	
Of	Death	
Conditions	 Mortality	 EM	 WB	 HFABP	
	
R43	 3h	 Sham	 N	 	 	 17.2	
R44	 3h	 Sham	 N	 X	 X	 14.64	
R68	 3h	 Sham	 	 	 X	 3.3	
R69	 3h	 Sham	 	 	 X	 3.4	
R76	 3h	 Sham	 N	 X	 X	 3.91	
R77	 3h	 Sham	 N	 X	 X	 38.26	
R90	 3h	 Sham	 N	 	 X	 3.33	
R91	 3h	 Sham	 N	 	 X	 3.48	
	 	 	 	 	 	 	
R41	 3h	 TH	 Y	 X	 	 334.28	
R42	 3h	 TH	 Y	 X	 	 (unable	to	bleed)	
R62	 3h	 TH	 N	 X	 X	 (unable	to	bleed)	
R64	 3h	 TH	 N	 X	 X	 432.60	
R78	 3h	 TH	 N	 	 X	 242.36	
R79	 3h	 TH	 N	 	 X	 193.57	
R81	 3h	 TH	 Y	 	 X	 76.43	
	 	 	 	 	 	 	
R65	 6h	 TH	 Y	 X	 X	 386.26	
R66	 6h	 TH	 N	 X	 X	 417.34	
R67	 6h	 TH	 N	 X	 X	 433.22	
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2.5	Histology	
2.5.1	Technique	
Immunohistochemistry	 is	a	useful	 tool	 in	visualisation	expression	of	a	protein	and	
its	pattern	of	localisation	in	tissue.	Specific	antibodies	targeting	epitopes	of	interest	
are	 attached	 to	 chromogens	 to	 allow	 identification.	 The	 advent	 of	 fluorescence	
immunohistochemistry	 has	 made	 it	 possible	 to	 label	 multiple	 proteins	
simultaneously.		
Tissues	 must	 be	 preserved	 and	 fixed	 to	 maintain	 their	 structure	 and	 avoid	
degradation	 of	 proteins.	 Samples	 can	 be	 formalin	 fixed,	 fresh	 frozen	 or	 paraffin	
embedded.	 Initially,	 I	 attempted	 fresh	 frozen	 sectioning	of	 the	cardiac	 tissue	as	 it	
retains	antigenicity	better,	however,	the	morphology	was	compromised,	therefore,	
experiments	were	completed	using	paraffin	embedded	sections.		
2.5.2.	Antibodies	
Mouse	Monoclonal	Anti-cardiac	Troponin	I	(Abcam	ab10231)	
Rabbit	polyclonal	Anti-AIF	antibody	(Abcam	ab2086)		
Rabbit	Monoclonal	Anti-Cleaved	Caspase	8	(Cell	Signalling	8592S)	
AntiRabbit	IgG	(Alexa	Fluor®	488)	(Abcam	ab150129)		
Donkey	Anti-Mouse	IgG	(Alexa	Fluor®	594)	(Abcam	ab175774)	
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2.5.3	Tissue	Handling	
Hearts	 were	 excised	 whilst	 animals	 were	 anaesthetised	 and	 immersed	 into	 4%	
paraformaldehyde	 and	 stored	 till	 enough	 samples	 were	 available	 for	 mass	
processing.	
2.5.4	Sectioning	
Tissues	were	dehydrated	with	70%	ethanol	three	times	for	30	minutes	each	at	room	
temperature,	 90%	 ethanol	 two	 times	 for	 30	minutes	 each	 at	 room	 temperature,	
100%	 ethanol	 three	 times	 for	 30	minutes	 each	 at	 room	 temperature	 and	 xylene	
three	 times	 for	 20	 minutes	 each	 at	 room	 temperature.	 The	 tissue	 was	 then	
embedded	 in	 paraffin	 at	 58	 °C	 using	 an	 automated	 system.	 10	 μm	 thick	 sections	
were	cut	using	a	rotary	microtome	and	the	sections	were	floated	in	a	56	°C	water	
bath	and	mounted	onto	gelatin-coated	histological	slides.	The	slides	were	left	to	dry	
overnight	 at	 room	 temperature.	 Slides	 with	 paraffin-embedded	 sections	 can	 be	
stored	either	at	room	temperature	or	in	at	2-8	°C	for	several	years	in	slide	storage	
boxes.	
2.5.5	Deparaffinisation	and	Rehydration	
The	 sections	were	 rehydrated	with	 xylene	 twice	 for	 10	minutes	 each	 time,	 100%	
ethanol	for	10	minutes,	95%	for	10	minutes,	70%	for	10	minutes,	5%	ethanol	for	5	
minutes.	Two	further	10	minute	washes	in	0.01M	PBS	was	performed	to	rehydrate	
the	sections.		
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2.5.6	Optimisation	of	Antigen	Retrieval	
The	methodology	described	below	was	finalised	following	the	evaluation	of	various	
conditions	for	antigen	retrieval	to	optimise	staining.	Prior	to	this,	a	many	
permutations	of	pH,	heating	method	and	timings	were	trialled.		Antigen	retrieval	
was	assessed	at	3	different	pHs	of	citric	acid	and	two	heating	methods	as	shown	in	
Table.	However,	despite	multiple	attempts,	the	staining	remained	poor.	Eventually,	
I	was	kindly	given	a	protocol	honed	over	the	years	by	one	of	the	postdoctoral	fellow	
in	the	centre	for	neurosciences,	Dr	M	Burgillos.	This	is	what	has	been	adapted	with	
changes	to	the	timings	alone.	
Table	2.3:	Different	variables	tested	for	antigen	retrieval		
	
Water	Bath	
10	minutes	
Water	Bath	
35	minutes	
Microwave	
10	minutes	
Microwave	
35	minutes	
pH	6.0	 pH	6.0	 pH	6.0	 pH	6.0	
pH	8.1	 pH	8.1	 pH	8.1	 pH	8.1	
pH	9.0	 pH	9.0	 pH	9.0	 pH	9.0	
2.5.7	Antigen	Retrieval	
The	 slides	 were	 placed	 in	 a	 plastic	 coupling	 jar	 with	 antigen	 unmasking	 solution	
(Vector	 Lab,	 Cat	 No.	 H-3300)	 into	 pre-heated	 saucepan	 of	 water	 pre-heated	 to			
90oC.	The	slides	were	heated	for	40	minutes,	and	then	placed	on	the	bench	for	30	
minutes	 to	 cool	 to	 room	 temperature.	 Slides	 were	 washed	 with	 0.1M	 PBS	 three	
times	for	10	minutes	each	time.	
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2.5.8	Staining	
The	tissues	were	demarked	with	a	barrier	pen	and	incubated	in	blocking	solution	for	
1	hour	at	 room	temperature.	The	blocking	solution	consisted	of	0.2%	Triton	+	5%	
normal	donkey	serum	diltuted	 in	PBS.	Following	this,	 the	slides	were	 incubated	 in	
primary	antibody	overnight.	The	slides	were	washed	3	times	for	15	minutes	each	in	
wash	 buffer	 and	 incubated	 in	 secondary	 antibody	 for	 2	 hours.	 The	 slides	 were	
mounted	with	Vectaschield	mounting	medium	with	DAPI	(Catalogue	No.	H-1200).		
2.5.9	Immunohistochemistry	Negative	Control	
Control	 experiments	 were	 carried	 out	 following	 protocol	 optimisation	 to	 gather	
information	 regarding	 background	 staining	 of	 cardiac	 tissue.	 Paraffin	 embedded	
sections	of	sham	and	TH	cardiac	tissue	was	processed	using	the	above	methodology	
with	the	omission	of	the	primary	antibody.	The	sections	were	incubated	with	the		
secondary	antibody	for	2	hours.	There	was	no	background	staining	of	these	slides.		
Figure	2.2:	Paraffin	embedded	cardiac	tissue	sections	from	sham-operated	animals	
stained	with	DAPI	(left)	and	chromogenic	secondary	antibodies	AF488	(centre)	and	
AF594	(Right)	in	the	absence	of	a	primary	antibody	
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2.5.10	Visualisation	
Zeiss	LSM710	confocal	microscope	was	used	for	the	imaging	and	processed	on	Zen	
imaging	software.	Image-J	image	processing	programme	was	used	to	calculate	pixel	
statistics	by	converting	the	single	colour	images	to	gray-scale.	The	mean	pixel	value	
was	 taken	 as	 a	 derivative	 of	 expression.	 Co-localisation	was	 calculated	 using	 Zen	
imaging	software.		
	
2.6	Western	Blotting	
2.6.1	Introduction	
In	 molecular	 biology,	 western	 blotting	 is	 used	 to	 separate	 and	 identify	 proteins	
based	 on	 their	 molecular	 size.	 Unlike,	 ELISAs,	 more	 than	 one	 protein	 can	 be	
identified	 at	 a	 time	 by	 re-probing	 the	 same	membrane	 after	 stripping.	 However,	
unlike	 ELISAs,	 large	 number	 of	 samples	 can’t	 be	 run	 at	 once	 due	 to	 the	 time	
intensive	nature	of	 the	 technique.	 	Proteins	extracted	 from	tissue	or	cells	are	 run	
through	a	porous	polyacrylamide	gel	to	separate	them	by	size.	The	gels	are	loaded	
into	an	electrical	chamber	with	positively	and	negatively	charged	electrodes,	filled	
with	 running	 buffer.	 	 The	 negatively	 charged	 proteins	 are	 driven	 downwards	
towards	the	positive	electrode	on	the	application	of	a	set	voltage.	The	proteins	are	
transferred	from	the	gel	 to	a	nylon	membrane	by	application	of	an	electrical	 field	
perpendicular	to	the	gel,	this	causes	the	negatively	charged	protein	to	move	away	
towards	 the	 anode	 and	 that	 leads	 it	 to	 the	membrane.	 The	membrane	 is	 probed	
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with	 antibodies	 of	 the	 protein	 of	 interest,	 followed	 by	 a	 secondary	 antibody	
attached	to	a	chemiluminescent	substrate	to	allow	for	visualisation.		
2.6.2	RIPA	buffer	for	protein	extraction	
RIPA	(Radio	immune	precipitation	assay)	buffer	consists	of		
50ml	of	50	mM	TrisHCl	(pH	7.4)	
8.76	grams	of	150	mM	NaCl	
10	ml	of	1%	Triton	X-100	
5g	0.5%	Sodium	deoxylcholate	
1g	0.1%	SDS	
2ml	1	mM	EDTA	(0.5	M	stock),		
0.42g	of	10	mM	NaF		
ddH2O	to	1000	ml	
Mixture	 of	 these	 reagents	 was	 then	 divided	 into	 50	 ml	 aliquots	 and	 cocktail	 of	
protease	inhibitor	and	phosphatase	inhibitor	tablets	were	added	(Pierce™	Protease	
and	Phosphatase	Inhibitor	Mini	Tablets	Cat	no88668).	
2.6.3	Protein	extraction	
A	 portion	 of	 the	 heart	 was	 excised	 and	 weighed.	 A	 millilitre	 of	 RIPA	 buffer	 was	
added	to	every	0.1g	of	tissue.The	tissue	was	placed	on	glass	slide	in	RIPA	over	dry	
ice	and	gently	minced	using	a	fresh	razor	blade.	Then	the	minced	tissue	was	further	
disrupted	 in	 Dounce	 homogeniser	 with	 20	 strokes	 on	 ice.	The	 sample	 was	 then	
sonicated	 on	 ice	 and	 centrifuged	 at	 13	 000	 rpm	 for	 20	 minutes	 at	 4oC.	 The	
supernatant	protein	was	collected	and	stirred	in	-80	for	further	analysis.	
2.6.4	Mitochondrial	separation	
A	mitochondrial	isolation	kit	(Abcam)	was	used	following	the	method	as	described	
by	manufacturers.	All	reagents	were	provided	in	the	kit.	
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1. 0.2-0.4	g	of	cardiac	tissue	was	washed	with	1.5	ml	of	wash	buffer.		
2. The	tissue	was	then	placed	in	the	pre-chilled	dounce	homogeniser	and	
disrupted	by	30-40	strokes.		
3. 	The	homogenate	was	transferred	to	2ml	microtubes	and	each	tube	filled	to	
2	ml	with	isolation	buffer.	
4. 	The	homogenate	was	centrifuged	at	1000g	for	10	minutes	at	4oC.	
5. The	supernatant	was	transferred	in	to	a	new	tube	and	the	pellet	containing	
all	large	organelles	was	discarded.		
6. The	supernatant	was	topped	up	to	2ml	with	the	isolation	buffer	and	
centrifuged	at	high	speed	at	12,000g	for	15	minutes	at	4oC.		
7. The	supernatant	was	transferred	to	a	new	tube.		
8. Pellets	were	suspended	in	500	μl	of	isolation	buffer	with	protease	inhibitor	
cocktail	
9. Aliquots	were	frozen	-80oC		
2.6.5	Protein	Quantification	
Protein	 extraction	 from	 the	 hearts	 of	 the	 trauma	 haemorrhage	 models	 was	
quantified	using	a	Bradford	assay.	Known	amounts	of	bovine	serum	albumin	were	
loaded	alongside	protein	extraction	samples	from	the	trauma	models.	The	protein	
concentration	 of	 the	 samples	 were	 then	 extrapolated	 for	 those	 samples	 to	
determine	quantity	to	be	loaded	for	the	protein	gels.	The	calculated	amounts	were	
loaded	on	to	the	gel	were	then	transferred	to	a	blot	for	protein	expression	analysis.		
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Figure	2.3:	Bradford	assay	standard	curve	utilised	for	extrapolation	of	protein	
content	in	tissue	samples	
	
A	 silver	 stain	 was	 performed	 on	 a	 gel	 run	 with	 the	 amount	 calculated	 from	 the	
Bradford	 assay.	 The	 silver	 stain	 that	 attaches	 to	 protein	molecules	 in	 the	 sample	
allows	determination	of	protein	concentration	in	the	tissue	lysate.	The	silver	stain	is	
captured	on	a	camera	to	allow	quantification	through	optical	density	using	the	gel	
pro	analyser.	Image	J	quantifies	the	intensity	of	the	optical	density	of	each	column.	
The	optical	density	correlates	to	the	concentration	of	protein.	This	was	then	used	to	
standardise	 proteins	 of	 interests.	 This	 was	 repeated	 for	 the	 mitochondrial	
separation	of	the	tissue	lysates.	
The	optical	density	from	each	sample	was	used	to	determine	how	much	of	the	cell	
lysate	was	to	be	loaded	to	determine	protein	concentration.	
2.6.6	Gel	Electrophoresis	
1. NuPAGE®	MOPS	 SDS	Running	Buffer	 (20X)-NP0001	was	made	up	 and	 tank	
filled	
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2. Bolt™	 4-12%,	 (10-well	 	 NW04122BOX)	 Bis-Tris	 Plus	 Gel	 was	 inserted	 into	
tank.	
3. 10ul	of	samples	were	loaded	with	protein	ladder	(RPN800E-GE	health	care)	
into	10	well	NuPage	Bis-Tris	Mini	gel	
2.6.7	Transfer	of	proteins	from	gel	to	nylon	membrane	
1. PVDF	 (poly	 vinyl	di	 fluoride)	nylon	memebrane	 (Thermo	 fisher	88518)	was	
activated	in	methanol	before	transfer	into	transfer	buffer	(Thermo	fisher	1-
Step	transfer	buffer-Cat	no	84742)	
2. Filter	papers	and	Gel	were	soaked	into	transfer	buffer	
3. Gel	was	 placed	 between	 transfer	 paper	 and	 blotting	 paper	 as	 a	 sandwich	
into	 Pierce	 power	 blotter.	 The	 protein	 transfer	 protocol	 for	 appropriate	
molecular	weight	was	carried	out	as	designated	by	the	power	blotter.	
	
2.6	Electron	Microscopy	
	
Electron	 microscopy	 (EM)	 enables	 visualisation	 of	 tissue	 to	 0.2nm	 scale.	 This	
uniquely	 allows	 for	 the	 study	of	 ultrafine	 sub	 cellular	 structures	 in	 a	 great	 detail.	
Using	EM	proteins	of	interest	can	be	visualised	using	antibody	labelling	with	metal	
particles.	Mice	hearts	were	collected	and	immediately	fixed	in	Glutaraldehyde.	The	
samples	 were	 further	 fixed	 and	 processed	 for	 imaging	 by	 Dr	 Guilia	 Mastroianni,	
School	of	Biological	and	Chemical	Sciences,	QMUL.	
2.6.1	Cacodylate	buffer	0.1	M	pH	7.4	
Sodium	 cacodylate	 buffer	 [Na(CH3)2	 AsO2	 •	 3H2O]	 was	 introduced	 for	 EM	
applications	by	Sabatini	et	al.	in	1963	(114).	The	buffer	acts	to	maintain	a	pH	5.0–
7.4	 and	 in	 doing	 so	 negates	 the	 need	 to	 add	 additional	 phosphates	 to	 sample	
		 	 	 	
	 67	
preparations.	Mitochondria	and	other	organelles	can	be	damaged	when	exposed	to	
the	high	concentrations	of	phosphates	present	in	the	traditionally	used	Sørensen’s	
buffers.	Cacodylate	does	not	react	with	aldehyde	fixatives	as	will	amine-containing	
buffers	 (e.g.,	Tris).	 Its	 efficacy	 in	 fixation	 solutions	 may	 be	 a	 result	 of	 the	
metabolism-inhibiting	 effect	 of	 the	 arsenate	 rather	 than	 any	 special	 buffering	
capacity.	
2.6.2	Preparation	of	Buffered	2%	Glutaraldehyde		
A	 stock	 solution	 (A)	 of	 0.2	M	 Sodium	 Cacodylate	 was	made	 by	 dissolving	 4.48	 g	
sodium	cacodylate	in	100	mL	distilled	water	and	the	acid	stock	solution	of	0.2	M	HCl	
(B)	is	made	by	diluting	20ml	of	1M	HCl	with	80ml	of	distilled	water.	Preparation	of	
the	 buffer	 solution:	 mix	 100	 mL	 of	 stock	 A	 and	 5.4	 mL	 stock	 B	 followed	 by	 the	
addition	 of	 distilled	 water	 to	 give	 a	 final	 volume	 of	 200	 mL.	 Then	 15mL	 of	 2%	
Glutaraldehyde	is	freshly	constituted	for	every	sample.	1.2ml	of	25%	glutaraldehyde	
is	added	to	13.8ml	of	cacodylate	buffer.	
	
2.6.3	Preparation	of	Osmium	Tetroxide	
4%	aqueous	solution	of	osmium	tetroxide	is	diluted	to	1%	with	ddH2O	of	the	
appropriate	volume.	
2.6.4	Preparation	of	Araldite	Resin	
1. in	 a	 disposable	 polythene	 beaker,	 40	 ml	 of	 araldite	 CY212,	 60	 ml	 of	
dodecenyl	succinic	anhydride,	2.0	ml	of	methyl	nadic	anhydride	and	1.0	ml	
of	benzyl	dimethylamine	were	combined	in	that	order.	
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2. The	mixture	is	stirred	for	at	least	5	minutes,	ensuring	as	little	air	as	possible	
is	incorporated	into	the	mixture.	
3. The	mixture	is	allowed	to	stand	for	1	hour	to	allow	any	air	to	escape.	
2.6.5	Processing	of	Tissues	
1. The	 tissue	was	dissected	and	 fixed	 in	2%	glutaraldehyde	 for	30	minutes	at	
room	temperature.	The	specimen	is	then	cut	into	small	1	mm3	and	stored	in	
fresh	fixative	in	4oC	for	1-7	days.	
2. The	 specimen	 was	 removed	 and	 washed	 for	 5	 minutes	 in	 the	 cacodylate	
buffer.	This	is	repeated	three	times.		
3. The	 specimens	 are	 removed	 from	 the	wash	 and	 incubated	 in	 1%	 osmium	
tetroxide	in	buffer	for	2	hours	at	4oC.	
4. Wash	in	distilled	water	3	x	5	minutes.	
5. Dehydration	 steps	 in	 25%	 acetone	 for	 15min,	 50%	 for	 15min,	 75%	 for	 15	
minutes	and	100%	twice	for	20	minutes.	
6. The	 samples	 were	 impregnated	 in	 increasing	 concentration	 of	 Araldite	 in	
acetone,	25%	for	30	minutes,	50%	for	30	minutes,	75%	for	30	minutes	and	
100%	for	1	h	three	times.	
7. Following	this,	the	sample	was	stored	in	fresh	Araldite	for	24-72	hours	
8. Samples	are	stored	at	48	hours	for	60°C.	
9. Thin	sections	were	cut	with	a	glass	knife	at	a	Reichert	Ultracut	E	microtome	
and	collected	on	uncoated,	300	mesh	copper	grids.		
10. High	contrast	was	obtained	by	post	staining	with	saturated	aqueous	uranyl	
acetate	and	lead	citrate	for	4 min	each	(115).		
11. The	 grids	 were	 examined	 in	 a	 JOEL	 JEM-1230	 transmission	 electron	
microscope	at	an	accelerating	potential	of	80 kV.	
2.7	Statistical	analysis	
	
Statistical	 analysis	 was	 performed	 using	 IBM	 SPSS	 v22	 and	 GraphPad	 Prism	 was	
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used	for	graph	generation.	Non-parametric	comparisons	of	groups	were	performed	
using	Mann-Whitney	U	and	Kruskal-Wallis	tests.	Significance	of	categorical	data	was	
determined	 using	 Fisher’s	 exact	 test.	 Linear	 relationships	 were	 determined	 using	
Spearman’s	 rank	 correlation	 coefficient.	Multivariate	 analysis	was	 also	 performed	
using	variables	with	a	univariate	correlation	with	a	statistical	significance	of	p<0.1.	
Overall,	p<0.05	was	taken	to	be	statistically	significant.		
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Chapter	3	
	
Trauma	Associated	Cardiac	Injury	and	Dysfunction	(TACID)	
A	Clinical	Study	
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3.1	Introduction	
	
Several	 studies	have	 retrospectively	 investigated	 the	presence	of	 cardiac	 injury	 in	
trauma	 patients.	 The	 incidences	 of	 cardiac	 events	 and	 rise	 in	 cardiac	 biomarkers	
have	 been	 correlated	 to	 pre-existing	 cardiac	 disease	 as	 well	 as	 the	 presence	 of	
direct	cardiac	injury.	The	Trauma	Associated	Cardiac	Injury	and	Dysfunction	(TACID)	
study	was	designed	as	a	prospective	observational	study	to	simultaneously	look	at	
these	different	contributory	factors	of	cardiac	injury	in	trauma	as	well	as	their	effect	
on	clinical	outcomes	and	biomarkers.		
	
Cardiac	 disturbances	 after	 severe	 injury	 remain	 poorly	 characterized	 and	 the	
underlying	mechanisms	 remain	unclear/unknown.	Deaths	 from	 fulminant	multiple	
organ	 failure	 are	 often	 associated	with	 inadequate	 cardiac	 output	 and	 increasing	
requirements	 for	 inotropic	 support(116,117).	 	 Trauma	 patients	 have	 been	
repeatedly	 demonstrated	 been	 shown	 to	 develop	 rhythm	 disturbances	 and	 to	
suffer	 from	 ischemic	 cardiac	 events(26).	 This	 Trauma-Induced	 Secondary	 Cardiac	
Injury	 (TISCI)	 may	 contribute	 to	 the	 late	mortality	 and	 long-term	morbidity	 after	
trauma(118).	
	
It	 has	 been	 previously	 shown	 that	 patients	 who	 develop	 adverse	 cardiac	 events	
(ACEs)	have	elevations	of	plasma	cardiac	injury	biomarkers	very	early	in	their	clinical	
course(118).	 Heart-specific	 Fatty	 Acid	 Binding	 Protein	 (h-FABP)	 in	 particular	 was	
elevated	 immediately	on	admission	and	correlated	with	 the	development	of	ACEs	
		 	 	 	
	 72	
and	subsequent	mortality(118).	 	 In	this	small	retrospective	study,	 it	appeared	that	
the	development	of	TISCI	appeared	to	be	strongly	related	to	the	degree	of	shock	on	
admission,	and	there	was	a	suggestion	that	the	presence	of	cardiovascular	disease	
prior	to	traumatic	injury	may	also	be	a	contributing	factor	(118).			
	
The	overall	objective	of	this	study	was	to	investigate	the	drivers	of	TISCI	and	further	
understand	the	risk	factors	and	outcomes	associated	with	this	condition.		Our	first	
aim	 was	 to	 determine	 the	 incidence	 of	 ACEs	 and	 their	 effect	 on	 outcomes	 in	 a	
prospective	 cohort	 of	 trauma	 patients.	 Our	 second	 aim	 was	 to	 determine	 the	
association	 of	 elevated	 admission	 levels	 of	 cardiac	 injury	 markers	 with	 the	
subsequent	development	of	ACEs,	and	to	determine	the	predictive	power	of	these	
biomarkers.		
3.2	Results	
3.2.1	Patient	characteristics	
TACID	was	conducted	at	Royal	London	Hospital,	a	 level	 I	 trauma	centre	 in	London	
from	September	2010	to	October	2012.	All	patients	who	were	above	the	age	of	16	
and	met	 the	 criteria	 for	 trauma	 team	activation	were	 screened	 for	 inclusion.	 The	
completion	of	the	study	was	marked	by	the	recruitment	of	300	patients	in	October	
2012.	 Following	attempts	 to	 seek	 consent,	 10	patients	were	excluded	as	 they	did	
not	want	to	be	included	in	the	study.		
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Figure	3.1	Patient	recruitment	flowchart	for	TACID	
	
The	study	population	had	a	median	age	of	38	years	and	73%	male.	The	majority	of	
the	 patients,	 82%	 had	 suffered	 a	 blunt	 injury,	 (82%)	 and	 with	 a	 median	 injury	
severity	 score	 (ISS)	 of	 20.	 Despite	 the	 high	 injury	 severity	 score,	 this	 was	 not	
reflected	by	clinical	parameters	of	shock	on	admission,	with	a	median	systolic	blood	
pressure	(SBP)	of	125mmHg	and	lactate	of	1.9mmol.		
3.2.2	Adverse	Cardiac	Events	
The	development	of	adverse	cardiac	events	was	the	primary	endpoint	of	this	study.	
Adverse	 cardiac	 events	 were	 diagnosed	 using	 ECGs	 and	 defined	 as	 arrhythmias	
requiring	 intervention,	 ischaemic	 ECG	 changes	 such	 as	 T	 wave	 inversion,	 ST	
elevation	or	 depression	 and	new	onset	 bundle	 branch	block.	 The	diagnoses	were	
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made	by	 the	clinician’s	 independent	 to	 the	 research	 team	using	a	combination	of	
clinical	evidence;	ECGs,	troponin	changes	and	requirement	for	intervention.		
	
During	their	admission	of	the	290	patients	recruited,	38	developed	ACEs.	The	study	
population	was	then	dichotomised	according	to	the	presence	of	ACE.	Although	not	
statistically	 significant,	 the	 ACE	 cohort	 had	 a	 higher	 median	 age	 of	 47	 years	
compared	to	37	years	in	the	no	ACE	group.	Notably	29%	of	the	patients	in	the	ACE	
group	were	less	than	30	years	old.	The	ACE	group	also	had	a	higher	percentage	of	
male	patients.	However	neither	of	these	differences	was	of	statistical	significance.	
	
The	 ACE	 cohort	 was	 more	 severely	 injured	 with	 higher	 ISS	 median	 of	 30	 in	
comparison	to	13	in	the	no	ACE	group.	The	ACE	group	was	more	hypotensive	than	
the	no	ACE	group	with	a	median	SBP	of	100	vs.	130	and	more	shocked	with	a	lactate	
of	3.5	vs.	2.0	respectively.	
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Table	3.1:	Patient	demographics	and	injury	characteristics	
	
		 All	patients	 No	ACE	 ACE	 Univariate	Analysis	
(p)	
No	Patients	(%)	 290	 252	(87%)	 38	(13%)	 <0.01	
Demographics	 		 		 		
Median	Age	(years)	 37	(16-91)	 37	(26-51%)	 47	(30-59)	 0.05	
<30	 102	(35%)	 91	(36%)	 11	(29%)	 		
31-45	 86	(30%)	 78	(31%)	 8	(21%)	 		
46-65	 71		(24%)	 61	(24%)	 10	(26%)	 		
66-80	 22	(8%)	 16		(6%)	 6	(16%)	 		
>81	 9	(3%)	 6	(2%)	 3	(8%)	 		
Male	 211	(73%)	 214	(85%)	 27	(71%)	 0.07	
Time	To	Sampling	 92	(71-	115)	 91	(73-	110)	 100	(76-	116)	 		
Injury	Characteristics	 	 	 		
Blunt	 237	(82)	 206	(82)	 31	(82)	 		
ISS	 17	(9-29)	 13	(9-25)	 30	(25-	43)	 <0.01	
Thoracic	AIS	 3	(0-3)	 1	(0-3)	 3	(2-4)	 <0.01	
H&N	AIS	 0	(0-3)	 0	(0-3)	 3	(0-4)	 0.01	
Admission	SBP	 126	(107-	146)	 130	(114-147)	 100	(67-125)	 <0.01	
Admission	Lactate	 2	(1.3-3.4)	 2	(1.3-3.1)	 3.2	(1.3-6.4)	 0.03	
	
Comparison	of	patient	characteristics	between	the	two	cohorts.	Median	values	are	
given	for	all	variables	with	interquartile	ranges	in	paranthesis	except	for	sex,	
number	of	patients	in	each	age	category	and	blunt	injuries	which	is	shown	as	the	
number	of	male	patients	in	the	cohort	with	percentage	in	parenthesis.	The	p	
values	were	obtained	from	mann-whitney	u	analysis	between	the	groups.	
	
	
Direct	thoracic	injury	has	been	shown	to	be	associated	with	cardiac	injury	and	a	rise	
in	 cardiac	 biomarkers.	 In	 addition	 the	 patients	 who	 developed	 ACE	 had	 more	
significant	 thoracic	 (AIS	score	3	vs.	1)	and	head	 injuries	 (AIS	0	vs	3).	Patients	with	
severe	thoracic	injury	were	more	likely	to	develop	an	adverse	cardiac	event	(42%	vs	
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18%,	p=0.01).	However,	severe	head	injury	(AIS>3)	was	not	associated	with	a	higher	
prevalence	of	cardiac	events.	
	
Table	3.2:	Prevalence	of	ACE	in	severe	head	and	thoracic	injury	
	
	 No	ACE	(n=252)	 ACE	(n=38)	 p	value	
Severe	thoracic	injury	(AIS	>3)	 45		(18%)	 16	(42%)	 0.01	
Severe	Head	injury	(AIS	>3)	 51	(20%)	 12	(32%)	
0.09	
	
Values	are	given	as	n	values	with	percentages	in	parenthesis.	The	p	values	were	
obtained	from	mann-whitney	u	analysis	between	the	groups.	
	
	
3.2.3 Pre-injury	factors	
Following	 recruitment,	 the	 patient’s	 past	 medical	 history	 and	 medication	 history	
were	obtained	from	the	patients	and	their	relatives.	These	were	confirmed	with	the	
medical	 history	 obtained	 from	 their	 general	 practitioner’s	 records.	Overall,	 7%	 of	
patients	had	a	pre-existing	diagnosis	of	 ischaemic	heart	disease.	Furthermore,	6%	
had	 a	 diagnoses	 of	 diabetes	 mellitus,	 11%	 Hypertension,	 8%	
Hypercholesterolaemia,	1%	cerebrovascular	accidents	and	1	patient	had	peripheral	
vascular	disease.	All	these	pathologies	could	be	indicative	of	potential,	undiagnosed	
arterial	disease.	
	
On	comparison	of	pre-injury	diagnoses	of	cardiovascular	disease	between	the	ACE	
and	no	ACE	cohorts,	although	the	prevalence	of	 IHD	was	comparable,	the	rates	of	
hypertension	(29%	vs	8%)	and	hypercholesterolaemia	(24%	vs	6%)	were	significantly	
higher	 in	 the	 ACE	 group.	 	 Patients	 who	 developed	 adverse	 cardiac	 events	 were	
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more	 likely	 to	have	been	using	calcium	channel	blockers	and	statins	prior	 to	 their	
injury.	 This	 may	 be	 reflective	 of	 the	 increased	 incidence	 of	 hypertension	 and	
hypercholesterolaemia	 in	 this	 group	 rather	 than	 the	medications	 being	 causative	
factors.	
	
	Table	3.3.	Patient	demographics	and	injury	characteristics	in	ACE	and	no	ACE	
groups	
	
		 All	patients	 No	ACE	 ACE	 P	value	
No	Patients		 290	 252		 38		 	
Cardiovascular	disease	 		 		 		
IHD		 20	(7%)	 14	(6%)	 5	(13%)	 0.13	
Diabetes	 16	(6%)	 11	(4%)	 4	(11%)	 0.18	
Hypertension	 32	(11%)	 20	(8%)	 11	(29%)	 0.02	
Hypercholesterolemia	 24	(8%)	 14	(6%)	 9	(24%)		 0.02	
PVD	 1	(<1%)	 0		 1	(3%)	 0.15	
CVA	 3	(1%)	 3	(1%)	 0	 0.61	
Medication	
Anti-Platelet	 10	(3%)	 6	(2%)	 4	(11%)	 0.03	
Oral	Hypoglycaemic	 7		(2%)	 5	(2%)	 2	(5%)	 0.23	
Insulin	 3	(1%)	 1	(<1%)	 2	(5%)	 0.05	
Anticoagulants	 4	(1%)	 2	(1%)	 2	(5%)	 0.08	
Beta	blocker	 6	(2%)	 4	(2%)	 2	(5%)	 0.18	
ACEi	 16	(6%)	 12	(5%)	 4	(11%)	 0.14	
Ca	Channel	blocker	 9	(3%)	 4	(2%)	 5	(13%)	 0.03	
Diuretic	 8	(3%)	 6(2%)	 2	(5%)	 0.28	
Anti	anginal	 1	(<1%)	 1	(<1%)	 0	 0.87	
Nitrate	 3	(1%)	 3	(1%)	 0	 0.66	
Statin	 18	(6%)	 10	(4%)	 8	(21%)	 <0.01	
	
Comparison	of	distribution	of	pre-injury	cardiovascular	diagnoses	and	medication	
between	the	two	cohorts.	All	values	are	given	as	n	values	with	the	value	as	a	
percentage	of	total	number	in	the	individual	cohort	in	parenthesis.	The	p	values	
were	obtained	from	mann-whitney	u	analysis	between	the	groups.	
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3.2.4	Electrocardiograms	
Electrocardiograms	 (ECGs)	 are	 a	 familiar	 and	 easily	 accessible	 examination	 tool,	
which	are	 in	fact	part	of	the	ATLS	guidelines	for	the	primary	survey	of	the	 injured	
patient.	 In	 routine	 practice	 however,	 due	 to	 the	 cumbersome	 nature	 of	 the	
equipment	 and	 the	 time	 critical	 environment	 they	 are	 often	 not	 completed.	
Patients	 included	 in	 the	 study	 were	 protocoled	 to	 have	 ECGs	 alongside	 blood	
sampling	 on	 admission,	 at	 24	 and	 72	 hours.	 Although	 94%	 patients	 had	 ECGs	 on	
admission	due	to	direct	 intervention	by	the	research	fellows,	only	56%	of	patients	
had	ECGs	at	24	hours	and	83%	at	72hours.	Nine	(3%)	patients	did	not	have	any	ECGs	
at	any	time	point.		
	
The	ECGs	were	studied	by	three	physicians;	two	clinical	research	fellows	(more	than	
3	years	post	qualification	from	medical	school,	and	independent	of	the	study)	and	
one	 independent	 medical	 registrar	 (5	 years	 post	 qualification	 from	medical	 with	
postgraduate	exams	in	general	medicine).	
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Table	3.4:	ECG	changes	on	admission,	24	hours	and	72	hours.	
	
	 Number	of	Patients	
ECG	Changes	
Admission	
n	(%	of	total=	272)	
At	24	hours	
n	(%	of	total=148)	
At	72	hours	
n	(%	total=	109)	
T	wave	inversion	 16	(6)	 19	(13)	 12	(11)	
RBBB	 9	(3)	 3	(2)	 3	(3)	
Sinus	Tachycardia	 8	(3)	 0	 1	(1)	
ST	changes	 7	(3)	 4	(3)	 2	(2)	
AF	 6	(2)	 1	(1)	 3	(3)	
LBBB	 4	(1)	 1	(1)	 0	
Prolonged	QT	 3	(1)	 1	(1)	 0	
LAD	 2	(1)	 1	(1)	 1	(1)	
1st	degree	heart	block	 2	(1)	 1	(1)	 1	(1)	
Ventricular	Ectopics	 2	(1)	 0	 2	(2)	
RAD	 1	(<1)	 3	(2)	 1	(1)	
Sinus	Arrhythmia	 0	 1	(1)	 0	
Sinus	Bradycardia	 0	 0	 1	(1)	
	
Changes	have	been	divided	into	changes	seen	T	wave	inversion	documented	if	
noted	on	2	leads	or	more,	right	bundle	branch	block	(RBBB),	Sinus	Tachycardia	
(HT>110bpm),	ST	segment	changes,	atrial	fibrillation	(AF),	left	bundle	branch	
block	(LBBB),	Prolonged	QT	time,	left	axis	deviation	(LAD),	Right	axis	deviation	
(RAD)	
	
	
Fifty-four	patients	had	ECG	changes	on	admission,	with	T	wave	inversion	being	the	
most	 common	ECG	 change	with	 a	prevalence	of	 6%.	 These	were	most	 frequently	
(63%)	seen	in	the	chest	leads.	Right	bundle	branch	block	(RBBB),	sinus	tachycardia	
and	 ST	 changes	 were	 also	 noted.	 Two	 of	 the	 nine	 patients	 who	 had	 RBBB	 had	
significant	thoracic	injury	with	a	thoracic	AIS	of	4	and	5	with	lung	injury.	The	other	
		 	 	 	
	 80	
seven	had	a	 thoracic	AIS	of	1	or	 less.	Of	 those	seven	patients,	one	had	persistent	
RBBB,	noted	on	admission	and	at	24	and	72	hours.	Whilst	it	was	transient	in	nature	
in	the	other	six	patients	noted	only	at	one	point,	with	1	patient	developing	RBBB	at	
24	hours.		
	
At	24	hours,	ST	changes	became	marginally	more	prevalent,	seen	in	3	%	of	patients,	
all	 were	 new	 at	 24	 hours	 and	 transient.	 Two	 of	 the	 four	 patients	 had	 significant	
thoracic	injury	with	an	AIS	of	3	and	5.		
	
Sinus	 tachycardia,	 atrial	 fibrillation	 and	 Left	 BBB	 (LBBB)	 were	 also	 commonly	
transient	 changes	 at	 admission.	 The	 initial	 changes	 are	 likely	 to	 be	multifactorial	
and	 individual	 to	 the	 patient	 due	 to	 a	 combination	 of	 direct	 cardiac	 injury,	 rate	
related	 changes,	 hypoperfusion,	 adrenergic	 stimulation	 and	 underlying	 vessel	
disease.		
	
Furthermore,	in	this	cohort	of	290	patients,	of	the	38	(13%)	patients	who	developed	
adverse	 cardiac	 complications,	 15	 (5%)	 patients	 had	 ischaemic	 changes	 on	 their	
ECGs,	of	whom	6	(2%)	had	one	or	more	cardiac	risk	factors.	In	most	settings,	these	
patients	 would	 have	 warranted	 further	 investigation	 and	 cardiology	 follow	 up.	
However,	only	one	of	those	6	patients	went	on	to	have	angiography.	These	changes	
are	often	attributed	to	high	heart	rates	and	therefore	often	forgotten	when	patient	
recovers	from	the	initial	resuscitative	period.	However,	the	manifestation	of	these	
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ischaemic	 changes	may	 signify	 underlying	 arterial	 disease	 and	 especially	 in	 those	
with	pre-disposing	risk	factors	validate	further	investigation.		
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3.2.5	Cardiac	biomarkers	in	trauma	patients	 	
Blood	samples	were	taken	from	patients	on	admission,	24	hours	after	injury	and	72	
hours	 after	 injury	 were	 centrifuged	 and	 the	 plasma	 stored	 in	 -80oC	 prior	 to	
processing.	All	admissions	samples	from	admission	were	processed	for	troponin,	nt-
ProBNP	and	h-FABP.	The	Troponin	ELISA	completed	for	the	admission	samples	did	
not	 show	any	 differentiation	 between	 the	 samples.	 Following	 discussion	with	 the	
manufacturers,	 it	was	decided	not	 to	 further	proceed	with	 testing	of	 the	24	hour	
and	72	hour	samples.		
	
All	 but	 one	 patient	 had	 blood	 sampling	 on	 admission	with	 the	 bloods	 (table	 3.1)	
taken	at	a	median	sampling	time	of	92	minutes	overall,	91	minutes	 in	the	no	ACE	
group	 and	 100	 minutes	 in	 the	 ACE	 group.	 The	 difference	 in	 time	 was	 not	 of	
statistical	significance.	(Table	3.1).		81%	of	patients	had	blood	sampling	at	24	hours	
and	 62%	 at	 72	 hours.	 At	 72	 hours,	 patient	 refusal	 for	 blood	 sampling	 reduced	
protocol	 compliance	 as	 on	 discharge	 to	 the	 ward,	 arterial	 or	 central	 lines	 were	
removed	necessitating	venepuncture	for	purely	research	purposes.		
	
On	admission,	the	patients	who	develop	ACEs	had	plasma	h-FABP	levels	that	were	
four	 folds	higher	 than	 the	patients	who	did	not	develop	ACE.	At	24	hours	and	72	
hours	there	was	no	significant	difference.	 	The	median	plasma	levels	of	nt-ProBNP	
in	 the	 patients	 who	 did	 not	 develop	 ACE	was	marginally	 higher	 than	 the	 normal	
reference	value	provided	by	the	manufacturers.	It	was	also	higher	than	the	median	
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value	 of	 nt-ProBNP	 in	 the	 no	 ACE	 group,	 however	 this	 was	 not	 statistically	
significant.		
	
Table	3.5:	Changes	in	cardiac	biomarkers	in	the	ACE	group	and	no	ACE	group	on	
admission,	at	24	hours	and	72	hours	
	
	 No	ACE	 ACE	 P	values	
h-FABP	(ng/ml)	
Admission	 15.2	(5.3-	50.7)	 62.0	(26.3	–	110.6)	 <0.001	
24	hour	 10.8	(3.5-	33.9)	 53.7	(8.2-	129.6)	 0.001	
72	hours	 4.4	(1.7-	9.6)	 8.9	(2.5-	54.5)	 0.04	
nt-ProBNP	(pmol/l)	
Admission	 400.6	(228.0	–	651.0)	 363.6	(0-473.5	 0.26	
24	hour	 422.8	(116.8-	994.9)	 461.5	(226.9-	1154.6)	 0.73	
72	hours	 246.3	(104.4-	447.6)	 231.3	(116.3-	573.7)	 0.73	
Troponin	
Admission	 0	(0-0)	 0	(0-0.3)	 0.299	
	
Values	given	as	medians	with	interquartile	ranges	are	given	in	parenthesis.	The	p	
values	were	obtained	from	mann-whitney	u	analysis	between	the	groups.	
	
	
There	was	no	difference	in	plasma	cardiac	biomarker	levels	between	groups	with	
and	without	severe	thoracic	injury.	In	the	group	with	severe	head	injury,	the	
patients	had	higher	levels	of	plasma	nt-ProBNP	on	admission	(396.2	vs	465.0	
pmol/l,	p=0.03).		
	 	
		 	 	 	
	 84	
	
Figure	3.2:	Comparison	of	h-FABP	levels	in	patients	with	and	without	ACE.	On	
admission	the	ACE	group	has	higher	levels	of	62	ng/ml	vs.	15.2	ng/ml,	p≤0.001	***,	
at	24	hours-	ACE	53.7	ng/ml	vs	10.8	ng/ml	in	the	no	ACE	group,		p	≤0.01**	and	at	72	
hours,	the	ACE	group	has	h-FABP	levels	of	8.9	ng/ml	vs	4.4	ng/ml	in	the	no	ACE	
group,	p≤0.05*.	
	
Figure	3.3:	Comparison	of	BNP	levels	in	patients	with	and	without	ACE.	On	
admission	the	ACE	group	had	BNP	levels	of	363.6	vs.	400.6	(p=0.26),	at	24	hours	the	
ACE	group	had	461.5	pml/L	vs.	422.8	pmol/L	in	the	no	ACE	group,	p=0.73	and	at	72	
hours	the	ACE	group	had	231.3	pmol.L	vs.	246.3	pmol/L,	p=0.73.	
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	Table	3.6:	Cardiac	biomarkers	in	mild	(AIS<3)	and	severe	(AIS>3)	head	and	
thoracic	injury	(AIS>3)	on	admission,	at	24	hours	and	at	72	hours	
	
	 Mild	Injury	
(AIS<3)	
Severe	Injury	
AIS>3	
p	value	
Thoracic	Injury	
HFABP		
Admission	 20.6	(6.2-	62.9)		 14.4	(5.4-	60.1)	 0.33	
24	hours	 12.9	(4.5-	53.7)	 18.4	(2.7-	37.9)	 0.44	
72	hours	 5.9	(1.9-	12.3)	 2.4	(0-12.0)	 0.06	
nt-ProBNP	
Admission	 380.9	(215.7-	614.7)	 435.2	(226.3-	706.4)	 0.55	
24	hours	 422.8	(117.0-	905.7)	 491.8	(137.4-	2169.5)	 0.19	
72	hours	 242.8	(108.7-	484.1)	 339.1	(95.7-	418.5)	 0.86	
Troponin	
Admission	 0	 0	 0.81	
Head	Injury	
HFABP		
Admission	 17.5	(6.2-	65.5)	 22.5	(5.1-	49.8)	 0.67	
24	hours	 15.6	(4.5-	48.4)	 8.8	(3.2-	27.3)	 0.13	
72	hours	 4.1	(1.7-	12.3)	 6.4	(2.0-	28.1)	 0.40	
nt-ProBNP	
Admission	 369.2	(208.7-	562.3)	 465.0	(318.8-	846.4)	 0.03	
24	hours	 448.0	(116.9-	1085.3)	 418.2	(181.5-	964.7)	 0.90	
72	hours	 231.4	(103.5-	417.0)	 325.1	(112.3-	541.3)	 0.41	
Troponin	
Admission	 0	 0	 0.16	
	
The	values	are	given	as	median	with	the	interquartile	ranges	in	parenthesis.		
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3.2.6	Echocardiograms	
Echocardiograms	 were	 requested	 through	 the	 hospital	 cardiac	 physiology	
department	at	 the	Royal	 London	on	all	 patients.	Due	 to	 the	 limited	availability	of	
the	 cardiac	 physiologist,	 only	 43	 (15%)	 patients	 had	 an	 echocardiogram,	 of	 those	
65%	 had	 complete	 data	 sets	 with	 good	 views.	 In	 the	 patients	 who	 had	
echocardiograms,	 19	 (44%)	 patients	 had	 an	 adverse	 cardiac	 event	 during	 their	
admission.	 	 The	 left	 ventricular	 stroke	 volume,	 ejection	 fraction,	 fractional	
shortening,	ventricular	volumes	and	E:A	ratios	were	all	measured.	
	
The	stroke	volume	is	the	amount	of	blood	expelled	from	the	ventricle	per	beat	and	
contributes	to	the	cardiac	output.	This	can	be	calculated	by	multiplying	the	velocity	
time	integral	by	the	left	ventricular	outflow	tract	(LVOT)	area.		Velocity	time	integral	
or	the	stroke	distance	is	a	measure	of	the	distance	the	blood	moves	with	each	beat.	
Doppler	signal	from	the	left	outflow	tract	is	recorded	and	the	sum	of	the	individual	
velocities	are	computed	and	divided	by	time	to	give	the	velocity	time	integral.	The	
diameter	 of	 the	 left	 ventricular	 outflow	 tract	 is	measured	 in	 the	 parasternal	 long	
axis	view	and	the	area	calculated	using:	
Stroke	Volume=	LVOT	area	x	VTI	
The	left	ventricular	stroke	volume	for	both	the	groups	were	at	the	lower	end	of	the	
normal	range	and	no	different	between	the	two	groups	(ACE	group	67	ml	vs.	66	ml	
no	ACE).	
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Figure	3.4:	Comparison	of	left	ventricular	stroke	volume	between	ACE	(median	
67ml-	IQR	60-74ml)	and	no	ACE	group	(median	66ml-	IQR	52-90ml).	The	p	value	of	
0.96	was	obtained	from	mann-whitney	u	analysis	between	the	groups.	
	
	
End	 diastolic	 and	 end	 systolic	 volumes	 can	 be	 used	 to	 approximate	 preload,	
afterload	 and	 contractility.	 The	 end	 diastolic	 volume	 is	 the	 volume	 of	 a	 filled	
vemtricle.	 Therefore	 a	 decrease	 in	 preload	 due	 to	 reduced	 venous	 return	 would	
lead	to	a	concurrent	decrease	in	the	end	diastolic	and	systolic	volume.	Changes	in	
ventricular	 contractility	 can	 also	 lead	 to	 changes	 in	 the	 ESV	 and	 EDV.	 Increase	 in	
heart	contractility	leads	to	a	reduction	in	ESV	and	a	concurrent	reduction	in	EDV.	
	
The	 left	 ventricular	 volumes	 are	 derived	 using	 the	 Teicholz	 formula	 to	 convert	
ventricular	 internal	 diameters	 during	 systole	 and	 diastole.	 The	 left	 ventricular	
internal	 diameter	 is	 calculated	 at	 end	 diastole	 and	 systole.	 The	 end	 systolic	
diameter	is	measured	at	the	end	of	the	t	wave	as	seen	on	ECG,	when	the	walls	are	
at	their	most	inward	position.		Similarly,	the	end	diastolic	measurement	is	taken	at	
the	beginning	of	 the	Q	wave.	Both	measurements	are	 taken	along	the	apical	 long	
axis	from	the	apex	to	the	midpoint	of	the	mitral	plane	on	echocardiography	in	the	
four-chamber	view	and	along	the	radial	axis	on	a	two-chamber	view.	
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The	 end	 systolic	 volume	 in	 the	 ACE	 group	 (29ml)	 was	 lower	 than	 in	 the	 no	 ACE	
group	 (38.5ml)	but	not	of	 statistical	 significance.	This	 is	 also	 reflected	by	 the	EDV	
with	 lower	EDV	 in	 the	ACE	 (median	99ml-	 IQR	86-109)	group	compared	to	 the	no	
ACE	 (median	109ml-	 IQR	90-	119)	group.	This	may	be	due	 to	 the	 reduced	venous	
pressure	 secondary	 to	 hypovolaemia	 in	 the	 ACE	 group	 or	 due	 to	 the	 increased	
myocardial	contractility	in	a	hyperdynamic,	critically	injured	patient.		
	
Figure	3.5:	Comparison	of	end	systolic	volume	between	ACE	(median	29ml-	IQR	
18.5-38.5)		and	no	ACE	(median	38.5ml-	IQR	24-47ml)	group.	The	p	value	of	0.20	
was	obtained	from	mann-whitney	u	analysis	between	the	groups.	
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Figure	3.6:	Comparison	of	end	diastolic	volume	between	ACE	(median	99ml-	IQR	
85.5-	109)	and	no	ACE	(median	108.5ml-	IQR	90-	119)	group.	The	p	value	of	0.28	
was	obtained	from	mann-whitney	u	analysis	between	the	groups.	
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Ejection	fraction	was	used	as	a	measure	of	left	ventricular	function.	It	is	a	derived	
ratio	of	the	change	in	left	ventricular	volume	over	the	cardiac	cycle	as	compared	to	
its	maximal	volume	during	diastole,	as	follows:	!"#$%&'( !"#$%&'( = !"!"# − !"!"#!"!"#  ! 100	
Surprisingly,	 despite	 the	 adverse	 cardiac	 events,	 the	 ejection	 fraction	 was	 not	
altered	in	the	ACE	group.	The	median	ejection	fraction	was	maintained	at	a	normal	
level	of	70%	for	both	groups.	
	
Figure	3.7:	Comparison	of	ejection	fraction	between	ACE	(median	70%-	IQR	64-	76)	
and	no	ACE	(IQR	70%-	IQR	58-70)	group.	The	p	value	of	0.27	was	obtained	from	
mann-whitney	u	analysis	between	the	groups.	
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Fractional	shortening	can	be	used	as	a	measure	of	contractility.	Measurements	of	
end	systolic	diameter	and	end	diastolic	diameter	are	taken	from	the	left	ventricle.	
The	ratio	of	the	change	in	diameter	over	the	cardiac	cycle	over	the	end	diastolic	
diameter	is	calculated	as:	!"#$%&'(#) !"#$%&'(') = !"#$$ − !"#$%!"#$$  ! 100	
Fractional	shortening	seemed	to	have	an	upward	trend	with	adverse	cardiac	events,	
rising	 to	 38%	 compared	 to	 32%	 in	 the	 no	 ACE	 group.	 Both	 values	 are	within	 the	
normal	range	for	fractional	shortening.	
	
Figure	3.8:	Comparison	of	fractional	shortening	between	ACE	(median	38%-	IQR	34-
42)	and	no	ACE	(median	32%-	IQR	27-45)	group.	The	p	value	of	0.48	was	obtained	
from	mann-whitney	u	analysis	between	the	groups.	
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The	 interventricular	 septal	 end	 diastolic	 diameter	 (IVSDd)	 is	 measured	 in	 the	
parasternal	view	at	 the	beginning	of	 the	Q	wave.	This	can	be	used	as	a	surrogate	
marker	for	left	ventricular	hypertrophy	and	ventricular	mass.	In	the	ACE	group	the	
IVSDd	was	1.2cm	compared	to	1	cm	in	the	no	ACE	group.	This	small	difference	may	
be	due	 to	 this	group	having	a	greater	number	of	hypertensive	patients,	however,	
both	values	are	still	within	the	normal	limits.	
	
Figure	3.9:	Interventricular	septal	end	diastole	diameter	in	ACE	(median	1.2cm-	IQR	
1.0-	1.3)	and	no	ACE	(median	1-	IQR	0.9-1.3)	group.	The	p	value	of	0.29	was	
obtained	from	mann-whitney	u	analysis	between	the	groups.	
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The	E:A	ventricular	 filling	 ratio	 can	be	used	as	a	marker	of	diastolic	 function.	 The	
ratio	 takes	 into	 account	 the	 early	 diastolic	 (E)	 filling	 and	 late	 (A)	 filling	 of	 the	
ventricles.	Normal	E:A	ratio	varies	between	1	and	2	with	a	reduction	below	1	likely	
to	represent	diastolic	dysfunction	due	to	impaired	relaxation	or	an	increase	in	ratio	
above	2	can	be	due	to	restrictive	diastolic	dysfunction.	In	this	cohort	the	median	for	
both	groups	remain	within	normal	 limits,	1	 in	the	No	ACE	group	and	1.2	 in	the	no	
ACE	group	with	no	statistically	significant	difference.		
	
	
Figure	3.10:	E:A	ratio	in	ACE	(median	1-	IQR1.12-1.39)	and	no	ACE	(median	1.2-	IQR	
0.9-1.47)	group.	The	p	value	of	0.96	was	obtained	from	mann-whitney	u	analysis	
between	the	groups.	
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3.2.8	In-	hospital	Medications	
	
During	the	patients’	hospital	admission,	notes	were	reviewed	and	initiation	of	new	
medication	documented	by	research	fellows	on	a	daily	basis.	A	higher	percentage	of	
patients	 developing	ACEs	 (37%)	 received	 Tranexamic	 acid	 compared	 to	 the	 group	
who	did	not	develop	ACEs	(15%).	Tranexamic	acid	administration	coincides	with	the	
initiation	of	 the	major	haemorrhage	protocol.	Therefore,	 this	may	be	 reflective	of	
the	increased	severity	of	injury	and	potentially	larger	number	of	patients	presenting	
with	active	bleeding.	The	higher	rates	of	inotropic	use,	as	well	as	diuretic	use,	in	the	
ACE	 cohort	 could	 be	 suggestive	 of	 a	 state	 of	 shock.	 As	 previously	 mentioned	 in	
Section	 3.2.4,	 15	 patients	 developed	 ischaemic	 changes,	 which	 would	 have	
warranted	 dual	 antiplatelet	 therapy	 in	 other	 patient	 groups.	 However,	 in	 the	
trauma	patients,	where	bleeding	 is	a	concern,	 this	 is	often	not	safe.	Although	not	
included	in	this	graph-	Aspirin	alone	was	initiated	in	one	of	these	20	patients.		
	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.11:	Comparison	of	medications	initiated	in	hospital	between	the	groups	with	ACE	group	and	without	development	of	no	ACE	(*	=	
p<group.	(*≤0.05,	***	=	p<**≤0.01,	***≤0.001)	
3.2.9	Clinical	Outcomes	
The	patients	that	developed	ACEs	were	twice	as	more	likely	to	require	admission	to	
ICU	 (95%	 vs	 47%,	 p<0.01)	 and	 on	 average	 required	 13	 days	 longer	 in	 ICU	 when	
compared	 to	 those	 who	 did	 not	 develop	 ACE.	 In	 addition,	 those	 that	 developed	
ACEs	spent	21	days	 longer	 in	hospital	(28	vs.	7	days,	p<0.01).	Cardiac	events	were	
also	associated	with	four-fold	increase	in	mortality	(24%	vs	6%,	p<0.01).	
	
Table	3.7:	Comparison	of	outcomes	
	
Outcomes	 No	ACE	 ACE	 p	value	
ICU	admission	(%)	 47	 95	 <0.01	
ICU	Length	of	Stay	(Days)	 0	(0-2)	 13	(6-19)	 <0.01	
Total	Length	of	Stay	(Days)	 7	(2-15)	 28	(14-47)	 <0.01	
Mortality	Rate	(%)	 14	(5)	 9	(3)	 <0.01	
ICU	admission	and	mortality	are	given	as	n	numbers	with	percentage	of	total	
patients	in	parenthesis.	Median	of	the	total	length	of	stay	is	stated	with	
interquartile	ranges	in	parenthesis.	
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3.2.10	Predicting	Adverse	Cardiac	Events	 	
H-FABP	was	 found	 to	be	associated	with	ACEs,	which	 in	 turn	was	associated	with	
longer	 critical	 care	 and	 hospital	 admission.	 Therefore,	 the	 use	 of	 h-FABP	 as	 a	
predictor	of	ACE	was	assessed	using	a	ROC	curve.	The	derived	area	under	the	curve	
(AUC)	was	0.76	indicative	of	its	positive	predictive	value.		
	
	
Figure	3.12:	ROC	curve	of	predictive	strength	of	h-FABP	for	adverse	cardiac	event	
with	AUC	of	0.76	
	
A	large	meta-	analysis	study	looking	at	h-FABP	levels	in	myocardial	ischaemia	used	5	
-16.8	ng/ml	as	diagnostic	cut-off	points.	 In	this	study	population,	16.8	ng/ml	has	a	
sensitivity	of	86%	and	specificity	of	51%	for	predicting	adverse	cardiac	events	(119)	
Patients	 with	 plasma	 h-FABP	 levels	 above	 16.8	 ng/ml	 were	 assumed	 to	 have	
myocardial	 injury	 and	were	 defined	 as	 having	 trauma	 induced	 secondary	 cardiac	
injury	(TISCI).	Outcomes	of	these	patients	were	compared	to	those	not	developing	
TISCI.		
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Table	3.8:	Comparison	of	patient	characteristics	in	development	of	TISCI	
	
	 No	TISCI	
H-FABP<	16.8ng/ml	
TISCI	
HFABP>16.8ng/ml	
P	value	
Demographics	
No	Patients	
%	developing	an	ACE	
129	(44%)	
6	(5%)	
161	(56%)	
32	(20%)	
	
<0.001	
Median	Age	
<30	
31-45	
46-65	
66-80	
>81	
34	(23-46)	
52	(40%)	
42	(33%)	
25	(19%)	
5	(4%)	
3	(2%)	
41	(28-59)	
49	(30%)	
43	(27%)	
45	(28%)	
17	(11%)	
6	(4%)	
0.03	
Male	 113	(88%)	 125	(78%)	 0.19	
Cardiovascular	Disease	
IHD		 8	(6%)	 12	(7%)	 0.59	
Diabetes	 4	(3%)	 11	(7%)	 0.35	
Hypertension	 11	(9%)	 21	(13%)	 0.27	
Hypercholesterolemia	 8	(6%)	 16	(10%)	 0.49	
PVD	 0	 1	(<1%)	 0.58	
CVA	 1	(<1%)	 2	(1%)	 0.62	
Injury	Characteristics	
ISS	 9	(4-16)	 25	(13-34)		 <0.001	
Thoracic	AIS	 0	(0-1)	 3	(1-4)		 <0.001	
H&N	AIS	 0	(0-2)	 0	(0-4)	 0.45	
Admission	SBP	 137	(119-149)	 120	(97-139)	 <0.001	
Admission	Lactate	 1.9	(1.3-3.0)	 2.5	(1.6-4.3)	 0.08	
Demographics	and	cardiovascular	diagnoses	are	given	as	absolute	n	values	with	
percentages	in	parenthesis.	Injury	characteristics	are	stated	as	median	values	
with	interquartile	ranges	in	parenthesis.	(*	=	p≤(*≤0.05,	**	=	p≤**≤0.01,	***≤0.001)	
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Overall	161	(56%)	patients	had	elevated	h-FABP	levels	of	>16.8	ng/ml	and	32	(20%)	
of	these	subsequently	developed	an	ACE	(compared	to	5%	of	those	without	TISCI,	
p<0.001,	Table	1).		Biomarker	evidence	of	TISCI	on	admission	was	associated	with	a	
greater	ISS	and	higher	thoracic	AIS.	TISCI	was	also	associated	with	lower	admission	
blood	pressures	and	higher	lactate	levels.			
	
Table	3.9:	Comparison	of	biomarkers	and	outcomes	in	TISCI	
	
	 No	TISCI	
H-FABP<	16.8ng/ml	
TISCI	
HFABP>16.8ng/ml	
P	value	
Admission	Cardiac	Biomarkers	
H-FABP	(ng/ml)	 54.8	(35.9-	95.7)	 51.3	(25.0-	88.8)		 <0.01	
nt-ProBNP	(fmol/ml)	 342.0	(257.6-631.6)	 310.0	(254.9-522.1)	 0.66	
Troponin	I	(ng/ml)	 0	(0-0)	 0	(0-0)	 0.65	
Outcomes	
Inotrope	days	 0	(0-0)	 0	(0-3)	 	
ICU	Length	Of	Stay	 0	(0-0)	 1	(0-7)	 <0.01	
Total	Length	of	Stay	 4	(2-10)	 15	(7-37)	 <0.01	
Mortality	 6	(5%)	 22	(14%)	 0.05	
Values	are	given	as	medians	with	interquartile	ranges	in	parenthesis.	(*	=	p≤0.05,	
**	=	p≤0.01)	
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Patients	with	 TISCI	 spent	 a	median	of	 1	 day	 longer	 on	 ICU	 and	11	days	 longer	 in	
hospital.	TISCI	was	associated	with	a	3-fold	higher	mortality	(14%	vs	5%,	p=0.01).		
	
Figure	3.13:	Difference	in	adverse	cardiac	events	20%	in	those	with	TISCI	vs	5%	in	
those	without	(p≤0.001***)		and	30	day	mortality	14%	in	those	with	TISCI	and	5%	in	
those	without	(p=0.01)	
	
3.3	Summary	of	Chapter	
	
This	chapter	presents	the	results	of	a	prospective	study	of	adverse	cardiac	events	in	
critically	 injured	 patients,	 and	 explores	 the	 associative	 factors	 and	 the	 impact	 on	
outcome.		
	
The	13%	incidence	of	adverse	cardiac	events	in	this	prospective	study	was	similar	to	
the	 previous	 smaller	 retrospective	 study	 presented	 by	 our	 group,	 but	 lower	 than	
that	 reported	 in	 other	 study	 populations	 (102,118,120).	 	 The	 commonest	 ECG	
changes	 was	 T	 wave	 inversion	 of	 which	 63%	 occurred	 in	 3	 or	 more	 chest	 leads,	
followed	 by	 supraventricular	 tachycardias	 predominated,	 but	 there	 was	 also	
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evidence	of	ischemic	injury.	Susceptibility	to	the	development	of	ACEs	is	identifiable	
on	admission	by	 levels	of	cardiac	biomarkers,	specifically	h-FABP.	 	While	age,	pre-
existing	 cardiovascular	 diagnoses,	 and	 direct	 thoracic	 trauma	 appear	 to	 be	 risk	
factors	 for	 the	 development	 of	 TISCI,	 one	 third	 of	 patients	 had	 none	 of	 these	
features.		The	degree	of	shock	was	strongly	associated	with	admission	TISCI	and	the	
development	of	ACEs.	
	
Patients	 with	 evidence	 of	 TISCI	 had	 double	 the	 baseline	mortality	 while	 in	 those	
who	 went	 on	 to	 develop	 an	 ACE	 mortality	 was	 tripled.	 	 Although	 we	 primarily	
identified	 rhythm	disturbances,	 it	 is	not	 clear	how,	or	 if,	 these	contributed	 to	 the	
mode	 of	 death.	 	 We	 did	 not	 specifically	 measure	 cardiac	 function	 but	 inotropic	
support	 was	 similar	 across	 the	 groups.	 	 There	 is	 some	 experimental	 evidence	 to	
suggest	that	myocardial	damage	occurs	following	trauma	and	haemorrhagic	shock	
via	 a	 variety	 of	 postulated	 mechanisms	 (102,121,122).	 	 Human	 data	 on	 this	 is	
lacking,	 however,	 and	 it	 remains	 unclear	 how	 cardiac	 injury	 and	dysfunction	may	
contribute	to	increased	morbidity	and	mortality	in	trauma	patients.		
	
The	potential	usefulness	of	three	cardiac	biomarkers	in	predicting	ACE	on	admission	
in	 trauma	patients	was	 studied.	 	On	 admission,	 h-FABP	was	 the	only	marker	 that	
was	 significantly	 raised,	 and	 56%	 of	 the	 patients	 had	 high	 levels	 of	 h-FABP	
suggestive	of	significant	myocardial	cell	damage	with	leakage	of	cytoplasmic	protein	
(123).	Furthermore,	the	patients	who	developed	ACE	also	had	persistently	higher	h-
FABP	 levels	 compared	 to	 the	 no	 ACE	 group.	 Although,	 h-FABP	 levels	 positively	
correlated	with	thoracic	injury	severity,	a	third	of	patients	with	myocardial	leak	had	
insignificant	chest	trauma.		Global	injury	severity	and	the	degree	of	shock	appear	to	
be	 strong	 factors	 in	 the	 development	 of	 TISCI.	 	 Putative	 mechanisms	 include	
ischemia,	 damage-induced	 inflammation	 or	 reperfusion	 injury	 (103,122,124,125).	
However,	the	specific	cardiac	pathology	and	underlying	mechanisms	have	not	been	
elucidated.	 	 Nevertheless,	 the	 presence	 of	 myocardial	 leak	 immediately	 on	
admission	 strongly	 correlated	 with	 adverse	 outcomes.	 	 H-FABP	 may	 be	 a	 useful	
early	biomarker	for	patient	risk	stratification.	In	an	inpatient	setting,	this	could	aid	
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clinical	decisions	regarding	monitoring	and	nursing		requirements	and	on	discharge,	
delineate	patients	who	may	need	ongoing	cardiac	surveillance.		
	
There	are	several	 limitations	 to	 this	study.	 	Although	prospectively	conducted,	we	
did	not	formally	measure	cardiac	output	or	other	aspects	of	cardiac	function	in	the	
cohort.	 	 Although,	 attempts	 were	 made	 to	 obtain	 echocardiographic	 data	 on	 all	
patients,	 deficiencies	 in	 service	 provision	 and	 a	 lack	 of	 availability	 cardiac	
physiologists	 or	 clinicians	 competent	 in	 echocardiography	 lead	 to	 the	 failure	 to	
obtain	sufficient	data.	Furthermore,	the	parameters	measured	in	this	study	are	all	
to	different	degrees	volume	and	rate	dependent.	Newer	techniques	such	as	tissue	
doppler	 index	and	global	 longitudinal	strain	(GLS)	as	measured	by	speckle	tracking	
are	more	reliable	 indicators	of	cardiac	function	(126).	 	Tissue	Doppler	 imaging	can	
be	 used	 to	measure	 the	 changes	 in	myocardial	 velocity	 over	 a	 cardiac	 cycle	with	
measurements	 taken	 at	 systole	 (S’),	 early	 diastolic	 relaxation	 (e’)	 and	 during	 late	
diastole	 (a’)	 (126).	 These	 show	 a	 linear	 correlation	 with	 LVEF	 but	 are	 also	 more	
sensitive	 markers	 of	 function	 as	 they	 are	 less	 volume	 dependent	 (127).	 	 Two-	
dimensional	 speckle	 tracking	 is	 an	 emerging	 technique	 for	 measuring	 cardiac	
contractility	through	analysis	of	the	migration	2	pixels	on	2-D	clips.	This	has	shown	
to	correlate	well	with	traditional	measures	of	systolic	and	diastolic	function	and	also	
more	 sensitive	at	 identifying	 reduced	 function.	 It	 is	 also	volume	 independent	and	
unlike	the	tissue	doppler	measurements	also	angle	independent	(128).		However,	in	
a	 centre	 with	 limited	 echocardiography	 facility,	 it	 was	 not	 possible	 to	 ascertain	
these	measurements.	No	other	functional	data	was	obtained	in	the	form	of	dynamic	
cardiac	 output	 monitoring	 (lithium	 dilution,	 thermodilution,	 pulmonary	 artery	
catheters)	or	cardiac	MRIs.	
	
Further	work	is	needed	to	monitor	and	image	cardiac	function	in	critically	ill	trauma	
patients.	Data	on	the	exact	mode	of	death	of	these	patients	were	not	collected	and	
therefore	we	were	not	able	to	link	the	adverse	cardiac	events	to	the	mode	of	death	
of	the	patients,	or	to	describe	how	cardiac	dysfunction	may	have	contributed.	The	
patient	 group	who	 develops	 cardiac	 injury	 is	 significantly	more	 injured	 and	more	
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shocked,	 therefore	 it	 may	 be	 inevitable	 that	 these	 patients	 go	 on	 to	 develop	 of	
secondary	cardiac	injury	as	part	of	the	systemic	inflammatory	insult	of	polytrauma,	
leading	 to	 multi	 organ	 failure	 and	 eventually	 leading	 to	 death.	 Late	 deaths	 in	
trauma	 are	 often	multifactorial,	 but	more	work	 needs	 to	 be	 done	 to	 explore	 the	
specific	contribution	TISCI	makes	to	morbidity	and	mortality	after	trauma.			
	
In	 this	 large	 prospective	 cohort	 study	 we	 have	 confirmed	 the	 presence	 of	
biomarker-identified	TISCI	on	admission	in	major	trauma	patients.	It	carried	a	high	
risk	of	subsequent	adverse	cardiac	events	and	poor	outcomes.			
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Chapter	4	
Catecholamines	In	
Trauma	Induced	Secondary	Cardiac	Injury	
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4.1	Introduction	
	
The	physiological	 stress	of	 severe	 injury	 leads	 to	a	hyperadrenegic	 state.	 In	1975,	
Jaattela	published	data	on	45	severely	 injured	patients	 in	whom	it	was	noted	that	
up	to	6	hours	post	injury	the	catecholamine	levels	were	greater	than	their	baseline	
taken	at	8	days	post	injury	(129).	This	was	also	mirrored	in	studies	in	traumatic	head	
injury,	 which	 induces	 with	 surge	 of	 catecholamines	 and	 unopposed	 sympathetic	
activation	 (130).	 Increased	 catecholamine	 levels	 have	 also	 been	 demonstrated	 in	
burns	 patients,	 which	 is	 furthermore	 associated	 with	 increased	 infection	 rates	
(131).	Hyperadrenergic	states	with	high	levels	of	catecholamines	can	be	deleterious	
to	the	heart	due	to	excessive	stimulation	of	the	adrenergic	receptors,	particularly	at	
the	apex	of	the	heart.	Excessive	adrenergic	stimulation	of	cardiomyocytes	 induces	
rapid	changes	in	calcium	influx	and	even	cardiomyocyte	death	(132).		
	
In	 traumatic	 brain	 injury	 patients	 studies	 have	 shown	 cardiac	 dysfunction,	 with	
prevalence	varying	from	8%	to	28%	in	different	studies	(133-135).	Beta-blockade	in	
TBI	has	been	shown	to	reduce	hospital	mortality	in	nine	observational	studies	(136).	
However,	 exposure	 to	 beta	 blockers	 was	 also	 associated	 with	 an	 increase	 in	
infection	rates	and	length	of	hospital	stay	(97)	(137,138).		
	
In	polytrauma	patients,	high	circulating	levels	of	adrenaline	have	been	shown	to	be	
associated	 with	 endothelial	 dysfunction,	 coagulopathy	 and	 increased	 mortality	
(139)	 (140).	 A	 retrospective	 study	 noted	 a	 greater	 incidence	 of	 atrial	 fibrillation	
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associated	with	catecholamine	use	(141).	Although,	Arababi	et	al	also	demonstrated	
an	 improvement	 in	mortality,	 the	results	 from	the	retrospective	study	by	Nieeden	
et	al	2008	demonstrated	contradictory	results	(96,98,99).	
4.2	Study	Aims	
	
Although,	 the	 deleterious	 effects	 of	 catecholamines	 have	 been	 alluded	 to	 in	
polytrauma,	 their	 association	with	adverse	 cardiac	events	has	only	been	explored	
retrospectively.	 Study	 data	 collected	 during	 TACID	 demonstrated	 the	 elevation	 of	
cardiac	enzymes	following	traumatic	injury.	Release	of	these	enzymes	is	suggestive	
of	 cardiomyocyte	 death	 in	 this	 cohort.	 The	 aim	 of	 this	 chapter	 is	 to	 explore	 the	
contribution	 of	 catecholamines	 to	 cardiac	 injury	 as	 well	 as	 length	 of	 stay	 and	
mortality	 in	 this	 patient	 group.	 Plasma	 levels	 of	 adrenaline,	 noradrenaline	 and	
dopamine	concentrations	were	measured	on	admission,	at	24	hours	and	72	hours	
following	injury.		
4.3	Results	
4.3.1	Plasma	Catecholamine	in	Adverse	Cardiac	Events	
On	admission	plasma	adrenaline	and	noradrenaline	levels	were	significantly	higher	
in	 the	 group	 who	 developed	 ACE.	 Although,	 the	 distribution	 of	 the	 admission	
plasma	 dopamine	 levels	 is	 skewed,	 this	 was	 not	 significantly	 different.	 The	 ACE	
group	had	a	median	noradrenaline	concentration	of	2.03μg/ml,	twice	that	of	the	no	
ACE	 group	 at	 1.08	 μg/ml	 (normal	 reference	 0.19–0.23	 ng/mL).	 The	 adrenaline	
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concentration	on	admission	was	three	times	higher	at	0.67	μg/ml	compared	to	the	
no	 ACE	 group	 at	 0.26	 μg/ml	 (normal	 reference	 0.06–0.08	 ng/mL).	 Although	 the	
dopamine	concentration	on	admission	in	the	ACE	group	was	higher	0.0031	μg/ml	as	
compared	 to	 0.0018	μg/ml,	 this	 difference	was	not	 significantly	 different	 (normal	
reference	0.05–0.1	ng/mL).		
	
At	24	hours	following	injury,	there	was	a	significant	difference	in	the	concentration	
of	 noradrenaline	 and	 dopamine	 but	 not	 adrenaline.	 	 The	 difference	 in	 plasma	
noradrenaline	concentration	became	much	more	apparent	with	a	concentration	of	
5.11	μg/ml	in	the	ACE	group	versus	0.88	μg/ml	in	the	no	ACE	group	-	representing	a	
six	 fold	 increase.	 	 The	 plasma	 adrenaline	 concentration	 at	 24	 hours	 is	 similar	
between	the	two	groups	with	0.095	μg/ml	 in	ACE	and	0.107	 in	the	no	ACE	group.	
Dopamine	concentration	only	demonstrates	a	difference	at	the	24-hour	time	point.	
The	concentration	of	dopamine	 is	 three	times	greater	 in	the	ACE	group	ay	0.0269	
μg/ml	compared	to	0.0083	μg/ml	in	the	no	ACE	group.		
	
At	72	hours,	the	only	demonstrable	difference	in	circulating	catecholamines	was	the	
plasma	 adrenaline	 concentration.	 	 The	 ACE	 group	 had	 four	 times	 greater	 at	 3.22	
μg/ml	compared	to	0.814	μg/ml.	This	may	be	due	to	the	exogenous	catecholamine	
use.	
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Figure	4.1	Boxplot	showing	difference	in	noradrenaline	(NA)	levels	with	the	presence	
of	ACE-	On	admission	 the	median	 serum	 levels	were	1.08	μg/ml	 (IQR:	0.49-2.0)	 in	
the	no	ACE	group	vs.	median	2.03	μg/ml	 (IQR:	0.82-	4.3)	 in	ACE	 (p<0.01).	At	24h-		
0.89	μg/ml	(IQR:	0.20-	2.52)	 in	the	no	ACE	group	vs.	5.11μg/ml	(IQR:	0.93-9.59)	 in	
ACE	(p<0.01).	At	72h-	0.07	μg/ml	(IQR:	0.04-0.13)	in	the	no	ACE	group	vs	0.07	μg/ml	
(IQR:	0-0.13)	in	ACE	(p=0.68).		
	
	
Figure	4.2	Boxplot	showing	difference	in	adrenaline	levels	with	the	presence	of	ACE-	
On	admission	the	median	serum	levels	were	0.26	μg/ml	(IQR:	0.49-2.0)	in	the	no	ACE	
group	 vs.	 0.67	 μg/ml	 (IQR:	 0.30-	 2.44)	 in	 ACE	 (p=0.01).	 At	 24h-	 0.11	 μg/ml	 (IQR:	
0.46-0.21)	 in	 the	no	ACE	group	 vs.	 0.10	 (IQR:	0-0.22)	 in	ACE	 (p=0.6).	At	 72h-	0.81	
μg/ml	 (IQR:	 0.44-2.28)	 in	 the	no	ACE	group	 vs	 3.22	μg/ml	 (IQR:	 1.25-6.49)	 in	ACE	
(p<0.01).		
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Figure	4.3	Boxplot	showing	difference	in	dopamine	levels	with	the	presence	of	ACE-	
On	admission	the	median	serum	levels	were	0.00.18	μg/ml	(IQR:	0-0.008)	in	the	no	
ACE	group	vs.	0.0031	μg/ml	(IQR:	0-	0.025)	in	ACE	(p=0.09).	At	24h-	0.008	μg/ml	
(IQR:	0.003-0.018)	in	the	no	ACE	group	vs.	0.027	(IQR:	0-.013-0.412)	in	ACE	(p<0.01).	
At	72h-		0.004	μg/ml	(IQR:	0-0.010)	in	the	no	ACE	group	vs	0.006	μg/ml	(IQR:	0-
0.009)	in	ACE	(p<0.01).		
	
	
In	summary	on	admission,	plasma	noradrenaline	and	adrenaline	were	significantly	
higher	in	the	ACE	group	at	baseline,	with	noradrenaline	remaining	higher	at	24	
hours.	Adrenaline	remains	elevated	in	the	ACE	group	at	72	hours,	potentially	due	to	
exogenous	administration	of	inotropes.	
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4.3.2	Catecholamines	and	Injury	Burden	
	
We	then	investigated	the	association	between	circulating	levels	of	catecholamines	
and	 the	 severity	 of	 injury	 patients	 had	 sustained.	 	 An	 ISS	 of	 greater	 than	 15	was	
used	to	identify	severely	injured	patients.	The	severely	injured	patients	had	higher	
plasma	noradrenaline	levels	on	admission	compared	to	the	less	 injured	group	(1.2	
μg/ml	 vs.	 0.99μg/ml,	 p=0.01).	 This	 difference	 was	 sustained	 and	 becomes	 more	
marked	 at	 24	 hours;	 with	 plasma	 levels	 of	 1.7	 μg/ml	 in	 the	 more	 injured	 group	
almost	double	that	on	the	less	injured	group	at	0.9μg/ml	(p=0.01).	However,	at	72	
hours,	 the	 levels	 of	 noradrenaline	 had	 diminished	 in	 both	 groups	 and	 no	 evident	
difference	was	detectable	between	the	two	groups	(Figure	4.2).			
	
Plasma	 adrenaline	 was	 also	 raised	 on	 admission	 and	 the	 severely	 injured	 group	
displayed	more	than	double	the	circulating	levels	demonstrated	in	the	less	injured	
cohort	 (0.5	 μg/ml	 vs.	 0.2μg/ml	 respectively	 (p=0.001)).	 Serum	 adrenaline	 levels	
reduced	at	24	hours	in	both	groups	and	then	increased	at	72hrs	with	median	levels	
in	the	severely	 injured	patients	more	than	double	that	of	the	 less	 injured	patients	
(1.4	 μg/	 ml	 vs.	 	 0.6	 μg/ml	 (p=0.001)).	 The	 change	 at	 72	 hours	 is	 secondary	 to	
exogenous	adrenaline	administration	rather	that	a	physiological	response.	
	
Dopamine	 levels	 are	 also	 raised	 on	 admission	 and	 higher	 in	 the	 more	 severely	
injured	group	0.003	μg/ml,	whereas	the	median	in	the	less	injured	group	in	0	μg/ml	
(p=0.008).	The	dopamine	levels	rise	further	at	24	hours,	with	levels	in	the	severely	
		 	 	 	
	 111	
injured	 group,	 double	 that	 of	 the	 less	 injured	 group,	 0.014	μg/ml	 vs	 0.007	μg/ml	
(p<0.001).	
	
We	 then	 dichotomised	 patients	 according	 to	 the	 head	AIS	 (≤3	 vs.	 >3)	 in	 order	 to	
evaluate	 whether	 sever	 head	 injury	 had	 a	 contributory	 effect	 on	 the	 level	 of	
circulating	catecholamines	(Figure	4.3).	When	the	two	groups	were	compared	there	
was	no	difference	seen	in	any	of	the	plasma	catecholamines	levels.	
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Figure	 4.4	 Boxplot	 showing	 difference	 in	 noradrenaline	 levels	 in	 severely	 injured	
patients	 as	 defined	 by	 ISS>15-	 On	 admission	 the	 median	 serum	 levels	 were	 0.99	
μg/ml	(IQR:	0.48-1.79)	in	the	ISS≤15	group	vs.	1.21	μg/ml	(IQR:	0.56-	3.05)	in	ISS>15	
(p=0.01).	At	24h-	0.87	μg/ml	(IQR:	0.31-1.68)	in	the	ISS≤15	group	vs.	1.69	(IQR:	0.18-
6.96)	in	ISS>15	(p=0.01).	At	72h-		0.07	μg/ml	(IQR:	0.05-0.11)	in	the	ISS≤15	group	vs	
0.06	μg/ml	(IQR:	0-0.14)	in	ISS>15	(p=0.9).		
	
	
Figure	 4.5	 Boxplot	 showing	 difference	 in	 adrenaline	 levels	 in	 severely	 injured	
patients	 as	 defined	 by	 ISS>15-	 On	 admission	 the	 median	 serum	 levels	 were	 0.21	
μg/ml	(IQR:	0.09-0.69)	in	the	ISS≤15	group	vs.	0.50	μg/ml	(IQR:	0.19-	1.41)	in	ISS>15	
(p=0.01).	At	24h-	0.11	μg/ml	(IQR:	0.05-0.21)	in	the	ISS≤15	group	vs.	0.10	(IQR:	0.03-
0.22)	in	ISS>15	(p=0.01).	At	72h-	0.07	μg/ml	(IQR:	0.003-0.014)	in	the	ISS≤15	group	
vs	1.36	μg/ml	(IQR:	0.70-4.19)	in	the	ISS>15	group	(p<0.01)	
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Figure	4.6	Boxplot	showing	difference	in	dopamine	levels	in	severely	injured	patients	
as	defined	by	ISS>15-	On	admission	the	median	serum	levels	were	0	μg/ml	(IQR:	0-
0.006)	in	the	ISS≤15	group	vs.	0.003	μg/ml	(IQR:	0-	0.018)	in	the	ISS>15	(p<0.01).	At	
24h-	0.007	μg/ml	(IQR:	0.003-0.014)	in	the	ISS≤15	group	vs.	0.015	(IQR:	0.005-0.031)	
in	 ISS>15	 (p<0.01).	At	72h-	was	0.003	μg/ml	 (IQR:	0-0.008)	 in	 the	 ISS≤15	group	vs	
0.006	μg/ml	(IQR:	0-0.12)	in	ISS>15	(p=0.2).	
	
	
Figure	4.7	Boxplot	showing	difference	in	noradrenaline	levels	 in	severe	head	injury	
as	 defined	by	head	and	neck	AIS>3	 -	On	admission	 the	median	 serum	 levels	were	
1.12	μg/ml	 (IQR:	0.53-2.35)	 in	minor	HI	vs.	median	1.04	μg/ml	 (IQR:	0.48-	2.11)	 in	
severe	HI	(p=0.8).	At	24h-	1.16	μg/ml	(IQR:	0.32-5.19)	in	minor	HI	vs.	0.82	(IQR:	0.09-
3.26)	in	severe	HI	(p=0.2).	At	72h-	0.06	μg/ml	(IQR:	0-0.12)	in	minor	HI	vs	0.13	μg/ml	
(IQR:	0.06-0.25)	in	severe	HI	(p=0.1).		
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Figure	4.8	Boxplot	showing	difference	 in	adrenaline	 levels	 in	severe	head	 injury	as	
defined	by	head	and	neck	AIS>3	 -	On	admission	the	median	serum	 levels	were	0.3	
μg/ml	(IQR:	0.11-1.07)	in	minor	HI	vs.	median	0.30	μg/ml	(IQR:	0.06-	1.43)	in	severe	
HI	(p=0.8).	At	24h-	0.11	μg/ml	(IQR:	0.05-0.23)	in	minor	HI	vs.	0.07	(IQR:	0.01-0.11)	
in	severe	HI	(p=0.06).	At	72h-	0.92	μg/ml	(IQR:	0.48-3.22)	in	minor	HI	vs	1.28	μg/ml	
(IQR:	0.74-3.37)	in	severe	HI	(p=0.2).		
	
	
Figure	 4.9	Boxplot	 showing	difference	 in	dopamine	 levels	 in	 severe	head	 injury	as	
defined	by	head	and	neck	AIS>3	-	On	admission	the	median	serum	levels	were	0.003	
μg/ml	(IQR:	0-0.012)	in	minor	HI	vs.	0	μg/ml	(IQR:	0-	0.007)	in	severe	HI	(p=0.2).	At	
24h-	0.010	μg/ml	(IQR:	0.004-0.03)	in	minor	HI	vs.	0.014	(IQR:	0.006-0.024)	in	severe	
HI	 (p=0.6).	 At	 72h-	 0.005	μg/ml	 (IQR:	 0-0.01)	 in	minor	HI	 vs	 0.003	μg/ml	 (IQR:	 0-
0.014)	in	severe	HI	(p=0.7).		
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4.3.4	Catecholamine	levels	and	cardiac	injury	
To	 further	 investigate	 the	 relationship	 between	 catecholamine	 levels	 and	 the	
development	 of	 cardiac	 injury,	 plasma	 catecholamine	 levels	 were	 divided	 into	
quartiles	 and	 compared	 to	 circulating	 h-FABP	 as	 a	 previously	 defined	 marker	 of	
cardiac	injury.	The	change	in	admission	catecholamine	level	was	compared	to	that	
of	the	levels	of	plasma	h-FABP	on	admission,	at	24	hours	and	72	hours.	Increasing	
levels	of	catecholamine	exposure	on	admission	is	associated	with	 increasing	 levels	
of	h-FABP	in	the	plasma.	On	admission,	increasing	adrenaline	concentration	occurs	
in	line	with	a	concurrent	increase	in	h-FABP	concentration.	However,	on	admission	
and	at	24	hours,	only	the	difference	between	the	1st	and	4th	quartile	as	well	as	the	
difference	 between	 the	 2nd	 and	 4th	 quartile	 of	 adrenaline	 concentration	 is	
statistically	 significant.	 At	 72	 hours,	 only	 the	 difference	 between	 the	 1st	 and	 4th	
quartile	is	statistically	different.		
	
With	noradrenaline	and	dopamine	the	1st	quartile	median	is	higher	than	the	second	
quartile	but	from	there	on	there	is	a	stepwise	increase	in	h-FABP	concentration.	At	
all	 time	points,	 the	concentration	of	h-FABP	 is	statistically	significant	between	the	
2nd	 and	4th	 quartile.	 The	only	 statistical	 difference	 in	h-FABP	 levels	 in	 comparison	
with	Dopamine	concentration,	is	at	24	hours	between	the	1st	and	4th	Quartile.		
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Table	4.1:	Summary	of	median	serum	hFABP	(ng/ml)	within	the	different	quartiles	
of	catecholamines	
	
	
Noradrenaline	Quartiles	
	
0-0.52	 0.52-1.11	 1.11-2.29	 >2.29	
Admission	 13.64	 13.44	 29.14	 27.87	
24	hours	 9.27	 4.95	 16.42	 32.19	
72	hours	 2.37	 2.31	 7.18	 38.29	
	
	
Adrenaline	Quartiles	
	
0-0.11	 0-0.11-0.030	 0.30-1.09	 >1.09	
Admission	 9.13	 13.04	 22.49	 43.23	
24	hours	 9.27	 4.95	 16.42	 32.19	
72	hours	 2.04	 5.215	 5.135	 8.835	
	
	
Dopamine	Quartiles	
	
0-0.0001	 0.0001-0.002	 0.002-0.0107	 >0.0107	
Admission	 17.03	 10.59	 18.62	 59.37	
24	hours	 9.515	 4.27	 17.98	 131.4	
72	hours	 2.37	 2.31	 7.175	 38.29	
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Figure	 4.10	 Boxplot	 graph	 showing	 changes	 in	 h-
FABP	 levels	with	 increasing	 levels	of	noradrenaline.	
On	admission	(p=0.04*),	at	24	hours	(p=0.04)	and	at	
72	 hours	 (p=0.04)	 there	 is	 a	 significant	 difference	
between	the	2nd	and	4th	quartile.		
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Figure	 4.11	 Boxplot	 graph	 showing	 changes	 in	 h-
FABP	 levels	with	increasing	 levels	of	adrenaline.	On	
admission	 (p<0.001***),	at	24	hours	 (p=0.04*)	and	
at	 72	 hours	 (p=0.002**)	 there	 is	 a	 significant	
difference	 between	 the	 1st	 and	 4th	 quartile.	 On	
admission	 (p=0.008**)	 and	 at	 24	 hours	
(p<0.001***)	 there	 is	 also	 a	 significant	 difference	
between	2nd	and	4th	quartile.	
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Figure	4.11	Boxplot	graph	showing	changes	in	h-
FABP	levels	with	increasing	levels	of	dopamine.	
There	is	a	significant	difference	between	the	1st	and	
4th	quartile	(p=0.04*).	On	admission	and	at	24	hours	
there	is	also	a	significant	difference	between	2nd	and	
4th	quartile.	
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Further	 analysis	 was	 conducted	 by	 comparison	 of	 the	 plasma	 levels	 of	
catecholamines	 to	 the	presence	of	 TISCI,	 as	 defined	by	 plasma	h-FABP	of	 greater	
than	 16.8	 ng/ml,	 at	 the	 corresponding	 time	 points.	 	 On	 admission,	 the	 median	
plasma	noradrenaline	 level	of	1.4	μg/ml	was	1.5	times	higher	than	 in	the	no	TISCI	
group	 at	 0.9	 μg/ml,	 (p=0.001).	 The	 admission	 adrenaline	 level	 was	 three	 times	
higher	at	0.6	μg/ml	compared	to	0.2	μg/ml	in	the	group	without	TISCI	(p	<	0.001).		
	
Although	there	is	a	difference	in	plasma	noradrenaline	levels	at	24	hours,	with	the	
median	 in	 the	 TISCI	 group	 of	 1.5	 μg/ml	 and	 the	median	 in	 no	 TISCI	 group	 of	 0.9	
μg/ml,	 this	 difference	 is	 not	 statistically	 significantly.	 The	 dopamine	 level	 at	 24	
hours	 is	 a	 third	 higher	 at	 0.012	 μg/ml	 compared	 to	 0.009	 μg/ml	 in	 the	 no	 TISCI	
group	(p=	0.03).	At	72	hours,	adrenaline	levels	are	significantly	higher	at	1.4	μg/ml	
vs.	0.9	μg/ml	(p=	0.03).	
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Figure	 4.13	 Boxplot	 showing	 difference	 in	 noradrenaline	 levels	 with	 TISCI	 -	 On	
admission	the	median	serum	levels	were	0.87	μg/ml	(IQR:	0.42-1.81)	without	TISCI	
vs.	1.40	μg/ml	 (IQR:	0.66-	2.70)	with	TISCI	 (p=0.001***).	At	24h	median	was	0.82	
μg/ml	(IQR:	0.18-2.16)	without	TISCI	vs.	1.50	(0.38-6.00)	with	TISCI	(p=0.03*).	At	72h	
the	median	was	0.06	μg/ml	(0.04-0.11)	without	TISCI	vs	0.08	μg/ml	(IQR:0.04-0.14)	
with	TISCI	(p=0.4).		
	
	
Figure	4.14	Boxplot	showing	difference	in	adrenaline	levels	with	TISCI	-	On	
admission	the	median	serum	levels	were	0.19	μg/ml	(IQR:	0.05-0.5)	without	TISCI	vs.	
0.61	μg/ml	(IQR:	0.20-	1.79)	with	TISCI		(p<0.001***).	At	24h	median	was	0.10	
μg/ml	(IQR:	0.04-0.21)	without	TISCI	vs.	0.11	(IQR:	0.05-0.22)	with	TISCI	(p=0.9).	At	
72h	the	median	was	0.74	μg/ml	(IQR:	0.35-1.25)	without	TISCI	vs	1.35	μg/ml	
(IQR:0.65-	4.31)	with	TISCI	(p=0.003**).		
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Figure	 4.15	Boxplot	showing	difference	 in	dopamine	 levels	 in	TISCI	 -	On	admission	
the	median	 serum	 levels	 were	 0.001μg/ml	 (IQR:	 0-0.008)	 without	 TISCI	 group	 vs.	
median	0.003	μg/ml	(IQR:	0-	0.018)	in	TISCI	group	(p=0.2).	At	24h	median	was	0.01	
μg/ml	(IQR:	0.004-0.016)	without	TISCI	vs.	0.01	(IQR:	0.005-0.029)	with	TISCI	(p=0.1).	
At	 72h	 the	median	was	 0.003	 μg/ml	 (IQR:	 0-0.008)	without	 TISCI	 vs	 0.005	 μg/ml	
(IQR:0-	0.012)	with	TISCI	(p=0.2).		
	
4.3.5	Catecholamines	and	Shock	
	
Severe	 physiological	 stress	 leads	 to	 the	 initiation	 of	 the	 sympathetic	 system	 and	
leads	to	a	hyperadrenergic	state.	This	was	demonstrated	in	this	trauma	population.	
A	 plasma	 lactate	 level	 of	 greater	 than	 2mmol/l	 was	 taken	 as	 a	 surrogate	 for	
hypoperfusion	and	therefore	shock.	The	shocked	group	had	higher	levels	of	plasma	
noradrenaline	on	admission	(1.5	μg/ml	vs.	0.9	μg/ml,	p<	0.001).	Plasma	adrenaline	
was	 higher	 at	 72	 hours	 (1.4	 μg/ml	 vs	 0.8	 μg/ml,	 p=0.002).	 Admission	 dopamine	
levels	were	higher	in	the	shocked	group	(0.013	μg/ml	vs.	0.008	μg/ml,	p=	0.04).	
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Figure	4.16	Boxplot	showing	difference	in	noradrenaline	levels	using	lactate	as	a	
marker	of	shock	-	On	admission	the	median	serum	levels	were	0.87μg/ml	(IQR:	0.39-
0.1.64)	in	the	not	shocked	group	vs.	1.46μg/ml	(IQR:	0.73-	3.18)	in	shocked	
(p<0.001***).	At	24h-	0.91μg/ml	(IQR:	0.18-2.56)	in	the	not	shocked	group	vs.	1.29	
(IQR:	0.36-	6.06)	in	shocked	(p=0.1).	At	72h-	0.06μg/ml	(IQR:	0.04-0.13)	in	the	not	
shocked	group	vs	0.07	μg/ml	(IQR:0.04-	0.14)	in	shocked	(p=0.7).		
	
	
Figure	 4.17	 Boxplot	 showing	 difference	 in	 adrenaline	 levels	 using	 lactate	 as	 a	
marker	of	shock	-	On	admission	the	median	serum	levels	were	0.22μg/ml	(IQR:	0.06-
0.69)	 in	 the	 not	 shocked	 group	 vs.	 0.60μg/ml	 (IQR:	 0.18-	 1.67)	 in	 the	 shocked	
(p<0.001***).	At	24h-	0.09μg/ml	(IQR:	0.05-0.22)	in	the	not	shocked	group	vs.	0.11	
(IQR:	 0.04-	 0.21)	 in	 shocked	 (p=0.4).	 At	 72h-0.80μg/ml	 (IQR:	 0.41-1.80)	 in	 the	 not	
shocked	group	vs	1.35	μg/ml	(IQR:	0.65-	5.65)	in	shocked	(p=0.002**).		
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Figure	4.18	Boxplot	showing	difference	in	dopamine	levels	using	lactate	as	a	marker	
of	 shock	 -	On	admission	 the	median	 serum	dopamine	 levels	were	0μg/ml	 (IQR:	 0-
0.007)	in	the	not	shocked	group	vs.	0.003μg/ml	(IQR:	0-	0.02)	in	the	shocked	group	
(p=0.04*).	At	24h-	0.008μg/ml	(IQR:	0.004-0.21)	in	the	not	shocked	group	vs.	0.013	
(IQR:	0.006-	0.03)	in	shocked	(p=0.08).	At	72h-	0.004μg/ml	(IQR:	0-0.009)	in	the	not	
shocked	group	vs	0.005μg/ml	(IQR:	0-	0.01)	in	shocked	(p=0.9).		
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4.3.6	Inotrope	administration	and	Catecholamine	levels	
The	difference	in	plasma	catecholamine	levels	at	24	hours	and	72	hours	could	have	
been	attributable	to	the	administration	of	exogenous	inotropes.	In	the	patients	who	
developed	ACE,	76%	received	inotropic	support	in	comparison	to	15%	in	the	cohort	
did	not	develop	ACE		and	23%	as	a	whole	population.	Of	the	patients	who	received	
inotropes,	81%	received	noradrenaline	alone,	where	as	3%	received	adrenaline,	9%	
dobutamine,	 7%	 Dopexamine	 and	 4%	 milrinone.	 In	 the	 no	 ACE	 group,	 the	 only	
inotropes	 given	 was	 noradrenaline	 and	 dopexamine.	 In	 this	 group,	 36	 (12%)	
patients	 received	 inotropes	 and	 of	 those	 92	 %	 received	 noradrenaline	 only.	 The	
reasons	for	catecholamine	administration	were	not	collected.	However,	49%	of	the	
patients	 who	 received	 noradrenaline	 had	 significant	 head	 injuries	 and	 the	 other	
51%	were	severely	injured	with	a	median	ISS	of	34.		
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Figure	4.6:		Comparison	of	inotrope	requirement	in	the	ACE	and	no	ACE	group.	
	
Figure	4.7:		Comparison	of	inotropes	initiated	in	the	ACE	and	no	ACE	group.	
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None	 of	 the	 patients	 included	 in	 this	 study	 received	 inotropes	 prior	 to	 baseline	
venepuncture;	 therefore	 the	 admission	 plasma	 catecholamines	 levels	 can	 be	
attributed	 to	 endogenous	 catecholamines	 production.	 The	 patients	 who	 require	
inotropic	 support	during	 their	 stay	have	higher	admission	 levels	of	noradrenaline,	
adrenaline	 and	 dopamine	 (Figure	 4.8).	 The	 high	 admission	 catecholamine	 levels	
may	 be	 a	 reflection	 of	 greater	 injury	 severity	 that	 consequentially	 leads	 organ	
dysfuction	 requiring	 inotropic	 support	 or	 it	 may	 be	 that	 the	 high	 levels	 of	
catecholamine	exposure	 lead	 to	cardiac	 injury	and	dysfunction	 requiring	 inotropic	
support.		
	
The	serum	catecholamine	 levels	at	24	and	72	hours	demonstrates	exogenous	and	
endogenous	 catecholamines.	 Catecholamine	 use	 is	 well	 established	 in	 the	
management	of	organ	 injury	 in	critically	 injured	patients	 (142).	Noradrenaline	and	
Dopamine	levels	are	higher	at	24	hours	in	the	group	of	patients	receiving	inotropes	
and	Adrenaline	levels	higher	at	72	hours	in	patients	receiving	inotropes.	It	is	difficult	
to	ascertain	from	this	data	whether	the	development	of	ACE	is	the	cause	or	effect	
of	inotrope	use.		
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Figure	 4.19	 Boxplot	 showing	 difference	 in	 noradrenaline	 levels	 with	 inotrope	
administration	-	On	admission	the	median	serum	levels	were	1.01μg/ml	(IQR:	0.47-
1.97)	 without	 inotrope	 use	 vs.1.87μg/ml	 (IQR:	 0.92-	 3.68)	 with	 inotropes	
(p<0.001***).	At	 24h-	 0.81μg/ml	 (IQR:	 0.18-1.66)	without	 inotropes	 vs.	 5.27	 (IQR:	
1.48-	9.89)	with	inotropes(p<0.001***).	At	72h-		0.08μg/ml	(IQR:	0.04-0.13)	without	
inotropes	vs	0.06	μg/ml	(IQR:	0-	0.12)	with	inotropes	(p=0.2).		
	
	
Figure	 4.20	 Boxplot	 showing	 difference	 in	 adrenaline	 levels	 with	 inotrope	
administration	-	On	admission	the	median	serum	levels	were	0.25μg/ml	(IQR:	0.10-
0.83)	 without	 inotrope	 use	 vs.	 0.78μg/ml	 (IQR:	 0.30-	 1.90)	 with	 inotropes	
(p<0.001***).	At	 24h-	 0.12μg/ml	 (IQR:	 0.05-0.23)	without	 inotropes	 vs.	 0.09	 (IQR:	
0.009-	 0.19)	 with	 inotropes	 (p=0.25).	 At	 72h-	 0.75μg/ml	 (IQR:	 0.41-1.39)	 without	
inotropes	vs	3.22	μg/ml	(IQR:	1.18-	5.93)	with	inotropes	(p<0.001***).		
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Figure	 4.21	 Boxplot	 showing	 difference	 in	 noradrenaline	 levels	 with	 inotrope	
administration	-	On	admission	the	median	serum	levels	were	0μg/ml	(IQR:	0-0.007)	
withour	 inotrope	 use	 vs.	 median	 0.004μg/ml	 (IQR:	 0-	 0.03)	 with	 inotropes	
(p=0.005**).	At	24h-	0.007μg/ml	(IQR:	0.004-0.015)	without	inotropes		vs.	0.03	(IQR:	
0.01-	0.04)	with	inotropes	(p<0.001***).	At	72h-	0.004μg/ml	(IQR:	0-	0.009)	without	
inotrope	use	vs	0.007	μg/ml	(IQR:	0-	0.02)	with	inotrope	(p=0.2).		
	
4.3.7	Catecholamine	levels	and	mortality	
	
The	difference	in	catecholamine	levels	were	examined	to	determine	whether	its	
deleterious	effects	extended	to	mortality.		
	
Admission	 noradrenaline	 levels	 in	 non-survivors	 were	 almost	 twice	 that	 seen	 in	
survivors,	1.74	μg/ml	vs	1.09	μg/ml.	This	difference	became	significantly	greater	at	
24	 hours	 with	 noradrenaline	 levels	 being	 nine	 times	 greater	 at	 8.08	 μg/ml	
compared	 to	 0.91	 μg/ml	 in	 survivors.	 However	 at	 72	 hours	 this	 difference	
diminishes.	
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Figure	4.22	Plot	showing	difference	in	noradrenaline	levels	in	survivors	and	non-
survivors-	On	admission	median	noradrenaline	levels	were	1.09μg/ml	(IQR:	0.50-
2.18)	without	inotrope	use	vs.	1.74μg/ml	(IQR:	0.81-	4.02)	with	inotropes	
(p<0.02**).	At	24h-	0.91μg/ml	(IQR:	0.18-4.18)	without	inotropes	vs.	8.08	(IQR:	
1.67-	20.23)	with	inotropes	(p<0.001***).	At	72h-	0.07μg/ml	(IQR:	0.04-0.13)	
without	inotropes	vs	0.1	μg/ml	(IQR:	0-	0.18)	with	inotropes	(p=0.9).		
	
	
Adrenaline	 levels	 were	 also	 significantly	 higher	 on	 admission,	 with	 plasma	 levels	
four	times	greater	in	the	non-survivors	at	1.12	μg/ml	in	comparison	to	0.27	μg/ml	in	
survivors.	At	24	hours	there	was	no	significant	difference	between	the	two	groups	
(0.18	μg/ml	in	non-	survivors	vs	0.10	μg/ml	in	survivors).	At	72	hours,	there	was	a	
second	elevation/rebound	in	plasma	adrenaline	levels,	the	non-survivors	having	five	
times	greater	(4.54	μg/ml)	compared	to	in	survivors	(0.91	μg/ml).	
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Figure	 4.23	 Plot	 showing	 difference	 in	 adrenaline	 levels	 in	 survivors	 and	 non-
survivors-	 On	 admission	 median	 levels	 were	 0.002μg/ml	 (IQR:	 0-0.009)	 without	
inotrope	use	vs.	median	1.12μg/ml	 (IQR:	0.36-	3.21)	with	 inotropes	 (p<0.02**).	At	
24h-	0.10μg/ml	(IQR:	0.04-	0.21)	without	inotrope	use	vs.	0.18	(IQR:	0.06-	0.36)	with	
inotropes	(p=0.1).	At	72h-	0.91μg/ml	(IQR:	0.51-	2.30)	without	inotrope	use	vs.	4.34	
μg/ml	(IQR:	2.25-	9.05)	with	inotropes	(p<0.001***).		
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Dopamine	levels	peaked	at	24h	post	admission	and	were	declining	at	the	24h	time	
point	 in	 both	 survivors	 and	 non-survivors.	 Non-survivors	 had	 elevated	 plasma	
dopamine	 at	 all	 time	 points,	 with	 a	 significant	 difference	 seen	 at	 24h,	 with	 non	
survivors	 having	 three	 times	 higher	 plasma	 dopamine	 levels	 at	 0.03	 μg/ml	 when	
compared	 to	 0.009	 μg/ml	 in	 survivors.	 This	 elevation	 is	 also	 in	 keeping	 with	
increased	prevalence	of	adverse	cardiac	events	at	24	hours.	
	
	
Figure	 4.24	 Plot	 showing	 difference	 in	 dopamine	 levels	 in	 survivors	 and	 non-
survivors-	 On	 admission	median	 dopamine	 levels	 were	 0.002μg/ml	 (IQR:	 0-0.009)	
without	 inotrope	use	vs.	0.003μg/ml	 (IQR:	0-	0.03)	with	 inotropes	 (p=0.1).	At	24h-	
0.010μg/ml	 (IQR:	 0.004-	 0.02)	 without	 inotropes	 vs.	 0.03	 (IQR:	 0.008-	 0.05)	 with	
inotropes	 (p=0.001**).	 At	 72h-	 0.004μg/ml	 (IQR:	 0-0.009)	 without	 inotropes	 vs	
0.009	μg/ml	(IQR:	0-	0.04)	with	inotropes	(p=0.2).		
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4.3.8.	Catecholamines	in	Predicting	Adverse	Cardiac	Events	
Binomial	 logistic	 regression	was	 conducted	 including	 the	 variables	 listed	 in	 Table	
4.2.	 The	 model	 had	 a	 -2	 log	 likelihood	 of	 71.3	 (p<0.001),	 compared	 to	 the	 chi	
squared	 of	 106.1	 of	 the	 base	 model,	 therefore	 the	 inclusion	 of	 the	 variables	
improves	 the	 predictive	 value	 of	 the	 model.	 The	 pseudo	 R2	 value	 of	 0.50	
(Nagelkerke)	suggest	the	model	accounts	for	50%	of	the	variance	in	predicting	ACE.	
In	 addition,	 the	Hosmer	 and	 Lemeshow	 test	 of	 goodness	 of	 fit	 gave	 a	 p	 value	 of	
0.936,	therefore	we	do	not	reject	the	null	hypothesis	that	the	model	 is	a	good	fit.	
Hence,	this	model	can	be	considered	a	robust	risk	predictive	tool.	The	output	from	
SPSS	are	given	below	in	Tables	4.2-	4.6.		
	
Table	4.2	Omnibus	Tests	of	Model	Coefficients	demonstrates	a	significant	
difference	between	the	null	model	and	the	block	model	
	
	 Chi-square	 df	 Sig.	
Step	1	 Step	 71.296	 15	 .000	
Block	 71.296	 15	 .000	
Model	 71.296	 15	 .000	
	
	
Table	4.3	Summary	of	the	model	
	
Step	
-2	Log	
likelihood	
Cox	&	Snell	R	
Square	
Nagelkerke	R	
Square	
1	 106.075a	 .282	 .502	
	
	
Table	4.4	Hosmer	and	Lemeshow	Test	of	goodness	of	fit	
	
Step	 Chi-square	 df	 Sig.	
1	 2.974	 8	 .936	
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Table	4.5	Classification	table	demonstrating	the	predictive	value	of	null	model	and	
model	with	variables	
	
	
	
Observed	
Predicted	
ACE	
%	Correct	No	ACE	 ACE	
Step	0	 ACE	 No	ACE	 202	 0	 100.0	
ACE	 36	 0	 .0	
Overall	%	 	 	 84.9	
Step	1	 ACE	 No	ACE	 177	 7	 96.2	
ACE	 16	 15	 48.4	
Overall	%	 	 	 89.3	
	
	
Table	4.6	Variables	included	in	the	model.	
	
	 B	 S.E.	 Wald	 Sig.	 Exp(B)	
95%	C.I.for	EXP(B)	
Lower	 Upper	
	
	
Sex	 .103	 .803	 .016	 .898	 1.108	 .230	 5.342	
Age	 .016	 .017	 .854	 .355	 1.016	 .982	 1.051	
ISS	 .016	 .029	 .320	 .571	 1.016	 .961	 1.075	
Thorax	AIS	 .361	 .192	 3.530	 .060	 1.435	 .985	 2.090	
H&N	AIS	 .321	 .182	 3.090	 .079	 1.378	 .964	 1.970	
IHD	 .763	 .968	 .621	 .431	 2.145	 .321	 14.311	
Diabetes	 -2.163	 1.247	 3.011	 .083	 .115	 .010	 1.324	
Hypertension	 2.131	 .765	 7.768	 .005	 8.424	 1.882	 37.698	
Hyperchol	 1.195	 .963	 1.539	 .215	 3.303	 .500	 21.813	
HR	 .006	 .010	 .367	 .545	 1.006	 .986	 1.027	
SBP	 -.016	 .007	 4.696	 .030	 .984	 .971	 .999	
Lactate	 .194	 .096	 4.094	 .043	 1.214	 1.006	 1.466	
Noradrenaline	 .007	 .013	 .273	 .601	 1.007	 .981	 1.033	
Adrenaline	 .041	 .164	 .061	 .804	 1.042	 .755	 1.437	
Dopamine	 3.470	 3.719	 .871	 .351	 32.142	 .022	 47068.853	
Constant	 -4.728	 2.053	 5.301	 .021	 .009	 	 	
	
B	is	the	co-efficient	of	variable	in	the	model,	with	associated	standard	error.	The	
Wald	chi-square	and	its	two	tailed	p	value	are	given	in	testing	the	null	hypothesis	
that	B=0.	Exp(B)	is	the	odds	ratio	for	each	variable	with	the	95%	confidence	
interval.		
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Within	this	model	hypertension,	Systolic	blood	pressure	and	lactate	were	identified	
as	independent	factors	in	the	development	of	adverse	cardiac	events.	According	to	
the	odds	ratio	from	the	model,	pre-existing	hypertension	leads	to	8	fold	higher	risk	
of	developing	an	adverse	cardiac	event.	Hypertension	may	affect	adverse	outcomes	
in	many	ways.	The	hypertensive	patients	are	predisposed	to	underlying	endothelial	
damage	 and	 coronary	 artery	 disease,	 which	 in	 turn	may	 lead	 to	 adverse	 cardiac	
events	with	 increased	physiological	 stress	 (143).	Hypertension	also	predisposes	 to	
the	development	of	atrial	fibrillation,	which	may	be	precipitated	by	the	injury	(144).	
An	alternative	explanation	may	be	that	patients	with	pre-existing	hypertension	and	
potentially	 left	 ventricular	 hypertrophy	 have	 poorer	 ability	 to	 autoregulate	 their	
coronary	 perfusion	 and	 even	 with	 minimal	 hypotension,	 there	 is	 a	 reduction	 in	
cardiac	 perfusion	 leading	 to	 myocardial	 ischaemia	 and	 therefore	 injury	 (145).	
Lactate	and	systolic	blood	pressure	are	both	indicative	of	hypoperfusion	leading	to	
potential	cardiac	injury.			
	
Within	 this	 model,	 thoracic	 injury	 does	 not	 significantly	 contribute	 to	 the	
development	 of	 ACE,	 therefore	 suggesting	 that	 it	 is	 not	 related	 to	 direct	 chest	
injury.	 Furthermore,	 this	 model	 also	 negates	 the	 contribution	 of	 catecholamine	
exposure	on	admission	to	the	development	of	adverse	cardiac	event.	On	examining	
the	 correlation	 matrix	 there	 was	 no	 significant	 co-linearity	 within	 the	 variables,	
suggesting	that	within	this	model	the	inotropes	levels	recorded	in	this	cohort	do	not	
contribute	to	the	development	of	ACE.	
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Figure	4.5:	Forest	plot	showing	the	odds	ratio	of	admission	variables	for	the	development	of	ACE	
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4.4	Summary	of	Chapter	
	
Beta-adrenergic	 blockade	 has	 been	 identified	 as	 having	 potential	 benefits	 in	
critically	ill	trauma	patients	based	primarily	on	retrospective	cohort	studies	of	pre-
injury	 beta-blocker	 use.	 There	 are	 a	 number	 of	 putative	 mechanisms	 for	
catecholamine-induced	 cardiac	 injury,	 including	 ischemia	 due	 to	 poor	 diastolic	
filling,	or	directly-induced	calcium	overload	and	cardiomyocyte	necrosis	(95).			
	
In	 our	 study,	 admission	 levels	 of	 plasma	 adrenaline	 and	 noradrenaline	 were	
significantly	 higher	 in	 the	 patients	 who	 developed	 ACE.	 Furthermore,	 increasing	
levels	of	adrenaline	and	noradrenaline	were	associated	with	increasing	levels	of	h-
FABP	 on	 admission	 and	 24	 hours	 after	 injury.	 Despite	 this,	 we	 were	 unable	 to	
statistically	separate	any	differential	effects	of	adrenergic	stimulation	from	general	
shock	 and	 hypoperfusion.	 	 While	 h-FABP	 levels	 were	 elevated	 on	 admission	 as	
shown	in	the	previous	chapter	they	continue	to	rise	over	the	first	24	hours.		There	is	
therefore	the	potential	to	modulate	on	going	cardiac	injury.		
	
At	the	point	of	admission,	all	patients	in	this	cohort	had	not	received	any	exogenous	
catecholamine	 and	 therefore	 the	 plasma	 levels	 recorded	 on	 admission	 could	 be	
purely	attributed	to	endogenous	production.		
	
Measurement	 of	 catecholamines	 can	 be	 difficult	 to	 perform	 and	 analyse	 due	 to	
their	 short	 half-life.	 However,	 the	 biomarker	 analysis	 employed	 here	 was	
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determined	 to	be	 the	most	practical	way	of	measuring	 catecholamines	 in	 trauma	
patients.		
	
In	 summary,	 adrenaline	 and	 noradrenaline	 levels	were	 associated	with	 TISCI,	 the	
development	of	ACEs	and	subsequent	outcomes	including	mortality.		The	exact	role	
of	 catecholamines	 in	 the	genesis	of	TISCI	 remains	unclear	and	 further	 clinical	 and	
experimental	work	is	warranted.		There	exists	an	opportunity	to	improve	outcomes	
for	these	patients	with	patient	stratification	and	future	targeted	therapy.	Finally,	as	
mentioned,	 with	 this	 cohort	 study	 we	 were	 unable	 to	 specifically	 determine	
whether	 TISCI	 is	 purely	 a	 catecholamine-induced	 phenomenon.	 	 This	 should	 be	
further	validated	with	animal	models.	
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Chapter	5	
	
Cellular	mechanisms	of	Trauma	Induced	Secondary	
Cardiac	Injury		
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5.1.	Introduction	
	
Traumatic	 injury	and	haemorrhage,	 imposes	elevated	state	of	physiological	stress.	
The	 bleeding	 combined	 with	 tissue	 injury	 leads	 to	 a	 varying	 concoction	 of	
hypoperfusion,	 coagulopathy,	 catecholamine	 excess,	 release	 of	 DAMPs	 and	
immunological	 disarray	 which	 poses	 a	 huge	 risk	 to	 cellular	 processes(146).	 The	
myocardium	 with	 its	 usual	 high	 oxygen	 demands	 and	 a	 delicate	 blood	 supply	 is	
prone	 to	 damage	 during	 this	 catastrophic	 state.	 The	 sustained	 effort	 required	 to	
maintain	 perfusion	 in	 the	 face	 of	 haemorrhage,	 alongside	 a	multitude	 of	 noxious	
assaults,	 exerts	 pressure	 directly	 on	 the	 cardiomyocytes.	 Clinical	 studies	 have	
shown	the	cardiac	dysfunction	in	trauma	haemorrhage	can	be	evidenced	by	clinical	
events,	 ECG	 changes	 and	 an	 increase	 in	 circulating	 biomarkers(118,147).	 The	
cardiac	 dysfunction	 has	 been	 replicated	 in	 animal	 models	 with	 cytokines,	
inflammatory	 pathways	 and	 apoptosis	 implicated	 in	 the	 pathogenesis	 (148).	
However,	 in	 the	studies	 looking	at	apoptosis	and	cardiac	dysfunction,	surprisingly,	
there	was	no	increase	in	cardiac	biomarkers	(104).		
	
Trauma	 haemorrhage	 is	 not	 a	 distinct	 pathology.	 It	 is	 a	 cumulative	 syndrome	
resulting	from	bleeding,	tissue	injury,	direct	organ	injury,	immune	dysregulation	and	
a	systemic	inflammatory	response		(146).	The	simulation	of	this	condition	in	animal	
models,	manipulation	of	the	control	factors	and	isolation	of	organs	help	further	our	
understanding.	 Animal	 models	 of	 trauma	 haemorrhage	 have	 been	 honed	 and	
standardised	over	years	(148).	Dr	Johanna	Wall	was	able	to	produce	these	models	
in	our	group	and	furthermore	demonstrate	a	rise	in	h-FABP	as	seen	in	our	patients,	
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providing	 a	 murine	 model	 of	 TISCI.	 	 The	 release	 of	 cardiac	 proteins	 into	 the	
bloodstream	is	thought	to	be	due	to	disruption	of	the	cardiomyocte	cell	membrane	
as	 a	 result	 of	 ischaemic	 insult	 (35).	 However,	 due	 to	 its	 abundance	 as	 a	 free	
cytosolic	protein	and	its	small	size,	h-FABP	may	be	released	during	early	ischaemia	
(65).	
5.2	Study	Aims	
	
This	study	aims	to	understand	the	nature	and	severity	of	cellular	changes	that	lead	
to	the	release	of	cardiac	proteins	upon	trauma	injury	and	haemorrhage	as	seen	in	
the	clinical	studies.	Cell	membrane	disruption	is	a	key	feature	of	cellular	stress	and	
augural	 of	 cell	 death.	 Myocardial	 death	 is	 not	 a	 reversible	 injury	 and	 will	 leave	
patients	 with	 prolonged	 morbidity	 (106).	 Increasing	 our	 understanding	 of	 the	
pattern	of	injury	and	the	causal	mechanisms	may	help	improve	patient	outcomes	in	
the	future.		
	
The	 work	 in	 this	 chapter	 aims	 to	 further	 investigate	 the	 effect	 of	 trauma	
haemorrhage	 specifically	 on	 the	 cardiomyocyte.	 Western	 blotting	 and	 histology	
were	used	to	study	structural	and	biochemical	changes	that	may	shed	further	light	
on	the	the	cellular	pathways	that	underlie	myocardial	cell	death	following	traumatic	
injury	and	haemorrhage	.			
	
Initially,	 through	 histopathological	 examination,	 the	 gross	 changes	 of	 the	
myocardium	in	TISCI	were	explored,	TEM	allowed	for	 further	visualization	of	 	 	 the	
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ultrastructure	structure	of	the	heart.	Subsequently,	western	blot	analysis	was	used	
to	 further	 interrogate	 changes	 in	 cellular	 levels	 of	 biomarkers	 and	 pathways	 that	
may	be	driving	the	structural	changes	
	
5.2	Results	
5.2.1	Ultrastructural	Changes	In	The	Trauma	Haemorrhage	Models		
	
The	 rise	 in	 serum	 cardiac	 proteins	 along	with	 their	 reflective	 depletion	 from	 the	
myocardial	 tissue	 indicates	 disruption	of	 cell	membrane	 integrity	 and	 subsequent	
cell	death.	In	myocardial	ischaemia,	necrosis	is	often	associated	with	the	ischaemic	
changes,	 therefore	 transmission	 electron	 microscopy	 (TEM)	 images	 of	 the	 heart	
were	 studied	 to	 identify	 ultrastructural	 changes	 in	 this	 TH	mice	model,	 that	may	
reveal	the	underlying	processes.		
	
The	 sham	 animals	 demonstrated	 normal	 myocardium	 with	 contracted	 myofibrils	
with	clearly	demonstrable	A	bands	and	Z	discs	(Figure	5.1).	The	nuclear	chromatin	is	
evenly	 distributed	 with	 a	 dense	 nucleoplasm	 with	 surrounding	 glycogen.	 The	
mitochondria	 are	 evenly	 distributed	 alongside	 the	 sacromere.	 	 The	mitochondria	
are	 smooth	 edged	with	 evenly	 dense	matrix	 scattered	with	matrix	 granules.	 	 The	
cristae	are	 intact	and	tightly	packed	(149)	(150).	Overall,	23%	of	the	mitochondria	
demonstrate	dense	bodies,	however,	there	are	no	associated	features	of	ischaemia	
surrounding	these	mitochondria.		
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Figure	5.1:	Transmission	Electron	Microscopy	(TEM)	of	myocardium	(left)	from	sham	
mice,	 showing	well-organised	myofibrils	 clearly	define	with	A	bands	 (green)	and	Z	
discs	(red),	M	band	(blue)	and	I	bands.	The	nucleus	(top	right)	shows	a	regular	intact	
nuclear	 envelope	 with	 evenly	 distributed	 chromatin	 in	 the	 nucleoplasm.	 The	
mitochondria	 (bottom	 right)	 are	 evenly	 distributed	 along	 the	 sarcoplasm	 with	
clearly	defined	cristae	and	even	electron	density	within	the	matrix.		
	
There	are	varying	degrees	of	 severity	 in	 the	changes	 seen	within	 the	heart	of	 the	
same	 animal.	 The	 organelles	 in	 different	 regions	 of	 the	 same	 heart	 demonstrate	
microscopic	changes	in	keeping	with	reversible	as	well	as	irreversible	cellular	injury.	
	
In	 areas	 with	 mild	 injury,	 the	 cardiac	 tissue	 maintains	 its	 similarity	 to	 the	 sham	
animals.	 These	 regions	 have	 well	 defined	 sarcomeres	 with	 linear	 myofibrils.	
However,	 the	 I	bands	are	more	prominent,	 indicative	of	 relaxation	of	 the	muscle,	
which	has	been	shown	to	be	associated	with	global	 ischaemia	 (150).	There	 is	also	
evidence	of	dispersed	interstitial	oedema	with	associated	mitochondrial	oedema	as	
evidenced	by	the	loss	of	electron	density.	 In	previous	studies	of	murine	models	of	
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cardiac	 ischaemia,	oedematous	changes	were	demonstrated	within	30	minutes	of	
coronary	 artery	 ligation	 (149).	 In	 these	 less	 affected	 regions,	 the	 mitochondria	
remain	linearly	distributed	and	retain	normality	in	their	appearance.	The	cristae	are	
intact	 and	 tightly	 packed	 with	 evenly	 dense	 matrix	 and	 the	 presence	 of	 matrix	
granules.	However,	the	mitochondria	 in	these	regions	do	demonstrate	amorphous	
dense	bodies.		
	
In	 the	 TH	 mice,	 33%	 of	 the	 mitochondria	 contain	 amorphous	 dense	 bodies	 in	
comparison	 to	 23%	 in	 the	 sham	 animals	 (p=0.006).	 Although,	 the	 loss	 of	 intra-
mitochondrial	 granularity	 has	 been	 described	 as	 one	 of	 the	 earliest	 changes	 in	
ischaemia,	 in	 these	 models	 and	 preceded	 by	 dense	 body	 formation.	 The	 nuclei	
within	these	regions	show	no	signs	of	adverse	changes.	
	
Figure	5.2:	TH	model	myocardium	(left)	demonstrate	interstitial	(cross)	and	
mitochondrial	oedema	(bottom	right-	asterik).	The	mitochondria	contained	dense	
bodies	(left-	arrow)	however	the	nuclei	remain	normal	(top	right)	
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In	 areas	 with	 more	 significant	 damage,	 the	 organelles	 lose	 their	 structural	
definition.	There	 is	diffuse	 interstitial	oedema	present	with	associated	myofibrillar	
disruption	and	autolysis.	This	may	be	indicative	of	necrosis.	The	mitochondria	also	
demonstrate	signs	of	sustained	hypoxia	such	as	mitochondrial	swelling,	with	loss	of	
electron	dense	material	from	the	matrix,	breakdown	of	the	cristae	and	vacuolation.	
Rarefaction	 of	 the	 nucleoplasm,	 where	 there	 is	 loss	 of	 the	 chromatin	 as	
demonstrated	in	these	models,	is	often	seen	when	ischaemia	extends	greater	than	
15	 minutes	 (151).	 The	 nuclei	 in	 our	 TH	 animals	 also	 exhibit	 signs	 of	 irreversible	
structural	 changes,	 for	 example	 margination	 of	 chromatin,	 associated	 with	
surrounding	 oedema.	 Nuclei	 with	 chromatin	 condensation	 are	 contained	 in	 an	
organised	 fashion	within	 an	 oraganelle	 like	 structure,	which	 is	 neither	 in	 keeping	
with	 disruption	 of	 cell	 membrane	 seen	 with	 necrosis	 nor	 the	 blebbing	 of	
apoptosomes	(152).		
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Figure	5.3:	Areas	of	severe	cellular	injury	with	rarefaction	of	the	nucleoplasm	(top)	
with	 surrounding	 oedema	 (top	 left)	 and	 glycogen	 depletion	 (top	 right).	 There	 are	
also	 significant	 amounts	 of	mitochondrial	 oedema	 (bottom	 left)	 seen	 throughout.	
Nucleus	(bottom	right)	seen	with	margination	of	chromatin	within	a	well	contained	
dead	cell	in	TH	model	cardiomyocytes.	
	
In	 two	 in	 the	 longest	 surviving	 animals,	 the	 sarcomere	 partly	 retains	 its	
ultrastructure	with	the	definition	of	 the	myofibrils,	however	they	are	 fully	 relaxed	
with	 visible	 contraction	 bands.	 	 The	 extracellular	 oedema	 is	 associated	 with	
widened	intercalated	discs	and	lifting	of	the	sarcolemma	with	widened	intercalated	
discs.	There	is	interstitial	oedema	with	disruption	of	the	linearity	of	the	sarcomeres	
with	mitochondria	dispersed	in	a	disorganised	fashion.	There	are	multiple	vacuoles	
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and	lipid	deposition	dispersed	throughout	the	sarcomere.	There	is	also	rarefaction	
of	the	nucleoplasm	with	margination	of	chromatin	in	the	nucleus.	The	mitochondria	
are	 fragmented	 and	 irregular	 in	 shape,	 raising	 the	 possibility	 of	 mitochondrial	
fission.	 The	 mitochondrial	 matrix	 demonstrates	 increased	 electron	 density	 with	
poorly	defined	cristae.	The	distribution	of	the	mitochondria	is	not	sustained	across	
the	sarcomeres	with	surrounding	vacuolisation.		
	
	
Figure	 5.4:	 TH	model	myocardial	 tissue	 displays	widespread	 disorganistion	 of	 the	
myocardium	and	relaxation	of	the	sarcomere	demonstrating	prominent	M	&	I	bands	
(left)	and	poorly	circumscribed	mitochondria	distributed	in	a	disorderly	fashion.	The	
nuclei	 (top	 right)	 shows	 margination	 of	 chromatin	 and	 rarefaction	 of	 the	
nucleoplasm.	 There	 is	 widespread	 interstitial	 oedema	 (bottom	 right)	 with	
vacuolation	and	lipid	deposition.	
	
Overall,	 electron	 microscopy	 of	 the	 TH	 mouse	 hearts	 demonstrate	 significant	
changes	within	the	myocardium	consistent	with	presence	of	myocardial	 ischaemia	
in	line.		
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5.2.2	Quantifying	Protein	Expression	In	The	Myocardium	
	
The	 TH	murine	model	 demonstrates	 cardiac	 injury	 through	 an	 increase	 in	 serum	
troponin	 and	 h-FABP	 (Methods	 2.3).	 Western	 blot	 analysis	 and	
immunohistochemistry	were	used	to	examine	 if	 these	 increases	 in	serum	proteins	
had	 concurrent	 effects	 on	 the	 intracellular	 protein	 expression	 and	 distribution	
within	the	cardiac	tissue.		
	
Paraffin	sections	from	the	hearts	of	8	sham	animals	and	6	resuscitated	TH	models	
were	 used	 for	 immunohistochemistry	 analysis	 of	 protein	 expression.	 In	 the	 sham	
animals	 3	 points	 of	 interest	were	 analysed	 on	 4	 separate	 sections	 and	 in	 the	 TH	
models	 4-5	 points	 of	 interest	 were	 studied	 from	 2	 different	 sections.	 The	 single	
colour	 images	 were	 transformed	 to	 pixelated	 images	 using	 Image-J	 software	 to	
allow	 for	 approximate	 quantification	 of	 the	 proteins	 of	 interest	 and	 expression	
reported	as	mean	fluorescence.		
	
Protein	 extraction	 from	 the	 hearts	 of	 the	 trauma	 haemorrhage	 model	 was	
subjected	 SDS	 PAGE	 gel	 electrophoresis	 and	 blotted	 on	 PVDF	 membrane	 with	
specific	 antibodies	 for	 analyzing	 target	 protein	 expression	 analysis.	 A	 silver	 stain	
was	 then	 used	 to	 standardise	 proteins	 of	 interests.	 This	 was	 repeated	 for	 the	
protein	 extracted	 from	 mitochondrial	 fractions	 isolated	 from	 mouse	 tissue	
(Methods	2.4).	
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5.2.2.1	Troponin-I	Expression	in	Cardiac	Tissue		
A	 cardiac	 tissue	 specific,	 mouse	 monoclonal	 cTnI	 antibody	 was	 used	 for	
identification	of	cTnI.	The	antibody	specifically	detects	the	full	length	of	the	cardiac	
cTnI	protein,	by	targeting	the	epitope	spanning	23	to	29	amino	acids.	
	
On	 gross	 examination,	 there	 were	 no	 obvious	 changes	 in	 the	 pattern	 of	 cTnI	
distribution	 upon	 IHC	 examination	 (Figure	 5.6).	 However,	 following	 the	 initial	
overview	of	the	protein	distribution,	 image-j	analysis	demonstrated	a	reduction	 in	
the	mean	fluorescence	of	cTnI	in	the	TH	hearts	when	compared	to	the	sham	hearts,	
17.1	and	12.2	respectively,	p=0.004.	The	loss	of	cTnI	proteins	was	also	observed	in	
the	TH	hearts	using	western	blotting.		The	optical	density	for	the	TH	animals	was	0.1	
compared	 to	 0.06	 in	 the	 sham	 animals.	 However,	 the	 difference	 was	 not	
significantly	 different	 when	 the	 intensity	 optical	 density	 of	 the	 blot	 signal	 was	
quantified.	The	downregulation	of	the	expression	of	troponin	I	in	the	TH	animals	as	
demonstrated	by	immunohistochemistry	and	western	blotting	is	in	keeping	with	the	
rise	in	serum	biomarkers	seen	in	these	animal	models.	
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Figure	 5.5:	 Troponin	 expression	 as	 demonstrated	 by	 IHC	 of	 paraffin	 embedded	
cardiac	 tissue.	 The	 sections	 were	 stained	 with	 primary	 mouse	 monoclonal	 cTnI	
antibody	and	conjugated	with	AF594.	Section	was	scanned	using	tiling	programme	
at	 20	 x	 magnification.	 Top-	 sham	 operated	 animal	 (n=8)	 and	 bottom-	 TH	 model	
(n=6).	A-	Left	ventricle,	B-	Interventricular	wall	and	C-	Right	ventricle	
	
	
Figure	 5.6:	 Troponin	 expression	 derived	 from	 IHC	 of	 paraffin	 embedded	 cardiac	
tissue.	 Mean	 fluorescence	 17.1	 in	 sham-operated	 animal	 (n=8)	 and	 12.2	 in	 TH	
animals	(n=6),	p=0.004		
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Figure	 5.7:	 Troponin	 expression	 as	 demonstrated	 by	 western	 blot	 analysis.	
Adjusted	mean	intensity	of	0.10	in	sham	(n=4)	and	0.06	trauma	haemorrhage	(n=7),	
p=0.06	
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5.2.2.2	H-FABP	Expression	In	Cardiac	Tissue	
Alterations	in	cellular	H-FABP	protein	expression	were	investigated	through	western	
blotting	 using	 specific	 antibodies.	 The	 expression	 of	 h-FABP	 in	 the	 TH	 mice	 was	
significantly	lower	when	compared	to	the	sham	animals,	0.05	vs.	0.03	(p=0.04).		
	
	
Figure	5.8:	Western	blot	of	h-FABP	expression.	Adjusted	optical	density	 is	0.05	 in	
sham-operated	 animals	 (n=8)	 and	 0.03	 in	 trauma	 haemorrhage	 (n-=6)	 murine	
hearts,	p=0.04.	
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5.2.3	Signalling	Pathways	to	Cell	Death	
	
The	 decrease	 in	 cardiac	 structural	 protein	 expression	 as	 well	 as	 the	 associated	
ultrastructural	 changes	 indicate	 the	 onset	 of	 cell	 death	 (153).	 	 Traditionally,	 cell	
death	 has	 been	 defined	 into	 distinct	 processes	 such	 as	 necrosis,	 apoptosis,	
autophagy	 and	 oncosis.	 However,	 with	 newer	 insights,	 it	 is	 becoming	 more	
apparent	that	there	is	a	degree	of	crossover	between	the	pathways	(106).	Although,	
a	 rise	 in	 cardiac	 biomarkers	 is	 contributed	 to	 myocardial	 necrosis	 and	 cell	
membrane	 disruption,	 previous	 studies	 have	 associated	 cardiac	 dysfunction	 in	
trauma	with	 increased	myocardial	 apoptosis	 (35,104).	 The	diversity	 in	 the	 cellular	
changes	 seen	 on	 EM	with	 the	 absence	 of	 profound	 autolysis	 suggests	 that	 there	
may	 be	 many	 drivers	 of	 cell	 death	 in	 these	 models	 and	 not	 all	 dying	 cells	 are	
condemned	 to	 the	 same	 eventuality.	 To	 identify	 the	 cell	 death	mechanisms	 that	
lead	to	these	changes,	downstream	proteins	of	the	extrinsic	and	intrinsic	cell	death	
pathways	were	examined.	
	
5.2.3.1	Caspase	8	Expression	
Caspase	 8	 is	 a	 downstream	 effector	 of	 the	 death	 receptor	 initiated	 cell	 death	
pathway.	 Upon	 western	 blotting	 using	 specific	 antibody	 and	 after	 adjusting	 the		
intensity	of	bands	expression	of	Caspase	8,	revealed	similar,	0.07	vs.	0.06	(p=0.20)	
levels	of	caspase	expression	in	the	samples	of	TH	and	the	sham	models.	However,	
IHC	 revealed	 significant	 down	 regulation	 caspase-8	 expression,	 18.69	 vs.	 1.6	
(p=0.001).		
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Figure	 5.9:	 IHC	 of	 Caspase	 8	 expression	 IHC	 of	 paraffin	 embedded	 cardiac	 tissue	
stained	 for	caspase	8	showing	reduced	 immunofluorescence	 in	 the	TH	mice	hearts	
when	compared	to	the	sham	animals.	Each	section	presented	in	the	figures	are	from	
a	separate	animal.	
	
Figure	5.10	Caspase	8	expression	derived	from	IHC	of	paraffin	embedded	cardiac	
tissue.	Mean	fluorescence	18.7	in	sham-operated	animal	(n=8)	and	1.6	inTH	animals	
(n=6),	p=0.004.	
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Figure	5.11	Western	blots	of	Caspase	8	expression.		Optical	density	in	sham-
operated	animals	is	0.07	compared	to	0.06	in	trauma	haemorrhage	animals,	p=0.20	
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5.2.3.2	Expression	and	Localisation	of	AIF	
	
The	activation	of	mitochondrial	driven	apoptosis	 is	dependent	on	the	influx	of	cell	
death	 proteins	 from	within	 the	mitochondria	 into	 the	 cytosol.	 Upon	 exposure	 to	
toxins	such	as	damaged	DNA	or	ROS,	PARP-1	receptors	are	activated	leading	to	the	
subsequent	activation	of	Bcl	pathways	which	in	turn	results	in	the	permeabilisation	
of	 the	 outer	 mitochondrial	 membrane	 (154).	 This	 permeabilisation	 leads	 to	 the	
cleavage	of	the	apoptosis	inducing	factor	(AIF)	to	its	death-inducing	active	form	into	
the	 cytosol,	 which	 then	 translocates	 to	 the	 nucleus	 where	 it	 leads	 to	 DNA	
degradation	 (110).	 Furthermore,	 the	 breakdown	 of	 the	mitochondrial	 membrane	
allows	the	release	of	cytochrome-C.	Free	cytochrome	C	within	the	cytosol	of	the	cell	
is	then	able	to	 induce	further	cell	death	pathways	through	activation	of	caspase-3	
dependent	apoptosis	((106)).		
	
To	 explore	 this,	 fresh	 murine	 hearts	 were	 homogenized	 and	 mitochondria	 were	
separated	 to	 look	 at	 the	 differential	 distribution	 of	 AIF	 and	 cytochrome	 C.	 In	
addition	to	the	whole	cell	expression	of	AIF	protein,	cells	were	fractionated	into	the	
cytosol	 and	 mitochondria	 portions	 in	 order	 to	 investigate	 alterations	 of	 AIF	
compartmentalisation	following	TH.		
	
Western	 blotting	 analysis	 demonstrated	 that	 the	 protein	 expression	 levels	 of	 AIF	
were	 comparable	 in	 both	 sham	 and	 trauma	 haemorrhage	 animals	 with	 mean	
densities	of	0.20	vs.	0.17	(p=0.50).	
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To	 further	 elucidate	 the	 distribution	 of	 proteins	 in	 the	 different	 sub	 cellular	
fractions	 obtained	 from	 heart	 tissue	 of	 TH	 models,	 the	 subcellular	 fractionation	
procedures	are	followed	and	differential	distribution	of	specific	proteins	of	interest,	
between	 the	 cytosol	 and	 mitochondria	 were	 investigated.	 Heart	 tissue	 was	
homogenized	 and	 then	 processed	 by	 differential	 centrifugation;	 at	 low	 speed	 to	
remove	 large	 organelles	 and	 debris	 and	 using	 a	 specific	mitochondrial	 extraction	
buffer	 (see	 methods	 section	 2.4.3)	 by	 high-speed	 centrifugation	 to	 isolate	 the	
mitochondria.	The	fractionated	samples	were	run	through	the	gels	and	probed	for	
AIF	and	positive	controls	were	used	to	confirm	mitochondrial	separation-	MTCO2	as	
a	 mitochondrial	 marker	 and	 GAPDH	 as	 a	 cytosolic	 marker.	 The	 change	 in	
distribution	 of	 AIF	 in	 the	 mitochondria	 versus	 the	 cytosol	 was	 assessed.	 The	
subcellular	 fractionation	procedure	 removes	 the	nuclei	 from	 the	 supernatant	 and	
therefore,	 further	 analysis	was	 done	 to	 compare	 the	mitochondrial	 expression	 of	
AIF	against	the	total	expression.		
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Figure	 5.12:	 AIF	 expression	 as	 demonstrated	 by	 western	 blot	 analysis.	Mean	 optical	 density	 for	
sham	group	was	0.20	vs	0.17	for	the	TH	group	
	
In	 comparison	 to	 the	 sham	 animals,	 the	 TH	 animals	 show	 a	 reduction	 in	 AIF	
distribution	 in	the	mitochondria	to	supernatant	ratio.	The	mean	ratio	 in	the	sham	
models	is	1.5	in	comparison	to	0.4	in	the	TH	models,	however	this	is	not	statistically	
significant.	 This	 is	 suggestive	 that	 there	 is	 an	 increase	 in	 release	 of	 AIF	 in	 to	 the	
supernatant	where	the	trauma	becomes	lethal	 in	these	mice.	When	the	ratios	are	
studied	 as	 the	 distribution	 between	 the	mitochondria	 and	 total	 cell	 content	 that	
include	the	nuclei,	 the	difference	 in	AIF	expression	becomes	statistically	different.	
The	mean	ratio	in	the	sham	models	is	0.6	when	compared	to	0.3	in	the	TH	models	
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(p=0.04).	 This	 is	 suggestive	 of	 mitochondrial	 AIF	 leaching	 into	 cytosol	 and	
potentially	its	translocation	to	the	nucleus.	
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Figure	 5.13:	 Comparison	 of	 mitochondrial	 vs	 Supernatant	 AIF	
compartmentalisation	 in	 sham	 and	 trauma	 haemorrhage	 murine	 hearts	 as	
demonstrated	 by	 western	 blots.	 The	 mean	 ratio	 of	 mitochondrial	 AIF	 (M	 AIF)	 to	
supernatant	AIF	(S	AIF)	is	1.5	in	sham	group	compared	to	0.4	in	TH	group,	p=0.16.	
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Figure	5.14:	Comparison	of	AIF	expression	in	whole	tissue	and	in	the	mitochondria	
of	sham	and	trauma	haemorrhage	murine	hearts	as	demonstrated	by	western	blots.	
The	ratio	of	total	AIF	(T	AIF)	to	mitochondrial	AIF	(M	AIF)	in	sham	operated	group	is	
0.6	compared	to	0.3	in	TH	animals,	p=0.04.	
	
Immunofluorescent	 microscopy	 was	 used	 to	 visualise	 the	 localisation	 of	 the	 cell	
death	 associated	 protein	 AIF	with	 concurrent	 staining	 of	 a	mitochondrial	marker,	
MTCO2.	 	The	nucleus	was	directly	stained	with	DAPI	(blue).	MTCO2	was	a	primary	
mouse	antibody,	that	was	further	incubated	with	an	anti-mouse	secondary	labeled	
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with	 AF	 594	 (red)	 and	 AIF	 was	 an	 anti-rabbit	 primary	 antibody	 that	 was	 further	
labeled	with	an	anti-rabbit	secondary	antibody	with	AF	488	label	(green).		
	
AIF	 expression	 was	 examined	 through	 immunohistochemistry.	 In	 contrast	 to	 the	
expression	 measured	 by	 western	 blot,	 this	 demonstrated	 an	 increase	 in	 AIF	
expression	in	the	TH	models.	The	mean	immunofluorescence	exhibited	by	AIF	in	the	
TH	models	was	double	that	of	the	sham	animals	13	vs.	6	(p0.001).		
	
	
Figure	 5.15:	 AIF	 expression	 as	 measured	 by	 immunofluorescence	 in	 paraffin	
sections.	The	mean	fluorescence	was	calculated	to	be	13	in	sham	animals	vs.	6	in	the	
TH	animals,	p=0.001	
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On	 IHC	 analysis	 the	 nuclear	 localisation	 of	 AIF	 was	 more	 apparent	 in	 the	
resuscitated	 TH	 models	 when	 compared	 to	 the	 Sham	 models	 (Figure	 5.16).	 The	
image-j	 software	 was	 utilised	 to	 account	 for	 the	 degree	 of	 co-localisation	 of	 the	
proteins.	 Mitochondrial	 localisation	 was	 calculated	 to	 be	 0.05	 in	 the	 TH	 models	
compared	 to	 0.18	 in	 the	 sham,	 however	 this	 was	 not	 statistically	 significant.	
Whereas,	 the	 difference	 in	 nuclear	 localization	 was	 statistically	 different	 with	 a	
mean	of	0	in	the	sham	and	0.06	in	the	TH	models.	
	
Figu.re	5.16:	Sections	from	sham-operated	animals,	DAPI	(blue),	AIF	(green),	MTCO2	
(red)	and	combined	images	
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Figure	5.17:	Paraffin	embedded	sections	from	TH	animals,	DAPI	(blue),	AIF	(green),	
MTCO2	(red)	and	combined	images.	In	the	combined	images,	localisation	of	AIF	in	
the	nucleus	can	be	seen	
	
Figure	 5.18:	 Mitochondrial	 Localisation	 of	 AIF	 as	 calculated	 by	 Image-J	 in	 sham	
animals	0.18	in	comparison	to	0.05	in	TH	animals,	p=0.25	
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Figure	5.19:	Nuclear	Localisation	of	AIF	as	calculated	by	Image-J	in	sham	animals	0	
in	comparison	to	0.06	in	TH	animals,	p=0.04	
	
5.3	Summary	Of	Chapter	
The	 aim	 of	 this	 chapter	 of	work	was	 to	 further	 understand	 the	mechanisms	 that	
lead	 to	 ACE	 and	 the	 release	 of	 cardiac	 biomarkers.	 Using	 a	 mouse	 model	 of	 TH	
allowed	 the	harvest	of	heart	 tissues	 in	order	 to	visualise	gross	and	ultrastructural	
changes	in	the	architecture	of	the	tissue.	Furthermore,	it	allowed	probing	of	several	
proteins	thought	to	be	associated	with	the	cardiac	stress	response	as	demonstrated	
in	chapter	3	and	4.	This	enabled	a	better	understanding	of	the	underlying	changes	
associated	with	the	rise	in	cardiac	biomarkers	and	ultra-structural	anomalies	in	the	
subcellular	 components	 such	 as	 the	 mitochondria	 in	 the	 murine	 trauma	
haemorrhage	models	 and	 potential	 drivers	 for	 the	 responses	 seen	 in	 our	 trauma	
patients.		
	
In	 the	 sham	 animals,	 EM	 demonstrated	 normal	 myocardial	 structure	 with	 well-
defined	 myofibrils,	 defined	 sarcoplasm	 and	 organized	 mitochondria	 throughout.	
Whereas	 in	 TH	mice	 this	 normal	 architecture	 and	 cellular	 organisation	 appeared	
disrupted.	 The	 most	 prominent	 feature	 in	 the	 myocardium	 of	 TH	 mice	 was	 the	
cellular	 oedema,	 varying	 from	 interspersed	 interstitial	 oedema	 to	 gross	 oedema	
leading	 to	 organelle	 swelling	 and	 myofibrillar	 disruption.	 Structural	 changes	 in	
mitochondria	 are	 markers	 of	 cell	 stress	 and	 these	 mitochondria	 fail	 in	 efficient	
energy	production.	This	occurs	due	to	 lack	of	the	Na+/K+	pump	functioning	 in	the	
outer	membrane	of	mitochondria,	and	therefore	leading	to	cytosolic	accumulation	
of	Na+	and	Cl-	ions	(155).	Furthermore,	under	hypoxic	stress,	anaerobic	respiration,	
		 166	
leads	 to	 lactic	acidosis	and	 increased	hydrogen	 ion	production.	This	directly	alters	
the	function	of	the	Na+/K+	pump	precipitating	the	damage	(155).		
	
Mitochondrial	amorphous	dense	bodies	was	present	in	both	sham	and	TH	models.	
There	 is	 a	 lot	 of	 variation	 in	 the	 significance	 of	 the	 amorphous	 dense	 bodies.	
Isolated	myocardial	cells	have	been	noted	to	develop	amorphous	dense	bodies	with	
just	 incubation	 at	 37oC	 without	 any	 change	 in	 their	 function,	 thought	 to	 be	
secondary	 to	 reorganisation	 of	 the	 structural	 proteins	 (155).	 However	 it	 has	 also	
been	associated	with	irreversible	injury	with	changes	in	the	mitochondria’s	ability	to	
utilise	 pyruvate	 and	 effectively	 respire	 (151,156,157).	 The	 intra-mitochondrial	
dense	 bodies	 occur	 following	 accumulation	 of	 precipitated	mitochondrial	 protein	
associated	 with	 calcium	 phosphate	 and	 influx	 of	 intracellular	 calcium,	 leading	 to	
ischaemia	(158).	However,	dense	bodies	have	been	noted	in	sudden	calcium	influx	
is	 also	 associated	 with	 hyperadrenergic	 states,	 (151).	 Dense	 body	 formation	 has	
also	been	demonstrated	following	anaesthesia	with	Propofol	in	murine	models	due	
to	the	reduced	coronary	flow	following	anaesthesia-induced	hypotension	(159).	The	
isoflurane	 similarly	 leads	 to	 hypotension,	 so	 its	 potential	 contribution	 to	 inducing	
dense	body	formation	should	be	taken	into	account.		
	
The	 TH	 mice	 demonstrated	 areas	 with	 severe	 injury,	 with	 widespread	
disorganisation	 of	 the	 myocardium	 and	 relaxed	 sarcomere	 in	 keeping	 with	
irreversible	 cell	 damage.	 These	 areas	 also	 demonstrated	 hollow	 mitochondrial	
matrix	with	 increased	electron	density.	Some	of	 these	changes	may	be	 in	keeping	
with	 reperfusion	 injury	 due	 to	 sustained	 hypoxia	 followed	 by	 reflow	 due	 to	
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crystalloid	 resuscitation.	 Cells	 that	 are	 irreversibly	 damaged	 with	 disruption	 to	
cellular	and	mitochondrial	membrane	integrity	have	been	shown	to	develop	further	
swelling	 and	 destruction	 with	 the	 presence	 of	 vacuolation	 as	 seen	 here	 (149).	
Reperfusion	of	the	cardiac	tissue	induces	calcium	influx	into	the	cells	perpetuating	
cellular	 damage	 in	 vulnerable	 cells	 which	 would	 be	 in	 keeping	 with	 the	
mitochondrial	changes	(149).		
	
Serum	troponin	and	h-FABP	has	been	shown	to	be	raised	 in	 trauma	patients	with	
associated	 adverse	 cardiac	 outcomes	 (Li2015,	 bahloul,	 (135,160).	 This	 has	 been	
reflected	in	our	animal	models	with	TH	associated	with	rise	in	troponin	and	h-FABP.	
In	this	study,	using	the	TH	models	of	cardiac	injury,	we	were	able	to	establish	a	link	
between	 corresponding	 cellular	 changes	 and	 associated	 changes	 in	 protein	
expression.	 The	 western	 blots	 and	 immunohistochemistry	 studies	 demonstrated	
that	 these	 changes	 had	 reflective	 reduction	 in	 these	 cardiac	 proteins	 within	 the	
cardiac	 tissue.	 Cardiac	 troponin	 has	 been	 used	 in	 murine	 models	 of	 ischaemia	
induced	 by	 the	 ligation	 of	 coronary	 arteries	 (161).	 The	 induced	 infarct	 has	 been	
correlated	with	 a	 rise	 in	 troponin	 alongside	 a	 reduction	 in	 cardiac	 function	 (161).	
The	rise	in	troponin	has	also	been	demonstrated	in	models	following	isoproterenol	
induced	 cardiac	 toxicity	 (162).	 In	 these	 models,	 the	 rise	 in	 serum	 troponin	 was	
comparable	to	the	degree	of	coagulative	necrosis	seen	on	histology.	In	TH	models,	a	
few	 studies	 have	 explored	 the	 role	 of	 cell	 death	 in	 cardiac	 dysfunction	 in	 animal	
models(104,163).	 The	 pro-apoptotic	 proteins	 were	 seen	 to	 rise	 with	 cardiac	
dysfunction	 without	 concurrent	 rise	 in	 plasma	 cardiac	 biomarkers,	 where	 the	
authors	suggested	the	dysfunction	was	due	inflammatory	mediated	and	not	due	to	
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myocardial	necrosis	(104).	However,	as	demonstrated	by	clinical	studies,	it	has	been	
noted	 that	 there	 is	 a	 rise	 in	 cardiac	proteins	 such	as	 troponin	and	h-FAPB.	 In	our	
study	we	have	demonstrated	 that	 this	 is	 associated	with	 changes	 in	 keeping	with	
ischaemia	 in	 the	myocardium.	 To	 distinguish	 the	 cell	 death	 pathways	 involved	 in	
inducing	myocardial	 cell	 damage	 and	 the	 leakage	 of	 proteins,	 caspase	 8,	 AIF	 and	
cytochrome	C	were	chosen.	In	our	models	there	was	no	significant	difference	in	the	
caspase	8	or	cytochrome	C	expression	as	measured	by	western	blot	between	sham	
and	TH.	
	
However,	 AIF	 a	 cell	 death	 factor	 that	 activates	 upon	 mitochondrial	 stress	 is	
observed	 to	 translocate	 into	 nucleus	 from	 mitochondrion	 as	 observed	 in	 our	
subcellular	 fractionation	 studies	 by	western	 blotting	 and	 IHC	 analysis	 in	 TH	mice.	
Altogether	these	studies	report	a	rise	in	cardiac	biomarkers	such	as	CTnI	and	hFABP,	
that	 correlate	 with	 gross	 changes	 in	 mitochondrial	 ultra	 structures	 there	 by	
triggering	the	translocation	and	activation	of	death	 inducing	factors	such	as	AIF	 in	
these	TH	mice	models.	Mitochondrial	damage	has	been	noted	previously	in	trauma	
but	 as	 a	 result	 of	 tissue	 injury.	 Studies	 have	 reported	 the	 inflammatory	 response	
induced	by	mitochondrial	DAMPs	(164).	I	propose	that	the	cell	injury	is	induced	by	
mitochondrial	dysfunction	in	itself.			
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Chapter	6	
	
Discussion	
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6.1	Summary	of	Findings	
	
The	prospective	cohort	study	of	290	patients	demonstrated	the	a	13%	prevalence		
of	TISCI	as	defined	by	clinical	events,	ECGs	and	rise	in	h-FABP.	This	correlated	with	
previous	 retrospective	 studies	 (32).	 Unlike	 the	 temporal	 trend	 of	 h-FABP	 in	
pathologies	of	myocardial	stress	such	as	PE	where	it	rises	and	falls	within	24	hours,	
in	 TISCI,	 it	 remains	 raised	 throughout	 the	 first	 72	 hours	 (72).	 This	 raises	 the	
possibility	that	TISCI	occurs	over	days	and	the	ongoing	ischaemia	does	not	resolve	
with	 resuscitation.	 Patients	 who	 had	 higher	 levels	 of	 h-FABP	 on	 admission	 had	
worse	 clinical	 outcomes	 including	 increased	 mortality,	 longer	 length	 of	 hospital	
stay,	prolonged	critical	admissions	and	 increased	 inotropic	requirement.	 In	an	age	
of	increasing	need	for	resource	management	particularly	within	the	NHS,	this	model	
for	identifying	patients	with	TISCI	could	prove	to	be	an	important	tool	in	prediction	
of	patient	placement	during	admission.		
	
Furthermore,	 this	 study	 highlights	 an	 opportunity	 to	 identify	 patients	 with	
subclinical	 coronary	 artery	 disease.	 In	 patients	 who	 develop	 transient	 ischaemic	
changes	 with	 pre-existing	 cardiac	 risk	 factors,	 cardiology	 follow	 up	 should	 be	
considered	on	discharge	for	further	investigation	and	management.	
	
Interestingly,	 hypertension	was	 revealed	 as	 a	 significant	 contributor	 to	 TISCI,	 the	
reasons	 for	 this	may	 be	multifactorial.	 Hypertension	 not	 only	 induces	 endothelial	
damage	 but	 also	 leads	 to	 changes	 to	 the	 myocardium	 and	 predisposes	 to	 the	
development	 of	 arrhythmias	 (144).	 It	 may	 also	 be	 that	 hypertensive	 patients	
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accustomed	 to	 higher	 coronary	 perfusion	 pressures,	 even	 a	 small	 degree	 of	
hypotension	leads	to	a	greater	degree	of	cardiac	ischaemia	(165).	
	
This	 study	 further	 demonstrated	 the	 role	 of	 catecholamines	 in	 TISCI.	 Serum	
adrenaline	 and	 noradrenaline	 were	 higher	 in	 patients	 who	 developed	 ACE	 and	
predicted	inotropic	requirement.	Furthermore,	adrenaline	and	noradrenaline	levels	
had	an	incremental	effect	on	h-FABP	levels,	provoking	thoughts	of	effect.	However,	
on	 multivariate	 analysis,	 these	 were	 not	 calculated	 to	 be	 independent	 factors,	
potentially	due	to	their	co-linearity	with	degree	of	shock	and	injury	severity.		
	
Murine	models	 enabled	 further	 examination	 and	 validation	 of	 increase	 in	 cardiac	
injury	 associated	 biomarkers.	 The	 increase	 in	 serum	 h-FABP	 in	 these	 models	 is	
associated	with	reduction	in	its	tissue	concentration.	Furthermore	tissue	expression	
of	 troponin-I	 was	 also	 reduced.	 The	 most	 impressive	 finding	 was	 the	 degree	 of	
changes	 in	 ultra	 fine	 structures	 of	 sub	 cellular	 components	 such	 as	 myofibril	
organisation	 and	mitochondrial	 fission	 as	 analysed	 by	 electron	microscopy	 in	 the	
fixed	sections	of	cardiac	tissue.	There	is	definite	evidence	of	ischaemia	displayed	as	
widespread	oedema,	organelle	swelling	and	mitochondrial	changes.		This	alongside	
the	 translocation	 of	 the	 death-related	mitochondrial	 protein	 AIF	 into	 the	 cytosol	
highlights	the	role	of	the	mitochondria	in	TISCI.		
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6.2	Strengths	of	this	Work	
The	 Centre	 for	 Trauma	 Sciences	 at	 Blizard	 Institute	 Queen	 Mary	 University	 of	
London	 provides	 an	 excellent	 structure	 for	 translational	 research	 through	
collaborative	 efforts	 of	 clinicians	 from	 pre-hospital	 to	 rehabilitation	 and	 the	
research	 fellows.	 The	 assiduous	 data	 collection	 by	 research	 fellows	 who	 are	
clinicians	with	 a	dedicated	 interest	 in	 trauma	 sciences	 attests	 the	 integrity	 of	 the	
data.	 This	 facilitated	 with	 ease	 the	 prospective	 recruitment	 and	 substantial	 data	
collection	for	the	clinical	study.	Due	to	the	prospective	design,	the	contributions	of	
past	medical	history	as	well	as	medications	were	explored,	in	addition	the	effect	of	
ACE	on	inotropic	support.		
	
	Trauma	haemorrhage	is	a	complex	entity	with	bleeding	and	tissue	injury	leading	to	
a	plethora	of	noxious	events	 including	but	not	 limited	 to	hypoperfusion,	bleeding	
diasthesis,	hyperadrenergic	stimuli	which	all	mediates	cellular	responses	leading	to	
inflammation,	multi-organ	 failure	 and	 death.	 To	 replicate	 this,	 is	 not	 a	 slight	 task	
and	 I	 was	 fortunate	 enough	 to	 be	 in	 a	 group	 with	 those	 extremely	 talented	 in	
animal	modeling.	Not	only	did	they	produce	trauma	haemorrhage	models	but	they	
also	 confirmed	 the	 presence	 of	 TISCI	 in	 the	models.	 Ease	 of	 access	 to	 the	 hearts	
from	the	TISCI	models	immensely	strengthened	the	work	produced	in	this	thesis	by	
facilitating	 the	exploration	 in	 to	 the	mechanisms	underpinning	cardiac	 injury.	This	
led	to	the	confirmation	of	cell	death	in	the	myocardium,	validating	cardiac	injury	as	
suggested	 by	 the	 increased	 blood	 levels	 of	 cardiac	 biomarkers	 and	 the	 novel	
identification	 of	 mitochondrial	 abnormalities	 on	 histology	 and	 the	 subsequent	
release	of	mitochondrial	death	protein	AIF.		
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6.3	Limitations	of	This	Work		
	
An	important	aspect	of	TACID	was	to	obtain	functional	cardiac	measures	in	trauma	
patients.	Unpredicted	 resource	 limitations	and	coinciding	 restructuring	of	 services	
at	our	hospital	 lead	to	poor	compliance	with	echocardiogram	examinations	 in	this	
cohort.	Despite	plans	to	obtain	echocardiograms	for	all	recruited	patients,	only	15%	
of	patients	had	one	completed	and	more	importantly	only	44%	of	the	patients	who	
developed	ACE	had	echocardiograms.	Surprisingly,	despite	higher	rates	of	initiation	
of	inotropes	in	the	ACE	group,	analysis	of	echocardiogram	results	did	not	reveal	any	
difference	 in	 cardiac	 function	 in	 the	 TH	patients.	Due	 to	 the	 variability	 in	 time	of	
examination	and	patient	selection,	I	am	reluctant	to	put	this	forward	as	an	absolute	
finding.	Furthermore,	the	echocardiography	parameters	that	were	reported	within	
the	 completed	 studies	are	all	 sensitive	 to	 changes	 in	 volume,	although	 they	were	
completed	 following	 the	 initial	 resuscitative	 period	 where	 one	 may	 assume	 the	
patients	are	euvolaemic,	it	will	still	be	affected	by	changes	in	volume	distribution	as	
seen	 in	 SIRS	 following	 trauma.	 It	 would	 have	 been	 pertinent	 to	 examine	 more	
robust	 parameters	 such	 as	 tissue	 doppler	 index	 and	 global	 longitudinal	 strain.		
Further	 functional	 data	 could	 have	 also	 been	 collected	 using	 dynamic	 cardiac	
monitoring.	 For	 the	 duration	 of	 the	 TACID	 study,	 LiDCO	 availability	 was	 limited.	
Nonetheless,	 use	 of	 LiDCO	brings	 its	 own	 limitations,	with	 difficulty	 in	 calibration	
and	need	for	expertise	in	utilisation,	and	therefore	may	not	have	been	particularly	
helpful	 in	 this	 study.	 Furthermore,	 not	 all	 patients	 got	 ECGs	 at	 all	 time	 points,	
however	they	were	still	pragmatically	included	in	the	analysis.		
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Financial	 restraints	 necessitated	omission	 of	 troponin	measurement	 at	 24	 and	 72	
hours.	 The	 troponin	examination	would	have	 shed	 light	on	 the	 temporal	 trend	of	
TISCI	 in	addition	 to	h-FABP.	Furthermore,	 to	allow	 for	 seamless	 translation	of	 this	
work	 into	 clinical	practice,	measurements	 should	have	been	made	using	an	ultra-
sensitive	troponin	assay.	However,	on	a	small	scale	without	an	established	clinical	
indication,	 it	 was	 not	 possible	 to	 collaborate	 with	 the	 hospital	 lab.	 These	 assays	
would	 also	 have	 to	 been	 performed	 on	 dedicated	 machines	 which	 require	
outsourcing	 to	 the	 manufacturers	 and	 provide	 further	 budgetary	 demands.	 A	
weakness	 of	 the	 catecholamine	 ELISA	 is	 that	 exogenous	 and	 endogenous	
catecholamines	cannot	be	differentiated,	however,	to	answer	the	question	whether	
catecholamine	 exposure	 is	 associated	 with	 poorer	 outcomes,	 I	 felt	 an	
understanding	 of	 the	 temporal	 trend	 of	 catecholamine	 levels	 at	 24	 and	 72	 hours	
would	 be	 useful.	 I	 did	 not	 anticipate	 the	 magnitude	 of	 the	 contribution	 of	
exogenous	 catecholamines	 and	 potentially	 an	 insignificant	 contribution	 of	
endogenous	 catecholamines.	 Especially,	 as	 often	 catecholamine	 use	 beyond	 the	
initial	 resuscitative	 stage	 can	 be	 necessary	 and	 unavoidable,	 this	 is	 an	 unlikely	
management	 strategy	 that	 would	 be	 amenable	 to	 change	 to	 potentially	 improve	
outcomes.	 On	 hindsight,	 resources	 may	 have	 been	 better	 spent	 focusing	 on	
troponin	at	24	and	72	hours.		
	
Despite	the	sophistication	of	the	TISCI	murine	models,	direct	translation	of	animal	
data	to	humans	should	be	done	with	caution.	Small	animal	models	such	as	mice	and	
rats	are	frequently	used	due	to	their	ease	of	handling	and	low	costs.	Despite	sharing	
80%	of	 their	 genes	with	humans,	 they	are	 still	 relatively	 genetically	distant.	Gene	
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expression	 studies	 in	 animal	 trauma	 models	 have	 shown	 low	 correlation	 with	
human	 genomic	 change	 (166).	 This	 can	 be	 overcome	 with	 correlation	 studies	 of	
genomic	changes	induced	by	trauma	in	mice	and	humans	with	subsequent	human	
cell	 studies	 to	 aid	 translation.	 The	 rodents’	 dissimilarity	 to	 humans	 make	 them	
insufficient	 as	 a	 stand	 alone	 model	 for	 development	 of	 novel	 therapeutic	
substances	 but	 one	 may	 argue	 sufficient	 for	 repurposing	 well	 established	
treatments.		
	
Although	 in	 combination,	 IHC	 and	 western	 blotting	 are	 useful	 for	 understanding	
pathologies,	 there	 are	 still	 many	 limitations.	 Western	 blotting	 provides	 an	
overarching	 measure	 of	 the	 protein	 expression	 whereas	 IHC	 enables	 study	 of	
protein	 distribution.	 In	 the	 data	 presented,	 the	 changes	 in	 expression	 did	 not	
correlate	between	the	two	methods,	for	example	the	total	AIF	expression.	Despite	a	
large	 number	 of	 repeated	measures,	 IHC	 still	 only	 allows	 investigation	 of	 a	 small	
region	of	the	whole	organ	whereas	western	blot	accounts	for	the	organ	as	a	whole,	
so	the	estimation	from	western	blotting	 is	more	 likely	 to	be	representative	of	 the	
global	protein	expression.	
	
Furthermore,	neither	of	 these	are	essentially	quantitative	methods.	 Technological	
innovations	 have	 enabled	 conversion	 of	 these	 techniques	 in	 to	 quantitative	
methods	and	now,	this	is	well-established	practice.	However,	it	is	still	important	to	
correlate	 the	 numbers	 with	 blots	 and	 sections.	 Sophisticated	 software	 for	
calculating	 immunofluorescence	 and	 localisation	 index	 has	 made	 data	 easier	 to	
manage,	 interpret	 and	 present.	 However,	 a	 lot	 of	 information	 can	 be	 lost	 or	
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misinterpreted.	 There	 is	 still	 there	 no	 better	 substitute	 for	 careful	 visual	
interrogation.	
	
Although,	 the	 involvement	 of	 AIF	 in	 cardiac	 dysfunction	 and	 TH	 is	 novel	 and	
exciting,	this	needs	further	validation	with	gene	expression	analysis.	
6.4	Future	Work	
The	 evidence	 from	 the	 clinical	 studies	 highlights	 the	 prevalence	 of	 TISCI	 in	 our	
trauma	population.	Especially	 in	 light	of	 the	evidence	 regarding	 the	prevalence	of	
cardiovascular	 disease	 in	 out	 of	 hospital	 deaths,	 ACE	 in-hospital	 should	 instigate	
further	 investigation.	Surprisingly,	only	44%	of	 those	 that	developed	an	ACE	went	
on	to	have	an	echocardiogram,	this	was	mainly	due	to	limitations	of	expertise	in	the	
technique.	Echocardiograms	are	now	much	more	utilised	due	to	 increase	in	multi-
disciplinary	 training	as	well	 as	 the	 recognition	of	 their	utility	 in	prognostication	 in	
many	 disease	 processes.	 Future	work	 is	 needed	 to	 increase	 clinical	 awareness	 of	
TISCI	 as	 a	 prognostic	marker	 in	 trauma	 patients	 to	 instigate	 further	 investigation	
through	an	echocardiogram	and	arrange	appropriate	follow	up	either	in	secondary	
or	primary	care.		
	
The	recognition	of	mitochondrial	involvement	and	translocation	of	AIF	has	given	our	
research	a	new	focus.	The	release	of	AIF	is	facilitated	by	the	Bcl-2	family	proteins	as	
well	 as	 the	 permeability	 transition	 pore	 of	 mitochondria	 (167).	 Recent	 human	
genomic	 studies	 of	 critically	 injured	 patients	 revealed	 the	 upregulation	 of	
mitochondrial	 stress	and	 respiration	genes	overall	and	 further	more,	upregulation	
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of	 cell	 death	 related	 genes	 in	multi-organ	 failure	 (168).	 The	 changes	 seen	 in	 the	
murine	 myocardium	 may	 potentially	 be	 reflective	 changes	 and	 intrinsic	 to	
multiorgan	 failure.	 Follow-up	 experiments	 replicated	 in	 stored	 lung	 and	 kidney	
tissues	from	the	same	models	could	aid	further	understanding.	Multiple	pre-clinical	
studies	 have	 highlighted	 melatonin	 as	 a	 potential	 candidate	 for	 alleviating	
mitochondrial	 swelling	 and	 permeability	 transition	 pore	 opening	 in	 ischaemia	
reperfusion,	 muscle	 injury	 and	 neurodegenerative	 diseases	 (169-171).	 Clinical	
studies	 showing	 reduction	 in	 intra-operative	 bleeding,	 post	 operative	 cardiac	
complications	and	multi	organ	dysfunction	in	sepsis	in	children	and	burns	(170,172).	
Melatonin	is	known	to	be	safe	in	high	doses	and	it	is	widely	used	in	critical	care	to	
reduce	delirium	and	aid	extubation,	therefore,	a	relatively	safe	therapeutic	agent	to	
explore(170).	 Further	 investigation	 in	 to	 therapeutic	 doses	 and	 effect	 on	 organ	
dysfunction	and	apoptosis	in	murine	studies	may	be	beneficial.	Additionally,	studies	
on	 the	 protein	 structure	 and	 interactions	 of	 AIF	 have	 suggested	 both	 hsp70	 and	
XIAP	as	potential	targets	for	mitigating	apoptosis.		However,	therapeutic	molecules	
to	 potentiate	 their	 anti-apoptotic	 properties	 are	 still	 being	 developed	 (167).	
Therefore	 characterisation	 of	 various	 proteins	 that	 regulate	 apoptotic	 signaling	
cascades	 could	 insight	 clues	 to	 disease	 mechanisms	 in	 these	 TH	 mice	 models.	
Moreover,	 ultra	 structural	 changes	 in	mitochondria	 and	 nuclear	 chromatin	might	
possibly	indicate	changes	in	genome	architecture	and	assembly.	This	could	lead	to	
increase	 in	DNA	damage	 response	 and	 changes	 in	 transcriptional	 state	 of	 cells	 in	
these	mice.	 Further	 exploration	 to	 understand	 the	 basic	 biology	 underlying	 these	
mice	 models	 could	 provide	 insight	 into	 disease	 mechanisms	 and	 therefore	 open	
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new	 avenues	 for	 targeted	 therapy	 and	 improved	management	 of	 care	 in	 trauma	
patients	
6.4	Conclusions	
	
The	 studies	 in	 this	 thesis	have	demonstrated	 the	presence	of	 TISCI	 in	 the	 trauma	
population	associated	with	hypertension	and	 raised	noradrenaline	and	adrenaline	
levels	on	admission	which	predicted	inotropic	use,	length	of	ICU	stay	and	mortality.	
Furthermore,	 in	the	animal	models	of	TISCI	revealed	significant	 ischaemic	changes	
on	 histology	 with	 signs	 of	 mitochondrial	 damage,	 nuclear	 condensation	 and	
translocation	of	mitochondrial	death	protein	AIF	to	its	active	site.	This	poses	a	new	
question	for	further	research	and	a	potential	target	for	treatment.		
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Appendix II 
Cambridgeshire 3 Research Ethics Committee 
Victoria House 
Capital Park 
FULBOURN 
Cambridge 
CB21 5XB 
 
 Telephone: 01223 597597  
Facsimile: 01223 597645 
03 September 2010 
 
Professor Karim Brohi 
Consultant in Trauma, Vascular & Critical Care Surgery 
Royal London Hospital 
Trauma Clinical Academic Unit 
Royal London Hospital 
Whitechapel Road, London 
E1 1BB 
 
Dear Professor Brohi 
 
Study Title: Trauma Associated Cardiac Injury, Dysfunction & Death 
(TACIDD) 
REC reference number: 10/H0306/47 
 
Thank you for your letter of 23 August 2010, responding to the Committee’s 
request for further information on the above research and submitting revised 
documentation. 
 
The further information has been considered on behalf of the Committee by the 
Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion 
for the above research on the basis described in the application form, protocol 
and supporting documentation as revised, subject to the conditions specified 
below. 
 
Mental Capacity Act 2005 
 
I confirm that the committee has approved this research project for the purposes 
of the Mental Capacity Act 2005. The committee is satisfied that the requirements 
of section 31 of the Act will be met in relation to research carried out as part of 
this project on, or in relation to, a person who lacks capacity to consent to taking 
part in the project.  
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to 
the start of the study (see “Conditions of the favourable opinion” below). 
The Committee has not yet been notified of the outcome of any site-specific 
assessment (SSA) for the non-NHS research site(s) taking part in this study. The 
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favourable opinion does not therefore apply to any non-NHS site at present. I will 
write to you again as soon as one Research Ethics Committee has notified the 
outcome of a SSA. In the meantime no study procedures should be initiated at 
non-NHS sites. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
 
Management permission or approval must be obtained from each host 
organisation prior to the start of the study at the site concerned. 
 
For NHS research sites only, management permission for research (“R&D 
approval”) should be obtained from the relevant care organisation(s) in 
accordance with NHS research governance arrangements.  Guidance on 
applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular 
site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as 
follows: 
  
Document    Version    Date    
 Investigator CV: Karim Brohi   07 June 2010  
 Protocol  1.1  02 June 2010  
 REC application  3  03 June 2010  
 Covering Letter    04 June 2010  
 Study Flowchart  07 June 2010  
 Letter from Sponsor    01 June 2010  
 GP/Consultant Information Sheets  1.1  02 June 2010  
 Participant Information Sheet: Information Sheet A  - Subject  1.2  30 July 2010  
 Participant Consent Form: TACIDD A professional legally 
appointed representative consent form  
1.2  30 July 2010  
 Response to Request for Further Information    23 August 2010  
 Participant Information Sheet: Information Sheet B - Subject  1.2  30 July 2010  
 Participant Information Sheet: Information Sheet C Consultee  1.2  30 July 2010  
 Participant Information Sheet: Information Sheet D - Consultee  1.2  30 July 2010  
 Participant Consent Form: A  1.1  02 June 2010  
 Participant Consent Form: Tissue  1.2  30 July 2010  
 Participant Consent Form: A -Subject  1.2  30 July 2010  
 Participant Consent Form: B -Subject  1.2  30 July 2010  
 Participant Consent Form: TACIDD B professional legally 
appointed representative consent form  
1.2  30 July 2010  
 Evidence of insurance or indemnity: Barts & The London   01 June 2010  
  
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
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After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to 
make your views known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
1.   Notifying substantial amendments 
2.   Adding new sites and investigators 
3.   Progress and safety reports 
4.   Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in 
the light of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 
10/H0306/47 Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Mr John Richardson 
Chair 
 
Email: lynda.mccormack@eoe.nhs.uk 
 
Enclosures: “After ethical review – guidance for researchers”  
 
Copy to: Mr Gerry Leonard 
R&D Department 
Queen Mary Innovation Centre 
Walden Street 
London 
E1 2EF 
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Appendix III 
Patient information sheet   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet A – Subject 
Version 1.2, 30/07/2010  
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  Trauma Associated Cardiac Injury and Dysfunction (TACID A)  
Principal Investigator: Mr. Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
Subject Name: _____________.   NHS Ref: ___________ Study Ref: ________ 
 
Introduction 
You are being invited to take part in a research study. This research will help us 
to improve the care of patients who suffer severe injuries in the future. Before you 
decide, it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully. 
Talk to others about the study if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
Why is this research being carried out? 
Trauma (serious injury) is a serious health problem worldwide. Once discharged 
home, trauma patients are more likely to be limited in their daily activities 
compared to similar people who have not been injured.  Injury, shock and blood 
loss may damage the heart, which might lead to the above. If this is the case, the 
extent and frequency of heart damage and dysfunction in trauma patients is not 
known, and we hope that this research will help us to determine if, who and how 
significantly the heart might be affected by trauma.   
 
		 197	
	
	  257 
Coupled with this, we want to find out what happens to trauma patients who 
already have diseased hearts before injury, and compare their outcomes to 
similar patients with normal healthy hearts.  
Why have I been chosen? 
On ___ - ___ - ______ (date), you were injured and admitted to the Royal 
London Hospital.  At the time, you were unable to give informed consent.  When 
you arrived in the emergency department, a full trauma team of doctors and 
nurses attended to you.  The trauma team leader, who is not part of this research 
study, gave consent as your representative.  As part of the immediate 
management, a heart trace (ECG) was performed and blood taken and sent to 
the laboratory for analysis.  A small amount of extra blood (approximately 1 
teaspoonful) was drawn and saved for research purposes.  We are now asking 
for your consent to allow us to use the samples we have collected and to 
continue to participate in the study, since all the procedures have not yet been 
completed. 
Do I have to take part? 
No, participation is completely voluntary.  It is up to you to decide whether or not 
to take part.  If you do, you will be given this information sheet to keep and be 
asked to sign a consent form.  You are still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
If you agree to continue with the study the following will happen: 
1. We will store and process the samples we have already collected. 
2. We will continue to collect blood samples and heart traces (ECGs) until the 
3rd day in hospital.  3 of each in total.  Each blood sample is equivalent to 1 
teaspoonful, and the total amount of blood drawn over 3 days is less than 1 
fluid ounce.  Wherever possible we will draw the blood out of a line already in 
a blood vessel, or coincide the blood draw with tests required for your care, 
in order to minimise any discomfort from the procedure. 
3. We will perform an echocardiogram (Echo) during your admission, at a time 
that is convenient to you and medically appropriate.  An Echo is an 
ultrasound of the heart, and will give us information on the appearance and 
function of your heart.  
4. This will take approximately 30 minutes, and is undertaking by placing some 
jelly on your chest followed by a probe that produces the images.  It is very 
safe, but if the chest wall is injured, can be a little uncomfortable.   
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We will give you painkillers if this is the case, which will allow the test to be 
performed pain free. 
5. When you go home, or at 30 days after your accident, we will ask you to fill 
in a questionnaire designed to assess your health perception.  It is easy to 
complete and should take no more than 10 minutes.   
6. We also need permission to access your health records, so that we can 
assess your health one year after your accident.  This information is 
confidential, and will only be seen by the research team.  It will only be used 
for the purpose described above in this study. 
What do I have to do? 
If you agree to continue with the study the following will happen: 
1.  We will collect ___ (number) of further blood samples and ___ ECGS from 
you, on ___________(date/times) 
2.  We will perform an Echo at a convenient time to you during the course of your 
admission. 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks to you from participating in this study.  The specific 
risks associated with each investigation are as follows: 
1. Blood samples: 
The risks of drawing blood include temporary discomfort from the needle stick 
and bruising. 
2. Echocardiogram: 
There is no risk to your health from an Echo, however, if you have chest wall 
injuries, you may find the procedure a little uncomfortable.  We will give you 
painkillers if this is the case and only proceed when you are happy for us to do 
so. 
What are the possible benefits of taking part in the study? 
In the event that we detect an abnormality with your heart, we will refer you with 
your consent to a specialist in order to ensure you get appropriate care and 
follow up.  In addition, we hope that the information we get will help to improve 
the care of trauma patients in the future. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  The detailed information on 
this is given in Part 2. 
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Will my taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be 
handled in confidence.  The details are included in Part 2. 
This Completes Part I. 
If the information in Part 1 has satisfied you and you are considering continuing in 
the study, please read the additional information in Part 2 before making any 
decision. 
 
Date: ___/___/_____         Researcher Initial: _____ 
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PART 2 
What will happen if I don’t want to carry on with the study? 
If you decide, at any time, to withdraw from the study all study procedures will be 
stopped immediately.  Any information and samples that have already been 
collected will be processed as part of the study unless you wish to have your 
samples withdrawn from the study, in which case we will destroy them.  Your 
decision will in no way result in a change in the type or quality of care you 
subsequently receive. 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after you.  It is 
extremely unlikely that this small change to normal practice would cause any 
problems.  However, if taking part in this study harms you, there is no special 
compensation arrangement.  If you are harmed due to someone’s negligence, 
then you may have grounds for legal action but you may have to pay your legal 
costs. Regardless of this, if you wish to complain or have any concerns about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be 
available to you.  Please contact Patient Advisory Liaison Service (PALS) if you 
have any concerns regarding the care you have received, or as an initial point of 
contact if you have a complaint.  Please telephone 020 7377 6335, minicom 020 
7943 1350, or email pals@bartsandthelondon.nhs.uk.  You can also visit PALS 
by asking at any hospital reception. 
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will 
be kept strictly confidential and will be stored securely in coded form.  If you 
consent to take part in the research, the people conducting the study will abide 
by the Data Protection Act 1998, and the rights you have under this Act.  Only 
authorised personnel such as researchers and research auditors will have 
access to the data.  Any subsequent use of the samples will have to be 
performed with approval from a research ethics committee, otherwise the 
samples will be destroyed.  
What will happen to the samples that I give? 
We would like your permission to store your blood samples for further research.   
Any further use of your samples outside of this research study will have to be 
approved by a research ethics committee.   
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What will happen to the results of the research study? 
We hope to publish the results in a scientific journal.  It will not be possible to 
identify any individual who has taken part from this scientific report.  Copies of 
the report will be available on request. 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given ethical approval by the Cambridgeshire 
3 Research Ethics Committee. 
Who can I contact for further information? 
1. If you require further information about the study, please contact the 
TACID study offices via the Trauma Surgery secretary at 020 7377 7000, 
x7695 or email: Henry.De’Ath@bartsandthelondon.nhs.uk 
2. If you require impartial, local advice, please contact the Patient Advice 
and Liaison Service, telephone: 020 7943 1335 or e-mail: 
pals@bartsandthelondon.nhs.uk 
Thank you for taking the time to read this sheet.  
Date: ___/___/_____         Researcher Signature: ______________ 
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Appendix IV 
Information for Consultee   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet C - Consultee 
Version 1.2, 30.07.2010  
 
Cambridgeshire 3 Research Ethics Committee 
REC number: 10/H0306/47 
 
Title: Trauma Associated Cardiac Injury and Dysfunction (TACID A) 
Principal Investigator: Mr. Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
Subject Name: _____________.   NHS Ref: ___________ Study Ref: ________ 
 
Introduction 
We feel your relative/friend is unable to decide for himself/herself whether to 
participate in this research.  To help decide if he/she should join the study, we 
would like to ask your opinion whether or not they would want to be involved.  We 
would ask you to consider what you know of their wishes and feelings, and to 
consider their interests.  Please let us know of any advance decisions they may 
make about participating in research.  These should take precedence.  If you are 
unsure about the role of consultee you may seek independent advice.  We will 
understand if you do not want to take on this responsibility.  The following 
information is the same as would have been provided to your relative/friend. 
Why is this research being carried out? 
Trauma (serious injury) is a serious health problem worldwide.  Once discharged 
home, trauma patients are more likely to be limited in their daily activities 
compared to similar people who have not been injured.  Injury, shock and blood 
loss may damage the heart, which might lead to the above. If this is the case, the 
extent and frequency of heart damage and dysfunction in trauma patients is not 
known, and we hope that this research will help us to determine if, who and how 
significantly the heart might be affected by trauma.   
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Coupled with this, we want to find out what happens to trauma patients who 
already have diseased hearts before injury, and compare their outcomes to 
similar patients with normal healthy hearts.  
Why have they been chosen? 
On ___ - ___ - ______ (Greenland P), your relative or significant other was 
injured and admitted to the Royal London Hospital.  At the time, they were unable 
to give informed consent.  When they arrived in the emergency department, a full 
trauma team of doctors and nurses attended to them.  The trauma team leader, 
who is not part of this research study, gave consent as their representative.  As 
part of the immediate management, a heart trace (ECG) was performed and 
blood taken and sent to the laboratory for analysis.  A small amount of extra 
blood (approximately 1 teaspoonful) was drawn and saved for research 
purposes.  We are now asking for your consent to allow us to use the samples 
we have collected and to allow their continued participation in the study, since all 
the procedures have not yet been completed. 
Do I have to agree? 
No, participation is completely voluntary.  It is up to you to decide whether or not 
your relative/significant other should take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a declaration form.  You are still 
free to withdraw at any time and without giving a reason.  A decision to withdraw 
at any time, or a decision not to take part, will not affect the standard of care your 
relative/significant other receives. 
What will happen to them if they take part? 
1. If you agree to continue with the study the following will happen: 
2. We will store and process the samples we have already collected. 
3. We will continue to collect blood samples and heart traces (ECGs) until the 
3rd day in hospital. 3 of each in total.  Each blood sample is equivalent to 1 
teaspoonful, and the total amount of blood drawn over 3 days is less than 1 
fluid ounce.  Wherever possible we will draw the blood out of a line already in 
a blood vessel, or coincide the blood draw with tests required for their care, 
in order to minimise any discomfort from the procedure. 
4. We will perform an echocardiogram (Echo) during the admission, at a time 
that is convenient and medically appropriate.  An Echo is an ultrasound of 
the heart, and will give us information on the appearance and function of the 
heart.  This will take approximately 30 minutes, and is undertaking by placing 
some jelly on the patient’s chest followed by a probe that produces the 
images.   
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It is very safe, but if the chest wall is injured, can be a little uncomfortable.  
We will give painkillers if this is the case, which will allow the test to be 
performed pain free. 
5. When home, or at 30 days after the accident, we will ask your relative or 
significant other to fill in a questionnaire designed to assess their health 
perception.  It is easy to complete and should take no more than 10 minutes.  
6. We also need permission to access their health records, so that we can 
assess their health one year after your accident.  This information is 
confidential, and will only be seen by the research team.  It will only be used 
for the purpose described above in this study. 
What do they have to do? 
If you agree to continue with the study the following will happen: 
1.  We will collect ___ (number) of further blood samples and ___ ECGS from 
them, on_________(date/times) 
2.  We will perform an Echo at a convenient time to you during the course of 
his/her admission. 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks to you from participating in this study.  The specific 
risks associated with each investigation are as follows: 
1.  Blood samples: 
The risks of drawing blood include temporary discomfort from the needle stick 
and bruising. 
2.  Echocardiogram: 
There is no risk to their health from an Echo, however, if they have chest wall 
injuries, they may find the procedure a little uncomfortable.  We will give them 
painkillers if this is the case and only proceed when they are happy for us to do 
so. 
What are the possible benefits of taking part in the study? 
In the event that we detect an abnormality with your relative/significant other’s 
heart, we will refer them with your consent to a specialist in order to ensure they 
get appropriate care and follow up.  In addition, we hope that the information we 
get will help to improve the care of trauma patients in the future. 
What if there is a problem? 
Any complaint about the way you or your relative have been dealt with during the 
study or any possible harm they might suffer will be addressed.  The detailed 
information on this is in Part 2. 
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Will taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
relative/significant other will be handled in confidence.  The details are included 
in Part 2. 
This Completes Part I. 
If the information in Part 1 has satisfied you and you are considering continuing in 
the study, please read the additional information in Part 2 before making any 
decision. 
 
Date: ___/___/_____         Researcher Initial: _____ 
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PART 2 
What will happen if I don’t want them to carry on with the study? 
If you or your relative/significant other decides, at any time, to withdraw from the 
study all study procedures will be stopped immediately.  Any information and 
samples that have already been collected will be processed as part of the study 
unless you wish to have their samples withdrawn from the study, in which case 
we will destroy them.  Your decision will in no way result in a change in the type 
or quality of care they subsequently receive. 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after your 
relative/significant other.  It is extremely unlikely that this small change to normal 
practice would cause any problems.  However, if they are harmed by taking part 
in this study, there is no special compensation arrangement.  If they are harmed 
due to someone’s negligence, then you may have grounds for legal action but 
you may have to pay your legal costs.  Regardless of this, if you wish to complain 
or have any concerns about any aspect of the way you or your relative have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you.  Please contact 
Patient Advisory Liaison Service (PALS) if you have any concerns regarding the 
care they have received, or as an initial point of contact if you have a complaint.  
Please telephone 020 7377 6335, minicom 020 7943 1350, or email 
pals@bartsandthelondon.nhs.uk.  You can also visit PALS by asking at any 
hospital reception. 
Will taking part in the study be kept confidential? 
All information collected during the course of the research will be kept strictly 
confidential and will be stored securely in coded form.  If you consent to take part 
in the research the people conducting the study will abide by the Data Protection 
Act 1998, and the rights you and your relative have under this Act.  Only 
authorised personnel such as researchers and research auditors will have 
access to the data.  Any subsequent use of the samples will have to be 
performed with approval from a research ethics committee, otherwise the 
samples will be destroyed.  
What will happen to the samples that are given? 
We would like your permission to store his/her blood samples for further 
research.   Any further use of the samples outside of this research study will have 
to be approved by a research ethics committee. 
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What will happen to the results of the research study? 
We hope to publish the results in a scientific journal. It will not be possible to 
identify any individual who has taken part from this scientific report.  Copies of 
the report will be available on request. 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given ethical approval by the Cambridgeshire 
3 Research Ethics Committee. 
Who can I contact for further information? 
1. If you require further information about the study, please contact the ACIT 
Study offices via the Trauma Surgery secretary at 020 7377 7000, 
ext7695 or email: Henry.De’Ath@bartsandthelondon.nhs.uk 
 
2. If you require impartial, local advice, please contact the Patient Advice 
and Liaison Service, telephone: 020 7943 1335 or e-mail: 
pals@bartsandthelondon.nhs.uk 
Thank you for taking the time to read this sheet.  
 
Date: ___/___/_____         Researcher Signature: ______________ _____ 
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Appendix V 
Trauma Associated Cardiac Injury and Dysfunction (A) 
 
Trauma patients are eligible for participation in TACID A trial unless they 
meet one of the following: 
 
x Patients transferred from other hospitals 
x Not expected to survive <72 hours  
x Pregnant 
x Patients <16  
x Prisoners 
x Trauma team leader deems recruitment inappropriate 
 
 
 
 
 
 
Patient Name  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _   
 
 
Patient ID _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
DOB  _ _/_ _/__    Approximate Age _ _ 
 
 
Date Recruited _ _/_ _/_ _ Time of Baseline Blood/ECG   _:_  
 
I, as trauma team leader, fully understand the TACID A research study 
and informed consent process.  I have read the consent documents and 
have provided consent in my capacity as a professional legally appointed 
representative of the above named patient and am independent of the 
trial. 
 
 
Name  _ _ _ _ _ _ _ _ _ _ _ _ _ _  Title _ _ _ _ _ _ _ _ _ 
 
 
Signature _ _ _ _ _ _ _ _ _ _ _ _ _ 
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Appendix VI   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consent Form A – Subject 
Version 1.2, 02.06.2010            
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  TRAUMA ASSOCIATED CARDIAC INJURY AND DYSFUNCTION (A) 
Principal Investigator:  Mr. Karim Brohi, FRCS FRCA    
Please initial box to 
indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 30.07.2010 
(version 1.2) for the above study and have had the opportunity to ask questions.  I have  
been given a copy of the patient’s information sheet to keep.   [  ] 
2. I understand that my participation in this study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected.        [ ] 
3. I understand that sections of any of my medical notes may be looked at by professional 
individuals involved in this study or by regulatory authorities where it is relevant to my 
taking part in research.  I give permission for these individuals to have access to my 
records. I understand that my personal data will be processed and stored securely in 
compliance with the 1998 Data Protection Act.  [ ]  
4. I agree to take part in the above study.    [ ] 
 
 
                   
Name of patient    Date    Signature 
 
 
I have explained this in terms which, in my judgement, are suited to the understanding of 
the patient. 
 
 
                                
Name of person taking consent  Date    Signature 
(if different from Investigator) 
 
 
                    
Investigator    Date                          Signature 
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Appendix VII     
 
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consultee Declaration Form C 
Version 1.2, 30.07.2010            
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  TRAUMA ASSOCIATED CARDIAC INJURY AND DYSFUNCTION (A) 
Principal Investigator:  Mr. Karim Brohi, FRCS FRCA    
Please initial box to 
indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 30.07.2010 
(version 1.2) for the above study and have had the opportunity to ask questions.  I have  
been given a copy of the consultee information sheet to keep.  [  ] 
2. I understand that his/her participation in this study is voluntary and that I am free to 
withdraw him/her at any time, without giving reason, without their medical care or legal 
rights being affected.       [ ] 
3. I understand that sections of any of his/her medical notes may be looked at by 
professional individuals involved in this study or by regulatory authorities where it is 
relevant to them taking part in research.  I give permission for these individuals to have 
access to his/her records. I understand that his/her personal data will be processed and 
stored securely in compliance with the 1998 Data Protection Act.  [ ] 
4. I agree to allow my relative/significant other take part in the above study. [ ] 
 
 
         
Name of Patient   Relationship 
 
                   
Name of Consultee   Date   Signature 
 
 
I have explained this in terms which, in my judgement, are suited to the understanding of 
the patient. 
 
 
                                
Name of person taking consent  Date   Signature 
(if different from Investigator) 
 
 
                    
Investigator    Date                Signature 
 
 
 
